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Abstract 
 
Herpes simplex virus type 1 virions contain a proteinaceous layer between the nucleocapsid 
and the virus envelope termed the tegument. The mechanism underlying tegumentation remains 
largely undefined for all herpesviruses, as does the role of many tegument proteins in virus 
replication. The networks of protein interactions involved in virus assembly have been largely 
explored and although large-scale studies have been carried out using yeast two hybrid analyses of 
herpesvirus protein interactions, few of the identified networks have been validated in infected cells. 
Here, the molecular interactions that occur between the major tegument proteins VP22, VP16 and 
VP13/14 and a range of glycoproteins and tegument proteins were defined in detail. Two alternative 
studies were performed from infected cells, however one based on the purification of GFP-tagged 
proteins and their protein partners proved more successful. These studies validated previous findings 
and also identified VP13/14, UL21, UL16 and vhs as novel binding partners of VP22, and VP22, 
UL21, UL16 and vhs as novel binding partners of VP13/14. Thus, these results have led to the 
identification of two discrete tegument protein complexes in the infected cell: VP22-VP16-VP13/14-
vhs and VP22-VP13/14-UL21-UL16. 
To investigate the nature of the VP22-VP16-VP13/14-vhs complex in more detail, a number 
of techniques were used and showed that VP22 and VP13/14 both bind directly to the C-terminus of 
VP16, but were unable to interact with each other. As anticipated from other studies on transfected 
cell extracts, vhs was shown to be incorporated into this complex by virtue of its direct binding to 
VP16 during infection, and did not have the capacity to interact directly with VP22. 
This work has established a defined network of protein-protein interactions encompassing 
over one third of tegument proteins, and will improve our understanding of the wider protein 
interaction networks that lead to the assembly of the herpesvirus tegument. 
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1.1 Herpesviridae 
The Herpesviridae are divided into three subfamilies: the Alphaherpesvirinae, 
Betaherpesvirinae and Gammaherpesvirinae. These subfamilies share four biological properties 
(Knipe et al. 2007): 
 They encode a large variety of enzymes involved in nucleic acid metabolism, DNA synthesis 
and protein processing.  
 Viral DNA synthesis and capsid assembly occur in the host nucleus, whilst the final 
processing of the virion is completed in the cytoplasm. 
 Infected cells are destroyed through the production of infectious particles. 
 A latent infection is established by all herpesviruses within the host. During this latent state, 
only a limited subset of viral genes are expressed. 
The subfamilies are divided according to their different host cell range and properties. This 
thesis concentrates on the Alphaherpesvirinae subfamily, and more specifically on the herpes simplex 
virus type 1 (HSV-1), a virus with a variable host range and a relatively short reproductive cycle 
(Knipe et al. 2007). Members of the Beta- and Gammaherpesvirinae generally have a more restricted 
host range. The Beta subfamily has a long reproductive cycle and infection progresses slowly in 
culture. Latency can be established in secretory glands, kidneys and other tissues. In contrast, the 
Gamma subfamily infect lymphoblastoid cells and are specific for either T- or B-lymphocytes (Knipe 
et al., 2007). Only recently the International Committee on Taxonomy of Viruses updated the 
taxonomy of herpesviruses and incorporated the former family Herpesviridae into the new order 
Herpesvirales. Also, two new family members were introduced into the new order, the 
Alloherpesviridae which incorporates the fish and frog viruses and the Malacoherpesviridae that 
contains a bivalve virus (Davison et al., 2009). 
1.1.1 Alphaherpesvirinae 
Viruses from Alphaherpesvirinae subfamily infect a wide range of mammalian hosts, like 
varicella-zoster virus (VZV) which causes chickenpox by destroying cells via lysis after intracellular 
reproduction and, when reactivated, causes herpes zoster, commonly known as shingles (Arvin, 
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1996). In pigs, pseudorabies virus (PRV), also known as Aujeszky’s, causes piglet mortality 
(Wittmann et al., 1980). Equids are infected by equine herpesvirus type 1 (EHV-1) that causes 
respiratory disease, abortion and neurological symptoms in horses and cattle, bovine herpesvirus type 
-1 (BHV-1) is the causative agent of infectious bovine rhinotracheitis (IBR) (Turin et al., 1999; 
Walker et al., 1999). Furthermore, in cats feline herpesvirus 1 causes upper respiratory or pulmonary 
infection called feline viral rhinotracheitis (Crandell & Despeaux 1959) and in puppies, canine 
herpesvirus causes a fatal haemorrhagic disease (Carmichael et al., 1965). This subfamily also infects 
avian species, mainly chickens. Another known virus is Marek’s Disease Virus (MDV), which causes 
asymmetric paralysis of one or more limbs in chickens (Biggs, 2001). Also, galllid herpesvirus 1 
(GaHV-1), also known as Avian herpesvirus 1, infects chickens causing avian infectious 
laryngotracheitis. This subfamily of viruses spreads rapidly in culture, efficiently destroying host cells 
during the production of virus progeny. Latency is primarily established in sensory ganglia. 
1.1.2 Herpes Simplex Viruses pathogenesis 
Herpes simplex virus type 1 (HSV-1) is the prototype of the Alphaherpesvirinae subfamily 
and it was among the first human herpesviruses to be discovered. In 1873, Vidal first demonstrated 
that HSV could be transmitted in humans and in 1919 Lowenstein confirmed that various strains of 
herpes simplex virus were infectious and not attributed to insect bites or genetic conditions (Kaplan, 
1973). HSV-1 and its closest relative, herpes simplex virus type 2 (HSV-2), share similar 
epidemiological and clinical manifestations, sharing 82% amino acid homology. HSV-1 is a common 
pathogen, capable of infecting humans of all ages, spreading easily via close personal contact and has 
a seroprevalence range from 50% to 90% across all ethnic groups. In the UK, an estimated 50% of the 
adult population is seropositive for HSV-1 (Pebody et al., 2004). Infection with HSV-1 results in a 
wide variety of clinical manifestations, ranging from asymptomatic infection to vesicular lesions of 
the skin and mucosa. Once latency is established in the sensory neurons, lesions can be reactivated at, 
or near, the point of entry into the body, hence the ancient Greek word “herpes”, which means to 
“creep” or “crawl” referring to the manner in which skin lesions spread (Roizman & Whitley, 2001). 
The more severe the primary infection, as reflected by the size, number, and extent of lesions, the 
more likely it is that recurrences will occur. Herpes labialis, commonly known as the cold sore, is the 
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best-known symptom of HSV-1 infection; however, serious complications of infection can give rise to 
encephalitis, especially in newborns and immunocompromised patients, such as transplant patients or 
individuals undergoing chemotherapy (Knipe et al. 2007). Another serious infection occurs in the eye 
where HSV-1 causes a range of diseases like blepharitis, conjunctivitis and dendrictic keratitis and is 
the second most common source of corneal blindness in the US (Lamb & Krug, 2001). HSV-1 is also 
linked to genital lesions, though to a lesser extent than HSV-2. Frequent reactivation of the lesions 
can lead to greatly reduced quality of life for the sufferer. There has been long recognition that a link 
between HIV and HSV infection exists, both at the cellular level (Ostrove et al., 1987; Schacker et al., 
1998) and with regards to anti-viral treatments (Nagot et al., 2007).  In fact, recent advances have led 
to findings which suggest that HSV-1/HSV-2 infected individuals may be more susceptible to HIV 
infection.  One hypothesis is that HSV-1/HSV-2 infection stimulates higher levels of circulating 
CD4+ T cells, the target cells for HIV infection (Barbour et al., 2007).  Further research has also 
highlighted that epithelial damage and inflammation caused by HSV infection produces a susceptible 
environment for HIV infection, making pre-existing infection with HSV at mucosal surfaces a major 
risk factor for HIV transmission (Horbul et al., 2011). 
1.1.3 Treatments and vaccines 
Herpes viruses establish lifelong infections, and cannot currently be eliminated or cleared 
from the body. However, use of antiviral therapies such as acyclovir, which has been administered 
clinically since 1982, and valacyclovir can reduce the frequency, duration and severity of outbreaks. 
Acyclovir (ACV), a nucleoside analogue of guanosine, is phosphorylated by the herpes-virus-specific 
thymidine kinase (TK) upon entry into the infected cell. The active form of the drug, ACV-
triphosphate (ACV-TP), is then formed through successive phosphorylation steps that are catalysed 
by intracellular kinases. ACV-TP works both as a direct inhibitor of herpes-virus DNA polymerase 
and as a DNA chain terminator (Elion, 1993). Since it blocks DNA replication, ACV is only effective 
against actively replicating viruses and does not affect viruses in persistent or latent states. There are 
no vaccines licensed to date for HSV-1 or HSV-2, because of the inherent challenge in developing 
vaccines for herpes viruses due to their large genome, which is difficult to manipulate or delete genes 
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since most are essential, and the long periods of latency in the host. However, many classes of herpes 
vaccines and delivery systems have been attempted during the last century.  
The first vaccine introduced was an inactivated virus in the early 1920s, which was prepared 
from formalin-treated tissues of HSV-infected animals (Tigges et al., 1992). Vaccines approaches 
changed from inactivated to replication-defective HSV strains, like infectious type HSV mutants 
which were missing ICP8, ICP10, dl5-29, or vhs, a discontinuously replicating virus known as 
disabled infectious single cycle or DISC, and a virus with a deletion of UL22, the late gene encoding 
glycoprotein H (Hoshino et al., 2005). A DISC HSV-2 vaccine has entered clinical trials and has been 
found harmless with no severe opposing effects (Boursnell et al., 1998). Furthermore, the most 
extensive human studies available with attenuated live HSV vaccine were with strain R7020, which 
was originated from HSV-1 strain F and had a deletion covering ICP27 through the promoter region 
of ICP4 (Branco & Fraser, 2005). However, patients infected with this attenuated virus experienced 
local reactions and systemic side effects during a dose increase study. 
It is worth noting that one of the most recent HSV-2 vaccine trials using glycoprotein D-2 as 
the antigen, despite early successes, failed to protect from HSV-2 infection but did provide a level of 
protection from HSV-1 infection and disease in women (Belshe et al., 2012). It was speculated by the 
authors of this study that the failure of protection from HSV-2 was partly due to the choice of study 
populations. Even though the gD-2 antigen was derived from HSV-2, 89% amino acid homology was 
shared with gD-2 HSV-1, which could explain the protection from HSV-1, in addition to the lower 
overall inoculum of HSV-1 in general and that the genital tract is a less hospitable for HSV-1 
replication than HSV-2 (Belshe et al., 2012). 
Molecular virology has recently been advanced enabling investigators to construct viruses 
that selectively destroy cancer cells, which are referred to as oncolytic virotherapy. HSV is an 
attractive candidate as oncolytic agent due to its efficient replication, cell lysis, spread of HSV, and its 
natural broad host range (Fu et al., 2007; Lachmann, 2004). An example is NV1020 oncolytic HSV-1, 
which was demonstrated to have noteworthy impact in the treatment of many different types of 
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tumours in preclinical studies in experimental animals, as well as in human clinical trials (Cozzi et al., 
2002; Gutermann et al., 2006; Kemeny et al., 2006). Also, HSV can be used as a gene delivery vector 
(Burton et al., 2002; Lilley et al., 2001), and those vectors are efficient vehicles for the delivery of 
exogenous genetic material to cells due to the highly infectious nature of HSV. Additionally, many of 
the HSV viral genes are dispensable for replication in vitro, allowing their replacement with large or 
multiple transgenes. 
1.1.3.1 Vaccines for alphaherpesviruses  
Vaccines are available for most of the alphaherpesviruses, including VZV and PRV, with the 
exception of HSV as discussed previously. The widely used live attenuated Oka VZV vaccine was 
prepared from cells isolated from a healthy Japanese child with varicella and attenuated by serial 
passage in cell culture (Arvin & Gershon, 2003; Asano et al., 1985; Seward et al., 2002). In the case 
of PRV, several PRV vaccine strains have been developed, such as the live attenuated Bartha vaccine 
strain (Bartha, 1961; Mettenleiter et al., 1985), due to the agricultural importance of PRV and the 
relative ease of vaccine testing in pigs. Furthermore, Marek’s Disease has been controlled since the 
late 1960s with the use of homologous avirulent vaccines (Churchill et al. 1969), which prevent the 
development of MDV-induced tumours and disease but do not prevent super-infection with 
pathogenic MDV (Gimeno, 2008). Vaccination against EHV has been widely introduced, particularly 
among racehorses and brood mares. The killed EHV vaccine has been demonstrated a reduction in 
clinical symptoms and virus shedding (Heldens et al., 2001). Moreover, BHV vaccines include 
inactivated, attenuated, subunit or gene-deleted vaccines. Although vaccines are used to reduce the 
severity of disease, infection cannot always be prevented due to the endemic nature of BHV infection 
(Fenner et. al. 1993). 
1.2 Herpes virus particle 
The complex infectious HSV-1 virion is approximately 120-200 nm in diameter and consists 
of four structural components. The HSV-1 152 kilo base double stranded DNA genome encodes 86 
genes and consists of a unique long (UL) and a unique short (US) segment. The protein capsid that 
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encases the double-stranded DNA genome is in an icosahedral shape approximately 110nm in 
diameter and consists of 162 capsomeres composed of 150 hexons and 12 pentons that lie on a T=16 
icosahedral lattice. There are five conserved proteins that comprise herpes capsids: UL19 (VP5), 
which is the major capsid protein, UL18 (VP23) and UL38 (VP19c), which are proteins that form 
triplect that interact and help stabilise adjacent capsids, UL35 that covers all hexons, and UL26, 
which forms the portal through which the viral genome is injected into the nucleus (Mettenleiter, 
2006).  In addition, the capsid packages one copy of the linear double-stranded DNA in the form of a 
spool, which circularises upon release into the host cell nucleus (Zhou et al., 1999). The process of 
DNA packaging requires a number of proteins, such as UL15 and UL28 proteins which are involved 
in site-specific cleavage of the viral DNA, UL26 which is an integral component of the capsid shell 
and UL25 which may be associated with capsids after scaffolding loss and DNA packaging by sealing 
the DNA within the capsids. Furthermore, a proteinaceous layer comprised of at least 23 proteins 
known as the tegument surrounds the capsid. This in turn is contained within a plasma membrane-
derived lipid envelope containing cellular proteins and 20 or more virally encoded glycoproteins 
(Loret et al., 2008; Roizman & Sears, 2001) (Fig. 1.1). 
1.2.1 Tegument 
The term tegument was first introduced by Roizman and Furlong to describe the layer of 
proteins between the capsid and the envelope (Roizman and Furlong 1974). At first, the tegument 
appeared to be an amorphous proteinaceous layer, however after the identification of non-infectious 
enveloped tegument structures lacking capsid protein and DNA, called light (L) particles, it was 
demonstrated that the tegument is stable and does not require a capsid in order to maintain its 
structure (McLauchlan & Rixon, 1992). It was shown that the tegument structure could self-assemble 
without capsids and that removal of the envelope from L particles did not alter the size and shape of 
the tegument suggesting that neither the presence of the envelope or the capsids were required for the 
tegument structure (McLauchlan & Rixon, 1992).  
Mass spectrometry analysis of purified HSV-1 particles placed 54% of all identified peptides  
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Figure 1.1: The HSV-1 virion (Flint et al.  2003) 
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within the tegument, making this by far the largest virion compartment, with at least 23 proteins 
identified to date (Loret et al., 2008). It also contains host proteins; one study identified 49 cellular 
proteins, including cytoskeletal, heat-shock and Rab proteins, within purified virions (Loret et al., 
2008). A number of studies have demonstrated that significant changes in the composition of the 
tegument did not disrupt virus assembly and viable virus was produced (Coulter et al., 1993; 
Pomeranz & Blaho, 2000; Zhang & McKnight, 1993). Also, in another report it was shown that the 
increase of an abundant tegument protein, VP22, under the control of the strong immediate early 
promoter of human cytomegalovirus (HCMV IE), induced a rise in its abundance in virions and L-
particles (Leslie et al., 1996). In contrast to the less abundant protein, UL37, whose rise in abundance 
did not induce any increase in its levels incorporated into virus particles, suggesting that a mechanism 
exists to control its abundance in the tegument (McLauchlan, 1997). Moreover, these irregularities in 
the composition of the tegument were also mirrored by large variation of copy numbers of VP22, and 
another abundant tegument protein VP16, between individual HSV virions (Clarke et al., 2007; del 
Rio et al., 2005). 
The tegument proteins can be divided into inner and outer layers based on whether proteins 
are intimately associated with capsid surfaces (Wolfstein et al., 2006). Previous research from our 
group and others suggest that protein-protein interactions, both within the tegument and between the 
tegument and envelope proteins, may facilitate tegument assembly and association of the viral capsid 
to the envelope (Chi et al. 2005; Elliott et al. 1995; Farnsworth et al. 2007; Fossum et al. 2009; Gross 
et al. 2003; Stylianou et al. 2009; Vittone et al. 2005). Furthermore, tegument proteins mediate a 
number of key functions before, during and after de novo protein synthesis of viral proteins. A few of 
these functions include: targeting of virion components to and from the nucleus during entry and 
egress; recruitment of cellular molecular motors during entry and egress; regulation of viral and host 
cell gene and protein expression; and assembly of virions during egress (Kelly et al., 2009). 
1.2.2 Envelope glycoproteins 
HSV-1 consists of at least 11 viral membrane glycoproteins: gB, gC, gD, gE, gG, gH, gI, gJ, 
gK, gL and gM, some of which, such as gB, are conserved amongst the herpes viruses. The 
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glycoprotein D, however, is unique to simplex viruses (Akhtar & Shukla, 2009; Shukla & Spear, 
2001). It is hypothesised that a high degree of organisation is required to localise all these proteins to 
the correct compartment for virion incorporation. These glycoproteins are involved in various aspects 
of the virus life cycle, including spread, entry, acquisition of the final envelope and egress. The 
essential glycoproteins B, D and the gH/gL complex mediate attachment and fusion of the virus at the 
cell surface, while gC performs an accessory role (Campadelli-Fiume et al.; Shukla and Spear 2001; 
Spear, 2004). The gE/gI complex and gM are required for efficient cell-to-cell spread of the virus, 
whilst the gE/gI complex is also involved in immune evasion by blocking immunoglobulin G (IgG), 
through their binding to the Fc domain of IgG (Dingwell & Johnson, 1998; Dubin et al., 1991; Frank 
& Friedman, 1989; Johnson et al., 1988). However, regarding the members of the Alphaherpesviruses, 
although the gE/gI complex is essential for the chicken pathogen Marek’s disease virus (MDV) and 
VZV replication, it is considered nonessential in HSV-1, PRV and EHV-1 replication (Cohen & 
Nguyen, 1997; Mallor et al., 1997; Schumacher et al., 2001).  PRV and EHV-1 mutants lacking both 
glycoproteins E and M failed to produce enveloped particles and accumulated capsids in the 
cytoplasm (Brack et al., 1999; Seyboldt et al., 2000). In contrast, in HSV-1, simultaneous deletion of 
the same two glycoproteins did not have a profound effect in production of infectious virions 
according to Browne and colleagues (Browne et al., 2004). However, a recent report by our group 
demonstrated that HSV-1 lacking gE and gM resulted in defective secondary envelopment with 
unwrapped capsids accumulating in the cytoplasm and a reduction in virus yield (Maringer et al., 
2012). Furthermore, simultaneous deletion of gD and gE did result in a striking defect in particle 
assembly (Farnsworth et al., 2003). Among their various roles, viral glycoproteins are also considered 
to facilitate secondary envelopment through their interactions with the outer tegument proteins 
(Maringer et al., 2012; Stylianou et al., 2009).   
 
1.3 Herpesvirus life cycle 
HSV-1 enters the body through damaged epithelia and initiates lytic replication in 
keratinocytes at the inoculation site. Following infection of sensory neurones and retrograde transport 
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to the ganglion, HSV-1 establishes latency within the nucleus of a subset of ganglionic neurones 
(Knipe et al. 2007). Latent virus can be reactivated and transported to the axonal termini, where the 
virus is released once more within the epithelial cells of the mucosal tissue, causing a secondary lytic 
infection at the primary site of infection. The virus can be reactivated at any time throughout the life 
of the host. This reactivation can be caused by numerous factors, such as stress, ultraviolet light, heat, 
fever and hormonal changes, and can result in recurrent mucocutaneous lesions as well as 
asymptomatic infection (Roizman & Whitley, 2001; Wagner & Bloom, 1997). Transmission of 
progeny virus can then spread to a new host via secretions (Knipe et al. 2007). 
1.3.1 Attachment and entry 
Three distinct steps are involved in the initiation of viral infection. First, the attachment of the 
virus to the host cell is followed by the interaction of glycoprotein D (gD) with cellular entry 
receptors, which then trigger fusion of the virus envelope with the cellular membrane. Glycoproteins 
gC and/or gB bind to glycosaminoglycan (GAG) chains of heparan sulphate on the cell membrane 
and form the initial contact of the virus with the host cell (Spear & Longnecker, 2003). The virus is 
concentrated on the cell surface in order for the appropriate virus ligands, like gD, to bind to the entry 
receptors. Glycoprotein D acts together with three other essential glycoproteins gB, gH and gL to 
induce fusion of the virus envelope with the cell membrane. Montgomery and colleagues used a 
cDNA library derived from HeLa cells and screened for entry of HSV-1 into non-permissive Chinese 
hamster ovary (CHO) cells, where they identified the herpes virus entry mediator (HVEM) or HveA 
as an entry receptor for gD (Montgomery et al., 1996). HVEM principally mediates entry of HSV-1 
and HSV-2 into human T lymphocytes and trabecular meshwork cells and is expressed in many foetal 
and adult tissue cells (Montgomery et al. 1996; Tiwari et al. 2005; Whitbeck et al. 1997). Through a 
similar cDNA screen an alternative entry receptor was identified, called nectin -1 or HveB, by using a 
mutant virus expressing an altered form of gD which cannot bind to HVEM (Warner et al., 1998). In 
the same report, nectin-2, or HveC, was shown to have a limited entry-mediating activity only for 
some HSV-1 mutant strains (Warner et al., 1998). Another entry receptor binding to gD identified was 
the non-protein receptor 3-O-sulfated heparan sulphate (3-OS HS), which mediates entry of HSV-1, 
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but not HSV-2 (Shukla & Spear, 2001; Spear & Longnecker, 2003). In more recent reports it seems 
that the entry receptors were not limited to an interaction with gD. Paired immunoglobulin-like 
receptor alpha has also been proposed as an entry receptor through an interaction with gB, as well as 
the non-muscle myosin heavy chain IIA (Arii et al., 2010; Satoh et al., 2008). 
Entry of HSV-1 into the cell occurs through fusion of the viral envelope with the plasma 
membrane or an internal endosomal membrane (Nicola & Straus 2004; Nicola et al. 2003; Spear 
1993). In some studies, entry at the plasma membrane was shown to be pH-independent, while entry 
via an endosomal compartment was shown to be pH-dependent. Although, HSV-1 has been shown to 
enter most cells via the pH-independent route, it has been hypothesised that the route of entry may 
vary depending upon the cell type (Nicola & Straus, 2004). In cell types such as Vero, HSV 
penetrates the plasma membrane and delivers its capsid directly into the cytosol (Sodeik et al., 1997; 
Spear & Longnecker, 2003).Whereas in other common continuous cell lines, such as CHO and HeLa 
cells, it is believed that endocytosis of virions is required to initiate successful entry of HSV (Nicola 
et al., 2003). It should be mentioned that CHO cells are regarded as non-permissive cells for HSV-1 
infection as they lack the specific entry receptors, and therefore they require modification to express 
HSV entry receptors such as HVEM, nectin 1 or nectin 2 in order to be infected (Nicola et al., 2003; 
Nicola & Straus, 2004). 
Upon entry into the cell, it has been suggested that HSV-1 capsids are driven toward the 
minus end of microtubules through the interactions of the HSV-1 inner tegument proteins, like VP1/2 
and UL37, with cellular dynein (Döhner et al., 2002; Mabit et al., 2002; Sodeik et al., 1997; Wolfstein 
et al., 2006; Ye et al., 2000). The capsids dock at nuclear pore complexes (NCP) and the viral genome 
is deposited into the nucleus in the presence of an energy source and cytosol or importin-β as 
demonstrated by in vitro studies (Ojala et al., 2000). A number of studies have shown that the host 
nuclear import factor importin β, as well as the NPC proteins Nup358/RanBP2 and Nup214/CAN, 
which both face the cytosol and interact with VP1/2 and UL25 respectively, are involved in capsid 
docking to the nuclear pores (Copeland et al., 2009; Ojala et al., 2000; Pasdeloup et al., 2009; Rode et 
al., 2011). It was, therefore, suggested that VP1/2 and UL25 are involved in docking at the nuclear 
pores via their interaction with Nup358/RanBP2 and Nup214/CAN proteins. 
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Even though there is consensus among researchers that the transport of virus particles occurs 
through the cellular microtubule network, what happens to the tegument proteins during this process 
is unclear. Past research findings suggest that the phosphorylation of HSV-1 tegument proteins 
VP13/14 and VP22, by casein kinase II and protein kinase UL13 respectively, upon entry supports 
their disassociation from the capsid, whereas VP1/2 and VP16 remain associated with the viral capsid 
(Morrison et al., 1998).  However, it was also proposed that VP16 was transported to the nucleus 
independently to the capsid (Batterson & Roizman, 1983; Post et al., 1981). In a more recent PRV 
study, using immunoelectron microscopy, it was demonstrated that VP1/2, UL37 and US3 proteins 
remained associated with the capsid after penetration of the cytoplasm (Granzow et al., 2005). In 
contract, UL11, UL46, VP13/14, VP16 and VP22 were lost after penetration, since no specific 
labelling was observed of any of these proteins on capsids after entry (Granzow et al., 2005). 
Therefore, at least a portion of the tegument remains attached to the membrane following viral entry 
(Maurer et al., 2008). 
1.3.2 Gene expression, genome replication and capsid assembly 
Following nuclear entry, any VP16 that disassociated from the capsid, in coordination with 
the cellular proteins Oct-1 and HCF-1 initiates transcription of the five viral immediate-early (IE) 
genes, ICP0, ICP4, ICP22, ICP27, and US1.5, by binding to specific promoter elements (Narayanam 
et al., 2005). In turn, the expression of the IE genes transactivates the early genes that mainly encode 
enzymes involved in viral DNA synthesis and replication. The late genes, which encode structural 
proteins and are involved in virus assembly, maturation, and egress, are transactivated by the IE 
proteins after the onset of DNA replication (Holland et al., 1980; Honess & Roizman, 1974; 
Mavromara-Nazos & Roizman, 1987). These late gene products can be segregated into ‘leaky’ or 
‘true’ late proteins based on their requirement for genome replication (Godowski & Knipe 1986; 
Knipe et al. 2007). 
Viral DNA molecules are produced via a rolling circle mechanism, which is facilitated by 
viral and host factors, and accumulate in domains that fill the nucleus. The cellular chromatin then 
becomes condensed and is marginalised at the periphery of the nucleus (Boehmer & Lehman, 1997). 
The autocatalytic formation of the capsids in the nucleus and the encapsidation of the viral genome 
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occur with the help of scaffolding proteins. These nucleocapsids are thought to obtain their primary 
envelope by budding at the inner nuclear membrane (INM) with the involvement of membrane 
proteins UL31, UL34, which form a complex, and Us3 (Mettenleiter et al., 2006; Mettenleiter, 2006; 
Reynolds et al., 2001; Reynolds et al., 2002). The viral kinase protein Us3 is thought to regulate the 
localisation of the UL31/UL34 complex within the INM, since, when Us3 is absent, the complex is 
mislocalised at the nuclear rim from a smooth pattern to discrete foci that accumulate adjacent to 
nuclear membrane ruptures (Kato et al., 2006; Klupp et al., 2001; Reynolds et al., 2002). In addition, 
viruses unable to express UL31 or UL34 produced low virus yield and capsids failed to bud through 
the INM, whereas onset virus production was delayed when Us3 was deleted (Chang et al., 1997; 
Mou et al., 2007; Reynolds et al., 2001; Roller et al., 2000; Ryckman & Roller, 2003). However, only 
Us3 has been detected in purified virions (Zhang et al., 1990), whereas UL31 and UL34 are thought to 
remain in the outer nuclear membrane during virion assembly, since they were not detected in 
cytoplasmic particles by immunoelectron microscopy (Fuchs et al., 2002; Reynolds et al., 2002). 
1.3.3 Virus assembly and egress 
The final steps of HSV-1 assembly remain controversial with a number of proposed potential 
routes for the mature virion to exit the cell. Initially it was proposed that particles formed during 
budding at the inner nuclear membrane and that maturation occurred within the lumen of the secretory 
pathway (Darlington & Moss, 1968; Schwartz & Roizman, 1969). Another study suggested that 
nucleocapsids exited directly into the cytoplasm via damaged nuclear pores before the addition of 
tegument in the cytoplasm and envelopment at the Golgi, although this is not widely accepted as 
demonstrated by Hofemeister and O’Hare (Hofemeister & O’Hare, 2008; Leuzinger et al., 2005). 
 The most commonly accepted model of HSV-1 assembly and egress, known as the 
envelopment-deenvelopment-reenvelopment model, suggests that nucleocapsids are shuttled to the 
cytoplasm via a budding-fusion event that occurs across the inner and outer membranes of the nucleus, 
respectively. In addition, this model has gained support from a wide range of biochemical, genetic and 
ultra-structural studies. According to this model, the primary envelope obtained from the inner nuclear 
membrane would be lost by fusion with the outer nuclear membrane, with final envelopment taking 
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place at a stage further downstream in the secretory pathway (Gross et al. 2003; Mettenleiter 2002; 
Naldinho-Souto et al. 2006; Skepper et al. 2001; Stackpole 1969). This model is still not broadly 
accepted as the exact location of final envelopment in the cellular secretory pathway and the exact 
mechanism for virion envelopment remains unclear. A number of studies have implicated the 
multivesicular body (MVB) components as the final envelopment site (Calistri et al., 2007; Crump et 
al., 2007; Pawliczek & Crump, 2009), however the trans-Golgi network (TGN) is commonly cited as 
the site for final virion maturation (Johnson & Baines, 2011).  
A recent publication from our group suggests that HSV-1 acquires its envelope from endocytic 
tubules containing glycoproteins derived from the plasma membrane, and not the TGN or other 
membranes from the secretory pathway (Hollinshead et al., 2012) (Fig. 1.2). The results of this study 
proposed that these membranes could wrap capsids within 2 minutes after endocytosis. This was 
revealed with the use of horseradish peroxidise (HRP), a fluid phase marker, with which the cells were 
incubated. Also, treatment to inhibit the endocytic pathway with dynasore, which acts as a potent 
inhibitor of endocytic pathways known to depend on dynamin by rapidly blocking coated vesicle 
formation within seconds of its addition, resulted in retention of envelope glycoproteins at the cell 
surface and inhibition of capsid wrapping. The same result occurred when Rab5, a cellular protein that 
regulates endocytosis, was depleted (Hollinshead et al., 2012). In addition, it was demonstrated that 
viral glycoproteins were retrieved from the plasma membrane to label wrapping capsids in a dynamin 
and Rab5 dependent process. When both Rab5 and Rab 11 were depleted it resulted in reduction of 
virus yield to less than 1% and an abnormal localisation of the capsids (Hollinshead et al., 2012). 
The molecular mechanisms that are responsible for the addition of tegument proteins to the 
nucleocapsid remain poorly understood. Tegumentation could occur  at various stages during the 
egress pathway: in the nucleus; at the nuclear membrane; or in the cytoplasm (Mettenleiter 2002). 
Understanding the process of tegumentation is vital, because evidence indicates that tegument 
proteins, probably together with certain viral glycoproteins, contain all the functionality required for 
budding at the site of final envelopment (McLauchlan & Rixon, 1992; Rixon et al., 1992; Szilágyi & 
Cunningham, 1991). Several lines of evidence suggest that the cytosolic domain of the envelope  
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Figure 1.2: Model of virus envelopment via endocytosis. (1) Virus glycoproteins are processed in the 
Golgi/TGN and exported to the cell surface. (2) The plasma membrane, which contains the 
glycoproteins, is endocytosed and transported through the early endosome to create wrapping tubules 
in a pathway dependent on dynamin, and Rab5 and 11. (3) Tubules, containing the glycoproteins, 
wrap cytoplasmic capsids forming virions with a double membrane. Fusion of the outer membrane at 
the cells surface results with a single-membrane virion being released outside the cell. EE, EEA1-
positive early endosome; ER, endoplasmic reticulum; GA, Golgi apparatus; PM, plasma membrane, 
TGN, trans-Golgi network (Hollinshead et al., 2012). 
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glycoproteins may provide a platform for tegument assembly and the recruitment of capsids followed 
by envelopment (Mettenleiter 2002). 
 
1.4 The tegument proteins 
The tegument is comprised of a complex repertoire of at least 23 proteins both essential and 
non-essential components, which have different functions and roles during infections (Loret et al. 
2008; Mettenleiter 2002). One of the essential tegument proteins is VP1/2, encoded by the UL36 gene 
and both necessary for virus replication and conserved across the family Herpesviridae (Knipe et al., 
1981; Lee et al., 2006). VP1/2 is synthesised late during infection and although it is a large protein of 
3164 amino acids, it has a relatively low abundance of between 60 and 120 copies per virion (Heine et 
al., 1974; McNabb & Courtney, 1992). It is considered as inner tegument protein due to its association 
with the nucleoplasmid and participation in its transport to the nucleus by the microtubule/dynein 
motor system (Roberts et al., 2009; Shanda & Wilson, 2008; Sodeik et al., 1997). VP1-2 localises to 
both the cytoplasm and the nucleus of infected cells (Abaitua & O’Hare, 2008; McNabb & Courtney, 
1992). In HSV-1 and PRV, deletion of VP1/2 resulted in accumulation of numerous cytosolic DNA-
containing capsids that did not reach full maturation as enveloped virus (Fuchs et al., 2004; Roberts et 
al., 2009). Furthermore, VP1/2 is required for nuclear targeting of capsids to nuclear pores and for the 
release of the viral genome into the nucleoplasm for transcription and replication (Abaitua et al., 
2012; Batterson & Roizman, 1983; Copeland et al., 2009; Roberts et al., 2009). VP1/2 interacts with 
another essential inner tegument protein, UL37 (Klupp et al., 2002; Vittone et al., 2005). This protein 
is also conserved among the Herpesviridae. In the absence of UL37 in PRV (Klupp et al., 2001) and 
HSV-1 (Desai, 2000), secondary envelopment is impaired, and aggregates of nucleocapsids are 
formed in the cytosol, suggesting that pUL37 is added early during tegumentation and is required for 
efficient addition of other tegument proteins (Mettenleiter 2002; Mettenleiter et al. 2006). There are 
numerous functions of different essential and non –essential tegument proteins that could be 
mentioned; however those proteins most relevant to this thesis are addressed in more detail below. 
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1.4.1 Function and role of VP22 
The tegument protein VP22 is a major component of the HSV-1 virion. This protein is 
encoded by the UL49 gene and is a highly basic, 38 kDa protein (301 aa) with an estimated 2000 
copies of the protein packaged per virion (Elliott & Meredith, 1992; Heine et al., 1974; Leslie et al., 
1996). Also, VP22 is conserved among alphaherpesviruses and while it is dispensable for HSV-1 in 
vitro growth and PRV replication in vitro and in vivo, it is important for in vivo virulence of the 
related BHV-1 (del Rio et al., 2002; Elliott et al., 2005; Liang et al., 1997). In addition, the VP22 
homologues of the alphaherpesviruses VZV and MDV are absolutely required for virus replication 
(Dorange et al., 2002; Tischer et al., 2007).  A cell type-specific growth defect has been reported 
when using an HSV-1 VP22 deletion mutant in epithelial cells, and it has been suggested that VP22 
facilitates efficient cell-to-cell spread in vivo and in tissue culture at low multiplicities of infection 
(Duffy et al., 2006).  
The known functions of VP22 map to the C-terminal half of the protein, even though N-
terminal sequences contribute to VP22 multimerisation (Hafezi et al., 2005; O’Hare et al., 2002; 
Mouzakitis et al., 2005) (Fig. 1.3). It is also nucelotidylylated by casein kinase II (CK II) and contains 
six serine phosphorylation sites targeted by UL13 and the cellular kinases CK II and protein kinase C 
(Blaho et al., 1994; Coulter et al., 1993; Elliott et al., 1999). Although the non-phosphorylated VP22 
is present in the virus particle, the phosphorylated form dominates in infected and transfected cells; 
the packaging of VP22 in HSV-1 is not entirely controlled by phosphorylation (Elliott et al., 1996; 
Knopf & Kaerner, 1980; Morrison et al., 1998; Potel & Elliott, 2005).  The conserved region in VP22 
among homologues of HSV-1, BHV-1, EHV-1, VZV and MDV is essential and sufficient for VP22 
packaging (Hafezi et al., 2005; Mouzakitis et al., 2005; O’Regan, Bucks, Murphy, Wills, & Courtney, 
2007). The same region is the interaction domain of VP22 with VP16 and gE (Hafezi et al., 2005; 
Mouzakitis et al., 2005; O’Regan, Bucks, et al., 2007). While it has been suggested that VP16 and/or 
gE could recruit VP22 into the virion, other studies concluded that neither of these proteins 
individually, or jointly, were required for VP22 assembly (Elliott et al. 1995; Hafezi et al. 2005; 
O’Regan, Murphy, et al. 2007; O’Regan et al. 2010). Furthermore, it was shown that the absence of 
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VP22 from infected cells had no effect on the packaging of VP16 into the virus particles, suggesting 
that VP22 is not involved in VP16 recruitment (Elliott et al., 2005). 
Experiments with a virus expressing green fluorescent protein (GFP)-tagged VP22 have 
shown that VP22 is predominantly located in the cytoplasm throughout infection and localises to 
rapidly moving trafficking complexes (Elliott & O’Hare, 1999). In addition, it has been demonstrated 
by our group, that the same region of VP22 which is essential to target the protein to its characteristic 
cytoplasmic trafficking complexes was also required for virion packaging (Hafezi et al., 2005). 
Moreover, one study has suggested that the localisation of the phosphorylated form of VP22 is mainly 
nuclear whereas the nonphosphorylated VP22 is cytoplasmic during infection; although in a later 
study by our group no difference in VP22 localisation in the nucleus was noticed using recombinant 
viruses expressing a phosphorylation-deficient variant of VP22 or a constitutively charged VP22 
(Pomeranz & Blaho, 1999; Potel & Elliott, 2005).  
Transiently transfected VP22 appears to bind and bundle to microtubules, inducing their 
stabilisation and hyperacetylation to render them more resistant to depolymerisation (Elliott & 
O’Hare, 1998; Martin et al., 2002). The minimal microtubule-binding domain is located in residues 
108-212 of VP22; however, additional flanking regions have been suggested to assist optimal 
microtubule cross-linking (Fig. 1.3). It has also been shown that, when entering mitosis, VP22 
translocates from the cytoplasm to the nucleus where it efficiently binds to mitotic chromatin (Martin 
et al., 2002).  Moreover, VP22 was shown to function as a carrier of mRNA from infected to 
uninfected cells for expression prior to viral infection (Sciortino et al., 2002). 
The exact role of VP22 is difficult to define since some VP22-null viruses carry mutations in 
the virion host shutoff protein (vhs), which is encoded by the UL41 gene (Sciortino et al., 2007). 
Studies of VP22 knockout mutants of strain F generated in a bacterial artificial chromosome (BAC) 
system showed that Δ22 viruses were only viable after obtaining spontaneous secondary mutations in 
the UL41 gene, confirming an important relationship between these two proteins (Mbong, Woodley, 
Dunkerley, et al., 2012; Sciortino et al., 2007). Sciortino and colleagues concluded that expression of 
the vhs protein in the absence of VP22 protein is lethal (Sciortino et al., 2007). It should be noted that 
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in contrast to the observations of Sciortino and colleagues, the Δ22 virus generated in our lab by 
homologous recombination, and which was used as a control in the studies analysed in this thesis, 
maintained a wild type vhs gene and had no obvious additional secondary mutations (Ebert et al., 
2013).  
1.4.2 VP13/14 function 
Proteins VP13 and VP14 are encoded by the UL47 gene with an apparent size of 72 and 74 
KDa respectively and are collectively referred to as VP13/14 (Donnelly & Elliott, 2001b; Heine et al., 
1974). Even though both proteins are thought to have an identical amino acid sequence, they are 
modified differently by post-translational modifications (Halliburton & Whittaker, 1991). The major 
product of the UL47 gene when transiently expressed is VP14, suggesting that some element of virus 
infection is required in order to produce VP13 (Donnelly & Elliott, 2001b). VP13/14 is 
phosphorylated and glycosylated in infected cells but was not found to be phosphorylated in 
preparations of purified virus (Meredith et al., 1991). Additionally, it is a major structural component 
of HSV-1 with approximately 1,800 copies in the virion tegument, however little is known about its 
role during virus infection (Heine et al., 1974). Some evidence suggests that it may be involved in 
modulating the activity of the tegument protein VP16, the trans-activator of immediate early gene 
expression. It was shown that co-expression of the VP13/14 expressing gene with the gene for VP16 
during transient transfection modulates the ability of VP16 to activate IE promoters (Zhang et al., 
1991). Moreover, viruses unable to express VP13/14 appear to be defective in the early stages of virus 
growth, supporting a potential role for the protein in gene expression or virus entry (Zhang & 
McKnight, 1993; Zhang et al., 1991). In addition, UL47 knockout viruses in PRV and MDV also 
replicate more slowly than wild-type viruses and display impaired secondary envelopment in PRV 
(Dorange et al., 2002; Kopp et al., 2002).  
Our group has previously characterised UL47 from HSV-1 as a nucleocytoplasmic shuttling 
protein that exhibits a steady-state nuclear localisation when expressed in isolation and during its 
early stages of expression in virus infection (Donnelly & Elliott, 2001a, 2001b). Localisation of GFP- 
labelled VP13/14 when transiently transfected, appeared to be diffuse throughout the nucleus in some  
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Figure 1.3: VP22 functional domains. VP22 schematic with a region conserved among the HSV-1, 
BHV-1, EHV-1, VZV and MDV VP22 homologues (grey), and serine phosphorylation sites located at 
residues 35, 71, 72, 73, 292 and 294 (triangles), is shown above (Mouzakitis et al., 2005; Potel & 
Elliott, 2005). Blue domains are involved in VP22 dimerisation, cell-to-cell spread and localisation to 
nuclear dots (Elliott & O’Hare, 1997; Hafezi et al., 2005; Mouzakitis et al., 2005; Nishikawa et al., 
2010). Orange domains mediate interactions with gE, VP16 and microtubules (Hafezi et al., 2005; 
Martin et al., 2002; O’Regan, Bucks, et al., 2007). 
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cells, whereas in other it was concentrated in either multiple speckles or even in larger punctuate 
domains (Donnelly & Elliott, 2001b). During infection YFP-expressing VP13/14 was initially seen 
diffuse in the nucleus and then progressed into intense punctuate domains as seen in transient 
transfection. Late in infection YFP-VP13/14 fluorescence was localised to the cell periphery and in 
extracellular virus particles, confirming that the protein is assembled in the virions (Donnelly & 
Elliott, 2001a). Furthermore Furthermore, studies by our group using fluorescence loss in 
photobleaching showed that nuclear VP13/14, and it’s bovine homologue VP8, undergo rapid 
nucleocytoplasmic shuttling (Verhagen et al., 2006; Williams et al., 2008). 
A non-classical arginine-rich nuclear localisation signal (NLS) has been identified by our 
group in the N terminus of VP13/14 (Fig. 1.4A). Although classical NLSs are usually basic with 
lysine-rich regions, VP13/14 is unusual in that as it contains three groups of four consecutive arginine 
residues towards the N-terminus of the protein (Donnelly & Elliott, 2001b; Görlich & Mattaj, 1996; 
Nigg, 1997). These arginine clusters are located at amino acid positions 9 to 12, 63 to 66, and 72 to 75 
and were identified as important for the nuclear targeting of VP13/14. It was shown that deletion of 
the last two arginine boxes within these 75 amino acids abolished nuclear targeting indicating that 
these arginine boxes were necessary to target VP13/14 to the nucleus (Donnelly et al., 2007). From 
the same study it was also proposed that the NLS of VP13/14 functions as an RNA binding domain 
(Fig. 1.4A). Also, the VP13/14 nuclear export signal (NES) was shown to be a C-terminal 10-residue 
hydrophobic peptide where several leucine-rich regions were identified.  These regions seem to share 
some homology with HIV-1 Rev and HSV-1 ICP27, which have been suggested to enhance the export 
of virus-encoded transcripts from the nucleus to the cytoplasm (Fischer et al., 1994; Phelan et al., 
1996; Sandri-Goldin, 1998). Although it was demonstrated that VP13/14 and VP8 undergo nuclear 
export in a similar way, the predominant NES in VP8 is located at the N-terminus and is resistant to 
Leptomycin B (LMB), whereas the VP13/14 NES is C-terminal located and sensitive to LMB, 
suggesting that it functions through the export receptor, chromatin region maintenance 1 (CRM1) 
(Verhagen, Hutchinson, et al., 2006; Williams et al., 2008).   
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1.4.3 Function and importance of VP16 
The abundant tegument protein VP16 (also known as Vmw65, ICP25, or α-TIF), which is 
encoded by the UL48 gene, is a 65 kDa phospho-protein with 1000 to 1500 copies per virion. The 490 
aa of VP16 can be divided into domains (Fig. 1.4B). The first domain consists of the N-terminal 410 
aa, which is targeted to the TAATGARATTC consensus sequence found in IE promoters through 
interactions with the host factors Oct-1 and HCF (Gerster & Roeder, 1988; Katan et al., 1990; O’Hare 
et al., 1988; Wilson et al., 1993; Xiao & Capone, 1990). The second domain is the C-terminal 80 aa of 
VP16, which contains the potent transcriptional activation domain of VP16. The activation domain is 
also divided into two subregions, spanning 411-456 (H1 or VP16N) and 450-490 (H2 or VP16C), 
each of which can function to activate expression of target genes (Greaves and O’Hare 1989; 
Sadowski et al. 1988; Tal-Singer et al. 1999; Triezenberg et al., 1988). The transcriptional activation 
function of VP16, when inactivated by mutations, results in reduced levels of IE gene expression 
during low-multiplicity infections and a greatly increased particle-to-pfu ratio (Ace et al., 1989; 
Smiley & Duncan, 1997; Tal-Singer et al., 1999). 
VP16 is a multifunctional protein involved in transcriptional regulation of viral immediate 
early genes, the modulation and down-regulation of the virion host shutoff activity and secondary 
envelopment and egress (Campbell et al., 1984; Mossman et al., 2000; O’Hare & Goding, 1988; 
Smibert et al., 1994). Recently, de novo synthesis of VP16 in neurons has also been shown to 
coordinate the expression of viral IE genes, resulting in reactivation from latency (Thompson et al., 
2009). While VP16 functions in the very early stages of virus infection, most VP16 is synthesised late 
in infection at a time when activation of IE genes no longer occurs. More importantly it was 
demonstrated that VP16 also plays a key role in the tegumentation and egress of HSV-1 and the 
related Alphaherpesvirinae subfamily members EHV-1 and PRV because when deleted, secondary 
envelopment is blocked in the cytoplasm; although it proved to be dispensable for replication of VZV 
and MDV (Cohen & Seidel, 1994; Dorange et al., 2002; Fuchs, Klupp et al., 2002; Mossman et al., 
2000; von Einem et al., 2006). Infection with a PRV UL48 deletion mutant revealed retention of 
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newly formed non-enveloped cytoplasmic nucleocapsids and a great amount of released capsidless 
particles (Fuchs, Granzow et al., 2002).  
La Boissière and colleagues constructed a recombinant virus expressing VP16 linked to the 
green fluorescent protein (GFP) in order to gain further insight into the compartmentalisation of this 
multifunctional protein. They observed that VP16 was equally distributed between the nucleus and the 
cytoplasm (La Boissière et al., 2004). Evidence derived from transmission immunoelectron 
microscopy (TIEM) studies suggests that during viral assembly, detectable amounts of VP16 are 
added to the capsid in the nucleus, with additional VP16 added as the nucleocapsid moves through the 
cytoplasm, prior to final envelopment (Miranda-Saksena et al., 2002; Naldinho-Souto et al., 2006).  
1.4.4 vhs 
The HSV-1 UL41 gene encodes vhs that is carried by the virion into the infected cell and 
causes the shutoff of host protein synthesis (Kwong & Frenkel, 1987, 1989; Kwong et al., 1988; 
Strom & Frenkel, 1987). The UL41 gene is a late gene and expresses two forms of the protein, the 
major 58 kDa polypeptide and a highly phosphorylated 59.5 kDa polypeptide (Read et al., 1993). It is 
a 489 amino acid phosphoprotein and endoribonuclease that degrades both cellular and viral mRNA 
(Kwong & Frenkel, 1987; Oroskar & Read, 1989). vhs association with mRNAs is through 
interactions with the translation initiation factors eIF4AII, eIF4H, and eIF4B, demonstrating that vhs 
is targeted to actively translating mRNAs (Doepker et al., 2004; Feng et al., 2005). Furthermore, 
Strom and Frenkel showed that the vhs protein was involved in the degradation of mRNAs transcribed 
prior to and during infection, including the housekeeping genes β-actin and α-tubulin, which were 
persistently present in the cells, and the heat shock protein 70 (HSP70), induced post infection in the 
presence of actinomycin D (Strom & Frenkel, 1987). 
Later in infection, the nuclease activity of newly synthesised vhs appears to be suppressed by 
the viral proteins VP16 and VP22 (Knez et al., 2003; Lam et al. 1996; Sciortino et al. 2007; Smibert et 
al. 1994; Taddeo et al. 2007). The down-regulation of vhs by VP16 was first demonstrated with the 
use of VP16-null virus, which displayed unrestrained vhs activity, and resulted in enhanced host and 
viral mRNA degradation and failure to synthesise viral proteins at intermediate and late times during 
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Figure 1.4: Line drawings of VP13/14 and VP16. (A) Schematic of VP13/14 with arginine clusters 
represented by black boxes at amino acid positions 9 to 12, 63 to 66, and 72 to 75. The NLS domain 
(50 to 75 aa) is highlighted in green, the RNA binding domain (50 to 76 aa) in pink and NES domain 
(647 to 670 aa) in purple (Donnelly et al., 2007; Verhagen, Donnelly et al., 2006; Williams et al., 
2008). (B) Diagrammatic representation of VP16, its activation domain (410 to 490 aa) (AD - grey 
box) and the interaction domain with VP22 (454 to 490 aa) (blue box) (Greaves & O’Hare 1989; 
Elliott et al. 1995; Triezenberg, Kingsbury, et al. 1988). 
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infection. Whereas, a VP16 mutant that lacks functional vhs did not display the severe inhibition of 
viral protein synthesis and mRNA decline that was observed with the VP16-null virus (Lam et al., 
1996). In another study it was demonstrated that both VP16 and VP22 were required for rescue of a 
reporter gene, and the accumulation of vhs in transiently transfected cells when co-transfected with 
vhs (Taddeo et al., 2007). The same group, in a more recent report, demonstrated that VP13/14 
regulates vhs activity in addition to VP16 and VP22 (Shu et al., 2013). Shu and co-workers 
demonstrated that VP13/14 attenuated the degradation of stable host and viral immediate early 
mRNAs and efficiently blocked the degradation of early and late mRNAs but had no obvious effect 
on the stability of adenylate-uridylate (AU)-rich mRNAs (Shu et al., 2013). VP13/14 is thought to 
attenuate vhs activity together with their interacting partner ICP27 in polyribosomes once the virus is 
entered into the cell (Dobrikova et al., 2010; Shu et al., 2013; Taddeo et al., 2010). 
1.4.5 Functions of UL11, UL16 and UL21  
The tegument proteins UL11, UL16 and UL21 have been shown to interact with the 
cytoplamic tail of gE (Farnsworth et al., 2007; Yeh et al., 2011), which VP22 also binds (O’Regan, 
Bucks, et al., 2007; Stylianou et al., 2009). Therefore these tegument proteins present potential 
interacting partners of VP22. Relevant to this report are the following. 
One of the smallest HSV-1 tegument components is the lipid modified, 96 aa protein, UL11. 
Even though the specific functions of UL11 are still unknown, it is thought to play a role in 
nucleocapsid envelopment and egress (Baines & Roizman, 1992). It is conserved among all 
herpesviruses and contains amino acid motifs that allow covalent modifications with two fatty acids, 
myristate and palmitate (Baines et al., 1995; Loomis et al., 2001;  MacLean et al., 1989). These 
modifications are required for the accumulation of UL11 on Golgi-derived membranes (Bowzard et 
al., 2000; Loomis et al., 2001). 
UL16 is a 373 aa late tegument protein that is needed for efficient envelopment and is 
conserved among all herpesviruses (Guo et al., 2009; Meckes & Wills, 2007; Mettenleiter, 2004; 
Nalwanga et al., 1996; Wing et al., 1996). Although UL16-null viruses are viable, there is a 10-fold 
reduction in virus titres (Baines & Roizman, 1991). This capsid-associated protein accumulates 
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initially in the nucleus and, at later times of infection, is found in the cytoplasm (Meckes & Wills, 
2007; Nalwanga et al., 1996). In addition, Meckes and Wills demonstrated that 87% of UL16 was not 
capsid associated once the envelope was removed from extracellular virions, but became associated 
once virions were exposed to mildly acidic pH (Meckes & Wills, 2007).  
Another capsid-associated tegument protein is the 535 aa protein, UL21. In the literature 
UL21 has been reported to be conserved throughout the Herpesviridae, however a recent analysis by 
Le Sage and colleagues indicated that this protein is conserved only among members of the 
Alphaherpesvirinae subfamily (Hatama et al., 1999; Le Sage et al., 2013; Telford et al., 1992). 
Viruses lacking UL21 gene are still competent to replicate, although they demonstrate a delay in the 
transcription of immediate early genes and in the production of infectious virus (Baines et al., 1994; 
Mbong et al., 2012). In PRV, differences exist depending from which strain UL21 is deleted; in NIA-
3 strain deletion of UL21 caused poor virus growth and defective capsid maturation in contrast to 
Kaplan strain which exhibits no defects (de Wind et al., 1992; Klupp et al., 2005).   
 
1.5 Viral glycoproteins in HSV-1 replication 
Viral glycoproteins are not only involved in virus entry, but are also thought to assist during 
secondary envelopment via interactions with outer teguments proteins (Mettenleiter 2002; 
Mettenleiter 2006; Mettenleiter et al. 2009). These interactions are discussed in section 1.6.2. Whilst 
some glycoproteins have homologs in all three subfamilies of herpesviruses, like gH and gL, others do 
not; gD for example is unique to the Alphaherpesvirinae (Browne et al., 1993; Gompels, Craxton, & 
Honess, 1988; Shukla & Spear, 2001).  Additionally, some of these glycoproteins have been found to 
exist as hetero-oligomers like the gH/gL complex, or as heterodimers like gE/gI (Hutchinson et al., 
1992; Johnson & Feenstra, 1987). The glycoproteins that are related to this thesis are addressed 
below.   
1.5.1 Functions of glycoprotein E 
The glycoprotein E, encoded by the US8 gene, is a phosphorylated 552 aa protein and together 
with its heterodimeric partner, gI that is encoded by the US7 gene, functions as a receptor for the Fc 
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portion of immunoglobulin G (IgG) (Baucke & Spear, 1979; Bellge et al., 1990; Johnson et al., 1988). 
While the gE/gI complex is a virion component, it does not contribute to HSV-1 attachment and entry 
(Dingwell et al., 1994; Dingwell et al., 1995; Loret et al., 2008). Moreover, gE is required for efficient 
lateral spread of HSV, which has been well documented by numerous studies (Dingwell et al., 1994, 
1995; Saldanha et al., 2000). As a result, viruses lacking gE are attenuated and display noticeably 
reduced cell-to-cell spread in epithelial and neuronal tissues both in vitro and in vivo (Dingwell & 
Johnson, 1998; Dingwell et al., 1994, 1995; McGraw, Awasthi et al., 2009; McGraw & Friedman, 
2009). Mutant viruses lacking the gE tail act identically to the gE deletion mutant, producing small 
plaques and being defective in cell-to-cell spread, suggesting that the gE cytoplasmic tail is a driving 
force for gE-mediated lateral spread (Farnsworth et al., 2007). Moreover, mutants lacking gE/gD or 
gE/gM in HSV and gE/gM in PRV accumulate large aggregates of unenveloped capsids in the 
cytoplasm (Brack et al., 2000; Farnsworth et al., 2003; Kopp, Granzow et al., 2004; Maringer et al., 
2012). Furthermore, the tyrosine motifs in gE have been shown to interact with the clathrin adaptor 
proteins AP-1 and AP-2 (Alconada, Bauer, Sodeik, & Hoflack, 1999; Fölsch, Ohno, Bonifacino, & 
Mellman, 1999; Olson & Grose, 1997). In addition, the gE-gI complex forms an Fc receptor that 
binds and blocks immunoglobulin G, preventing immune clearance of infected cells by antibody-
dependent cellular cytotoxicity (Bell et al., 1990; Dubin et al., 1991; Frank & Friedman, 1989; 
Johnson & Feenstra, 1987; Johnson et al., 1988). 
1.5.2 Glycoprotein M 
The UL10 gene codes for a glycoprotein of 473 amino acids referred to as gM, which is 
conserved across the Herpesviridae family (Crump et al., 2004; Fuchs, Klupp, et al., 2002). This N-
glycosylated viral type III membrane protein, predicted to contain eight transmembrane domains, is 
expressed as a precursor of 47 kDa, modified with high mannose-type oligosaccharides to yield a 50 
kDa molecule, and finally processed into a 53 to 63 kDa mature protein (Baines & Roizman, 1993; C 
A MacLean, Robertson, & Jamieson, 1993). HSV-1 gM is not essential in cell culture but is 
conserved throughout the herpesvirus family (Montague & Hutchison, 2000). In several 
herpesviruses, gM has been shown to form a disulphide bond and/or noncovalent linked heterodimer 
with glycoprotein N (gN), although an interaction between HSV-1 gM and gN has yet not been 
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proven. In most herpesviruses the UL49.5 gene product is glycosylated and is called gN, except for 
the nonglycosylated homologues of HSV-1, BHV-1 and EHV-1 that are referred to as UL49A (Jöns et 
al., 1998; Koyano et al., 2003; Lake et al., 1998; Liang et al., 1996; Mach et al., 2000; Rudolph et al., 
2002; Wu et al., 1998). Deletion of gM results in reduction in viral titres by 10- to 100-fold in various 
herpesviruses, including HSV-1 (Baines & Roizman, 1991; Dijkstra et al., 1996; Leege et al., 2009; 
Maringer et al., 2012). Interestingly, a synergistic reduction of viral yields occurs when gM is 
depleted in combination with UL11 or gE/gI in the related PRV, as it did for HSV-1 according to a 
recent publication from our group (Brack et al., 1999; Leege et al., 2009; Maringer et al., 2012). The 
accumulation of unenveloped capsids in the cytosol in these mutants indicates that gM may play a 
role during secondary envelopment of the virus. Furthermore, gM prevents syncytium formation 
mediated by gB, gD, and gH/gL and has also been reported to have a role during PRV cell entry 
(Dijkstra et al. 1996; Klupp et al., 2000; Koyano et al. 2003;Turner et al. 1998). The HSV-1 gM 
glycoprotein functionally interacts with multiple viral proteins. For instance, gM redirects gD and 
gH/gL from the plasma membrane to the TGN in transfected cells (Crump et al., 2004). In a later 
report it was demonstrated that gM mediates the internalisation of gH/gL from the plasma membrane 
of infected cells and incorporation of this complex into mature virions (Ren et al., 2012). 
 
1.6 Protein-protein interactions 
Up to 23 viral tegument constituents have been identified to date, but only a few of these 
proteins, in particular VP22, VP16 and VP13/14, are packaged in high abundance (Heine et al., 1974; 
Loret et al., 2008).  The incorporation of tegument proteins into the virion is thought to occur in an 
orderly but multistage process via numerous tegument-capsid, tegument-tegument, and tegument-
envelope interactions throughout the virus assembly process (Johnson & Baines, 2011; Kelly et al., 
2009; Mettenleiter et al., 2009). Although large-scale studies have been carried out using yeast two-
hybrid analysis of herpesvirus protein interactions, only a few of the identified interactions have been 
validated in infected cells (Fossum et al. 2009; Lee et al. 2008; Vittone et al. 2005). However, the 
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contribution these interactions make to tegument assembly and virus morphogenesis of HSV-1 has yet 
to be proven. In Figure 1.5 the protein interactions identified in infected cells are illustrated. 
This thesis focuses on the validation and identification of novel interaction partners involving 
VP22, VP16 and VP13/14 during infection. 
1.6.1 Capsid-tegument and tegument-tegument interactions 
The tegument proteins can be divided into inner and outer layers based on whether proteins 
are intimately associated with capsid surfaces (Wolfstein et al., 2006). The largest tegument protein 
VP1/2, which is encoded by the UL36 gene, is considered to be one of the first tegument proteins to 
associate with capsids. This is because VP1/2 remains associated with capsids from purified virions 
after detergent/solubilisation extraction that removed other tegument proteins and also has been 
demonstrated to co-immunoprecipitate with the major capsid protein VP5 (McNabb & Courtney, 
1992; Spear & Roizman, 1972). In more recent reports, VP1/2 was shown to directly interact with 
another major capsid protein, UL25, in HSV-1, PRV and VZV (Coller et al., 2007; Uetz et al., 2006). 
In addition, VP16 and UL37 were shown to interact with UL25, although this interaction is thought to 
occur through their direct binding partner, VP1/2 (Bucks et al., 2011; Bucks, O’Regan et al., 2007; Ko 
et al., 2010; Lee et al., 2008; Vittone et al., 2005). Another tegument protein found to interact with a 
capsid protein was VP13/14, which bound to the capsid protein encoded by UL17 (Scholtes et al., 
2010). These proteins were shown to co-immunoprecipitate in the presence and absence of intact 
capsids and also co-localise at later times post-infection. Moreover, data from other studies have 
revealed that the tegument protein UL16 is associated with capsids isolated from the cytoplasm but 
not those from the nucleus of infected cells, through its interaction with VP5 (Meckes & Wills, 2007). 
The two essential tegument proteins, VP16 and VP1/2 as mentioned previously, have been 
shown to interact and it has been proposed that VP1/2 recruits VP16 into the virion (Ko et al., 2010; 
Svobodova, Bell, & Crump, 2012; Vittone et al., 2005). Svobodova and colleagues demonstrated that 
the substitution of lysine 343 in VP16 with alanine abrogated the interaction of VP1/2 with VP16. 
However, VP16 was still packaged into the virion suggesting that VP16 is recruited to the virion via 
an additional route (Svobodova et al., 2012).  Moreover, VP1/2 was shown to interact directly with 
UL37 in a number of alphaherpesviruses including HSV-1, PRV and VZV (Vittone et al. 2005; Klupp 
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et al. 2002; Uetz et al. 2006). In the case of HSV-1, the 512-767 residues of VP1/2 contained the 
minimal binding region for UL37, while the residues within the carboxy-terminal of UL37 (568-1123 
residues) were important for the interaction with VP1/2 (Bucks et al., 2011; Vittone et al., 2005). 
One well-documented tegument-tegument interaction is between VP22 and VP16 (Elliott et 
al. 1995; Hafezi et al. 2005; O’Regan, Murphy, et al. 2007). Elliott and colleagues were the first to 
show that VP16 directly interacts via its C-terminal activation domain with VP22; in other studies the 
C-terminal of VP22 was sufficient for binding to VP16 (Elliott et al. 1995; Hafezi et al. 2005; 
O’Regan, Murphy, et al. 2007).  When these proteins were co-expressed transiently, their localisation 
dramatically altered. In the presence of VP16, VP22 was reorganised into a spherical structure within 
the cytoplasm at the edge of the nucleus from the very distinctive perinuclear localisation. Whereas, a 
proportion of VP16 was present in this structure, remaining in a diffuse pattern within the cytoplasm 
as well (Elliott et al. 1995).  Another binding, although not direct, partner of VP22 is ICP0, whose 
assembly into the virus particle is dependent on VP22 (Elliott et al. 2005; Maringer and Elliott 2010). 
Furthermore, these two proteins localise at the same cytoplasmic sites during HSV infection. 
However, ICP0 localisation changes in the absence of VP22, as it was found to be mainly diffuse in 
the cytoplasm throughout infection (Elliott et al., 2005). 
A yeast-two-hybrid study showed an interaction between VP13/14 and VP16, which was later 
confirmed by co-immunopreciptation and GST studies (Donnelly et al., 2007; Stylianou et al., 2009; 
Vittone et al., 2005). One of the objectives of this thesis was to characterise this relationship, as it has 
not yet been studied. Furthermore, VP13/14 interacts directly with ICP27, which is another RNA-
binding and nucleo-cytoplasmic protein (Dobrikova et al., 2010; Mears & Rice, 1996; Sandri-Goldin, 
1998). Interestingly, VP13/14 and ICP27 also share an interacting partner, vhs (Shu et al., 2013; 
Taddeo et al., 2010). This potential complex is proposed to interfere with the decapping of the mRNA 
and consequently the degradation of specific mRNAs.  
Interestingly, vhs interacts with two more tegument proteins, which were also shown to 
regulate its activity (Lam et al., 1996; Smibert et al., 1994; Taddeo et al., 2007). Vhs was first shown 
to directly interact with VP16 and this interaction has been mapped to residues 335 to 369 of VP16 
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and 310 to 330 of vhs (Schmelter et al., 1996). In a more recent report, VP16 was demonstrated to 
form a tripartite complex with VP22 and vhs in order to rescue mRNAs; it should be noted that VP22 
could interact with vhs only in the presence of VP16 (Taddeo et al., 2007). In the same report it was 
proposed that VP16 and VP22, through their interaction with vhs, rescue mRNA and make it available 
to the machinery of the cell for translation. Also, Taddeo and coworkers suggested that the main 
function of VP16 and VP22 in this tripartite complex was to enable the translation of the mRNA, 
rather than block the RNase activity (Taddeo et al., 2007).  
The capsid-associated tegument protein UL16 has been shown to interact with an acidic 
cluster in the first half of UL11, a membrane associated tegument protein (Loomis et al., 2003). The 
UL11-null mutants have revealed large defects in packaging of UL16, which is also needed for 
efficient virion production with null-mutants having an approximate 10-fold reduction in titre (Baines 
& Roizman, 1991; Baird et al., 2010; Meckes et al., 2010). In addition, UL21 was demonstrated to 
form a complex with UL11 through its direct binding to UL16 (Harper et al., 2010). The same group 
revealed that the second half of UL21 (residues 268-535) was sufficient for UL16 binding and 
packaging of UL21 into virions (Harper et al., 2010). 
A number of self-associations were identified using a yeast-two-hybrid study, which involved 
the tegument proteins US11, UL37, and VP22 (Vittone et al., 2005). The self-association of UL37 
was confirmed by co-immunoprecipitations studies, although only under conditions when VP1/2 was 
not present, or present only in low amounts, suggesting that these proteins compete for binding 
(Bucks et al., 2011; Lee et al., 2008). VP22 self-association was also confirmed as Mouzakitis and 
colleagues demonstrated its ability to oligomerise as a dimer and tetramer (Mouzakitis et al., 2005).  
1.6.2 Glycoprotein-tegument interaction 
While tegument proteins may recruit each other to the virus, it is also thought that 
glycoproteins may recruit at least outer tegument proteins via their cytoplasmic tails. Only recently 
two reports presented data demonstrating the requirement for glycoproteins to facilitate the packaging 
of tegument proteins into the HSV-1 virion (Han, Chadha, Meckes, Baird, & Wills, 2011; Maringer et 
al., 2012). The first report revealed that the absence of the cytoplasmic tail of gE resulted in the 
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reduction of UL11 packaging into virions by at least 80% (Han et al., 2011). While, the second report 
demonstrated that VP22, which binds to the cytoplasmic tails of gE and gM, was not packaged, and 
consequently neither was ICP0, into the virus particle when both gE and gM were deleted (Maringer 
et al., 2012; O’Regan et al., 2010; O’Regan, Bucks, et al., 2007; Stylianou et al., 2009). Although, 
simultaneous deletion of gE, its known binding partner gI, and gM was first shown in PRV to 
completely abrogate VP22 assembly into the virion (Fuchs, Klupp, et al., 2002). Likewise, it was first 
demonstrated in PRV the interaction of VP22 with gE and gM by a yeast two-hybrid assay (Fuchs, 
Klupp, et al., 2002). Furthermore, the gE binding domain, according to our GST-gE pull down and 
co-immunoprecipitation assays, was present within the C-terminus of VP22, confirming and refining 
the previously defined binding domain (O’Regan, Bucks, et al., 2007; Stylianou et al., 2009). When 
the residues between 213 and 226 of VP22 were deleted within the gE-binding domain, the interaction 
between VP22 and the cytoplasmic tails of gE and gM were abolished resulting in reduced VP22 
content in the virus particle (Stylianou et al., 2009). Also, when these 14 residues were deleted, VP22 
was localised diffusely in the cytoplasm, whereas full-length VP22 co-localised with gE in the Golgi 
region of the cell, suggesting that gE is the dominant partner in this relationship (Stylianou et al., 
2009). However, glycoprotein binding partner of VP22 was shown to be gD, as demonstrated by co-
immunoprecipitation and GST pull-down studies (Chi et al., 2005; Farnsworth et al., 2007). Although, 
after extensive attempts in various model systems, the reported interaction between VP22 and gD 
could not be verified within our group (Maringer et al., 2012; Stylianou et al., 2009). Moreover, VP22 
was shown to interact with another glycoprotein, US9, in a yeast two-hybrid assay; however this 
interaction has not been yet characterised (Lee et al., 2008). 
 Another tegument protein shown to directly interact with the cytoplasmic tail of gE was 
UL16 and it was demonstrated that the N-terminus of UL16 (1-55 residues) was sufficient for this 
interaction (Yeh et al., 2011). Interestingly, UL11, UL16 and UL21, via its interaction with UL16, 
formed a complex with gE through coordinated interactions (Han et al., 2012). Also, in the same 
report it was demonstrated that the interaction of these tegument proteins with the cytoplamic tail of 
gE was required for the efficient function of gE. Moreover, gE was shown to interact, during 
Chapter 1  General Introduction 
52 
 
 
 
 
 
Figure 1.5: Protein interactions identified in HSV-1 infected cells (Elliott et al. 1995; Dobrikova et 
al. 2010; Farnsworth et al. 2007; Han et al. 2011; Harper et al. 2010; Ko et al. 2010; Loomis et al. 
2003; Scholtes et al. 2010; Smibert et al. 1994; Stylianou et al. 2009; Yeh et al. 2011)  
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infection, with the protein kinase UL13, which mediates the phosphorylation of gE (Ng et al., 1998).   
Gross and colleagues showed that gH binds to the tegument protein VP16 by GST pull-down 
and co-immunoprecipitation studies, whereas gB and gD were able to chemically cross-link with the 
same tegument protein (Gross et al., 2003; Zhu & Courtney, 1994). Furthermore, in a yeast two-
hybrid study it was demonstrated an interaction between the cytoplasmic tail of gM and UL46, which 
requires further investigation (Lee et al., 2009).  
 
1.7 Aim and objectives 
The aim of the present study is to improve our understanding of the wider protein networks 
that may lead to the assembly of the HSV-1 tegument by defining the molecular interactions that 
occur between the three major tegument proteins VP22, VP16 and VP13/14 and their partners. The 
objectives of this study are to: 
1. Define the network of protein-protein interactions around these three major tegument proteins 
in infected cells  
2. Examine and characterise the relationship between VP22, VP13/14 and VP16 in infection and 
transient transfection; and to examine the nature of such interactions 
3. Analyse possible complexes formed between these tegument proteins with other tegument 
proteins or  glycoproteins 
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2.1 Tissue culture techniques 
2.1.1 Cell lines and medium 
Vero and COS-1, which are both African green monkey kidney fibroblasts, HFFF2 (Human 
Foetal Foreskin Fibroblasts), HeLa (Henrietta Lacks “immortal” human cervical cancer cells) and 
BHK-21 (Baby Hamster Kidney) cells were obtained from the European Collection of Cell Cultures 
(ECACC) (Health Protection Agency, Porton Down, UK). The human primary immortalised 
keratinocyte cell type HaCaT (Human adult low Calcium Temperature) was kindly provided by 
Professor Judith Breuer. Cells were grown in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 100 U/ml Penicillin and 100 µg/ml Streptomycin (1% pen/strep) at 37C in a 
Heraeus
®
 HERAcell 240 incubator (Thermo Fisher Scientific Inc., Waltham, MA USA) with a 
humidified 10% carbon dioxide atmosphere. All the media were supplemented with 10% newborn 
calf serum (NCS), except for the HFFF2 and HaCaT medium contained 10% heat-inactivated foetal 
bovine serum (FBS) (all reagents from Gibco-Invitrogen). Monolayer cultures were routinely grown 
in 225cm
2
 plastic tissue culture flasks and cells were generally split at 1 in 3 (HFFF2) or 1 in 10 
dilutions (all other cells) twice a week and used in experiments below passage 20. Cells were washed 
with trypsin –EDTA (Gibco-Invitrogen) and then detached with trypsin-EDTA at 37oC for a short 
while. After detachment, cells were loosened by hitting the flask and resuspended in medium by 
pipetting. The sf9 cell line (Spodoptera frugiperda pupal ovarian tissue cells) was grown in TC100X 
medium supplemented with 0.1% fungizone (Gibco–Invitrogen), 1% pen/strep and 10% FBS. Sf9 
cells were grown in solution in spinner flasks (Techne) on a stirrer at 27

C in a humidified incubator. 
They were split twice a week to a concentration of 4x10
5
 cells/ml. Tissue culture was performed in a 
BioMAT
2
 class II microbiological safety cabinet (Medical Air Technology, Oldham, UK) under 
biosafety level 2 containment.  
2.1.2 Freezing and reviving cell lines 
Low passage cell stocks were frozen in liquid nitrogen. Trypsinised cells were pelleted in 10 
ml tissue culture medium at 3,000 rpm for 5 min at 4˚C in a TX-750 swinging bucket rotor for the 
Heraeus
®
 Megafuge 40R centrifuge (both Thermo Fisher Scientific Inc.). Cell pellets were 
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resuspended at a density of 3 x 10
6
 cells/ml in Recovery
TM
 cell culture freezing medium (Invitrogen) 
and were then frozen at -80˚C in 1 ml aliquots using a 5100 Cryo 1˚C freezing container (Thermo 
Fisher Scientific Inc.) prior transfer to liquid nitrogen. To revive, cells were thawed at 37˚C and 
pelleted in 10 ml culture medium at 3,000 rpm for 5 min at 4˚C in a TX-750 swinging bucket rotor for 
the Heraeus
®
 Megafuge 40R centrifuge. Cells were resuspended in 10 ml culture medium and initially 
grown in 25 cm
2
 tissue culture flasks to 100% confluence before being transferred to 75 cm
2
 flasks. 
 
2.2 Plasmids and transfections 
2.2.1 QIAprep spin Maxi DNA purification kit 
Large-scale preparations of DNA were performed using the QIAGEN Plasmid Maxi kit 
(Qiagen, Hilden, Germany) following the manufacturer’s protocol and buffers provided in the kit. 
Typically, 0.5 ml of starter culture was used to inoculate 250ml of LB media supplemented with 50 
µg/ml ampicillin or 30 µg/ml kanamycin (both Sigma-Aldrich) as appropriate and cultures were 
grown overnight in an Innova
TM
 4300 incubator shaker (Eppendorf) at 37C.  The next day, bacterial 
cells were pelleted at 6,000 rpm for 15 min at 4C in a SLA-3000 Super-Lite rotor for the Sovall® 
RC5C centrifuge and resuspended in 10 ml Buffer P1 with added RNase A (100µg/ml). Cells were 
lysed in 10 ml of Buffer P2 and tubes were inverted 5 times. After 5 min incubation at room 
temperature, 10 ml of cold Buffer P3 was added to neutralise the lysis reaction and incubated on ice 
for 20 min. The mixture was centrifuged at 12,000 rpm for 30 min at 4C in a SLA-3000 Super-Lite 
rotor for the Sorvall
®
 RC5C centrifuge to pellet genomic DNA, protein and cell debris. The 
supernatant was applied to a QIAGEN-tip 500 that had been equilibrated with 10 ml Buffer QBT. The 
QIAGEN-tip was then washed twice with 30 ml Buffer QC and DNA was eluted in 15 ml Buffer QF. 
DNA was precipitated by adding 10.5 ml room temperature 100% isopropanol (Thermo Fisher 
Scientific Inc.) and pelleted at 4,600 rpm for 30 min at 4C in the Sorvall® Legend RT+ centrifuge. 
The pellet was washed in 5 ml 70% ethanol, re-pelleted at 4,600 rpm for 10 min at 4C in the Sorvall® 
Legend RT+ centrifuge, allowed to air-dry, dissolved in a small volume of TE buffer (pH 8.0) and the 
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DNA yield determined using a NanodropND-1000 spectrophotometer (Thermo Scientific). DNA was 
diluted accordingly to 1 mg/ml and stored at -20C. 
2.2.2 Transient transfection of DNA 
Transfection of plasmid DNA in 90% confluent cells was achieved by the Lipofectamine™ 
2000 transfection reagent (Invitrogen) method following manufacturer’s instructions. Routinely, 
medium was removed and replaced at 80% volume with antibiotic free culture medium. Opti-MEM
®
 I 
reduced serum media (Gibco-Invitrogen) containing plasmid DNA and Lipofectamine™ 2000 at a 
ratio 1:2 formed the remaining volume. DNA and Lipofectamine™ 2000 were diluted separately in 
Opti-MEM
®
 I reduced serum media as required. After 5 min, DNA and Lipofectamine™ 2000 
solutions were combined and incubated at room temperature for 20 min before being added to cell 
monolayers. 
2.2.3 Plasmids 
Plasmids used in this study are listed in the Table 2.1. 
 
2.3 Virus techniques 
2.3.1 Viruses  
Viruses that were used in this study are recorded in the Table 2.2. 
2.3.2 Virus working stock production 
Virus working stocks were prepared from master or sub-master stocks on BHK-21 cells 
grown to confluency in five 225 cm
2
 tissue culture flasks. The culture medium was removed from 
monolayers and cells infected at a multiplicity of infection (moi) of 0.02 in 50 ml infection medium 
consisting of DMEM supplemented with 2% v/v NCS and 1 % pen/strep. Cells were incubated at 
37˚C until advanced cytopathic effect (c.p.e) was visible, harvested into the medium and pelleted at 
3,000 rpm for 30 min at 4˚C in a Sorvall® Legend RT centrifuge (Thermo Fisher Scientific Inc.). The 
cell pellet was resuspended in 2 ml sterile phosphate buffered saline (PBS) (VWR) and subjected to 
three freeze/thaw cycles using dry ice (The Linde Group, Munich, Germany)/ethanol (VWR) and a 
37˚C SUBAqua 12 Plus water bath (Grant Scientific, Shepreth, UK). Cell debris was pelleted at 3,000  
rpm for 5 min at 4˚C in a Sorvall® Legend RT centrifuge and aliquots of the supernatant stored at  
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Plasmid Referred as Protein expressed Ref. 
pGE120 pGE120 UL49 flanking sequences (Elliott & O’Hare, 1999) 
SF-TAP VP22 SF-TAP VP22 Strep FLAG TAP tagged VP22 This thesis 
pGE155 GFP-VP22 GFP tagged VP22 (Elliott & O’Hare, 1997) 
pGE179 YFP-VP13/14 YFP tagged VP13/14  
pGE176 CFP-VP16 CFP tagged VP16  
pMD10 GFP-VP13/14 GFP tagged VP13/14 (Donnelly & Elliott, 
2001b) 
pMD12 SV5-VP13/14 SV5 tagged VP13/14 (Donnelly & Elliott, 
2001b) 
pCP1 G22P-v GFP-tagged mimic of 
nonphosphorylated VP22 
(Potel & Elliott, 2005) 
pCP5 G22P+ GFP-tagged mimic of 
phosphorylated VP22 
(Potel & Elliott, 2005) 
pAM8 G22:1-160 GFP tagged VP22 1-160aa (Martin et al., 2002) 
pAM5 G22:1-212 GFP tagged VP22 1-212aa (Martin et al., 2002) 
pGFP160-301 G22:160-301 GFP tagged VP22 160-301 (Martin et al., 2002) 
pGE192 G22:192-301 GFP tagged VP22 192-301 (Martin et al., 2002) 
pcVP16 VP16 VP16  
pcVP16Δ VP16Δ VP16 1-411aa  
pCDN3-gM gM Wt gM  (Crump et al., 2004) 
pGEX2T GST GST  
pMK6 GST-VP16 GST tagged VP16 (Hayes & O’Hare, 1993) 
pMK7 GST-16 1-
410aa 
GST tagged VP16 1-410aa 
(Elliott et al. 1995) 
pPO76 GST-16 410-
490aa 
GST tagged VP16 410-454aa 
(Elliott et al. 1995) 
SW17 GST-16 410-
490aa 
GST tagged VP16 410-490aa 
(Elliott et al. 1995) 
pGEX2T1 GST-gE GST tagged gE cytoplasmic tail Colin Crump 
pGEX2T2 GST-gM GST tagged gM cytoplasmic tail Colin Crump 
pMD10ΔSal Δ1-127 GFP tagged VP13/14 128-693aa (Donnelly & Elliott, 
2001b) 
pMD10ΔSac Δ1-87 GFP tagged VP13/14 88-693aa (Donnelly & Elliott, 
2001b) 
pMD10ΔKpn Δ1-36 GFP tagged VP13/14 37-693aa (Donnelly & Elliott, 
2001b) 
pPW1 1-104 GFP-SV40/NLS tagged 
VP13/14 1-104 aa 
(Williams et al., 2008) 
pPW2 99-208 GFP-SV40/NLS tagged 
VP13/14 99-208aa 
(Williams et al., 2008) 
pPW3 203-305 GFP-SV40/NLS tagged 
VP13/14 203-305aa 
(Williams et al., 2008) 
pPW4 300-410 GFP-SV40/NLS tagged 
VP13/14 300-410 
(Williams et al., 2008) 
pPW5 405-527 GFP-SV40/NLS tagged 
VP13/14 405-527aa 
(Williams et al., 2008) 
pPW6 522-602 GFP-SV40/NLS tagged 
VP13/14 522-602aa 
(Williams et al., 2008) 
pPW7 597-692 GFP-SV40/NLS tagged 
VP13/14  
(Williams et al., 2008) 
pEGFP-C1 GFP GFP Clontech 
GFP-NLS GFP-NLS GFP tagged NLS  
Table 2.1: Plasmids used in this study 
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Table 2.2: Viruses utilised in this study 
 
Virus Referred as Description Ref. 
sc16 sc16 Wild type HSV-1 strain sc16 Helena Browne 
s17 s17 Wild type HSV-1 strain17  
166v 
G22v s17 expressing GFP fused to VP22 (Elliott & O’Hare, 1999) 
169v Δ22v s17 expressing GFP in place of VP22 (Elliott et al., 2005) 
193v 
G22v: 1-
212 
s17 expressing GFP fused to VP22 
residues 1-212 
(Hafezi et al., 2005) 
187v 
G22v: 108-
301 
s17 expressing GFP fused to VP22 
residues 108-301 
(Hafezi et al., 2005) 
195v 
G22v: 160-
301 
s17 expressing GFP fused to VP22 
residues 160-301 
(Hafezi et al., 2005) 
G22P-v G22P-v 
s17 expressing GFP tagged non-
phosphorylated form of VP22 
(Potel & Elliott, 2005) 
G22P+v G22P+v 
s17 expressing GFP tagged VP22 
mutant mimicking the phosphorylated 
form of VP22 
(Potel & Elliott, 2005) 
EB2v ΔgEbd 
s17 expressing GFP fused to VP22 
with a deletion between residues 213 
to 226 
(Stylianou et al., 2009) 
RP3v ΔCt 
KOS strain expressing VP16 with 
deleted 452-490 aa 
(Tal-Singer et al., 1999) 
RP3Rv ΔCtRev 
KOS strain expressing revertant of 
RP3v 
(Tal-Singer et al., 1999) 
GFP-VP16 GFP-VP16 s17 expressing GFP fused to VP16 (La Boissière et al., 2004) 
∆UL47 ∆13/14 
KOS BAC strain expressing mCherry 
in place of UL47 
Colin Crump 
KOS KOS WT Wild type HSV-1 strain KOS  
KOS-BAC KOS-BAC 
Wild type HSV-1 strain KOS derived 
from BAC system 
 
179v Y13/14 s17 expressing YFP fused VP13/14 (Donnelly & Elliott, 2001a) 
ΔgE ΔgE sc16 strain lacking gE (Balan et al., 1994) 
ΔgM ΔgM sc16 strain lacking gM (Browne et al., 2004) 
ΔgEgM ΔgEgM sc16 strain lacking both gE and gM (Browne et al., 2004) 
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-80˚C as virus working stocks.  
 
2.3.3 Titrations 
To determine the titre of virus stocks in plaque-forming units (pfu)/ml, Vero cells were 
seeded into 6 well plates at 6 x 10
5
 cells per ml in order to form confluent monolayer. Titrations were 
carried out in duplicate. A ten-fold dilution series of virus was prepared with 900 µl of infection 
medium and 100 µl of virus, to get dilutions of 10
-1
 to 10
-8
. Culture medium was removed from 
confluent cell monolayer and replaced with 800 µl of virus dilution. Plates were incubated for 1 hour 
at 37

C. The inoculums were removed after 1 hour and replaced with 2 ml infection medium 
supplemented with 1% human serum (Sera Laboratories Ltd., Haywards Heath, UK). Cells were 
incubated at 37

C until plaques were a reasonable size to count; monolayers were fixed with 2 ml 2x 
formal saline solution per well and stained with 0.5 ml 0.1 % crystal violet (see section 2.7). 
2.3.4 Growth curves 
Vero cells were cultured in 12-well plates at 3 x 10
5
 cells per ml in order to form a confluent 
monolayer. Cells from a spare well were trypsinised and counted. Virus working stock was diluted in 
the reduced serum (2%) cell culture media to give the multiplicities of infection stated in figure 
legends accordingly. The cell culture medium was replaced with 500 l of inoculum and incubated for 
1 hour at 37˚C, 5% CO2. Cells (intracellular virus) and supernatant (extracellular virus) were collected 
at the indicated times and stored in 2 ml screw-top microtubes at -80˚C.  The extracellular virus 
samples were then titrated at described in the section 2.3.3. Whereas, the intracellular virus samples 
before being titrated, were subjected to three freeze/thaw cycles using dry ice/ethanol and a 37˚C 
SUBAqua 12 Plus water bath. Cell debris was pelleted at 3,000 rpm for 3 min at RT in the Eppendorf 
centrifuge 5424 (Eppendorf, Hamburg, Germany) and each sample supernatant was titrated as 
described in section 2.3.3. For concurrent analysis of protein expression, duplicate plates of cells were 
washed once in PBS and lysed in 200µl 2X SDS-PAGE loading dye (section 2.7). Samples were 
denatured and analysed by SDS-PAGE and western blotting (sections 2.5.1 and 2.5.2). 
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2.3.5 Titration of recombinant baculovirus 
To obtain the titre of baculovirus stocks, 1x10
6
 sf9 cells were seeded in three 6 well tissue 
culture plates and left to settle for 10 min at 27

C. Two plates were infected with 0.5 ml of 10
-3
 to 10
-8
 
dilutions of stock virus, while 1 plate was used as a negative control. The infected cells were 
incubated for 1 hour at room temperature with  rocking. After 1 hour, infections were overlaid with 2 
ml of 0.5% sterile agarose made up in 1:1double distilled water and medium (SeaPlaque® Agarose, 
Lonza USA) and left to settle for a few minutes. When the agarose was set, 1 ml of medium was 
added on top. The plates were then returned to 27C and left to incubate for 5 days. To visualize the 
plaques, the 1 ml medium on the top was replaced with 2 ml of 50 µg/ml neutral red (Sigma) and left 
to stain for 20 minutes. The neutral red was removed and the virus plaques were counted to obtain the 
titre of the recombinant virus stock. The titre is given in plaque forming units per ml (pfu/ml).  
2.3.6 Purification of virus particles 
BHK-21 cells were grown to 100% confluency in 225 cm
2
 flasks before being infected at a 
multiplicity of 0.02 in 50 mls of infection medium. Cells were collected into the supernatant once 
c.p.e. was extensive and centrifuged at 3,000 rpm for 30 min at 4

C in a Sorvall
®
 Legend RT 
centrifuge to remove cell debris. Infectious virus particles were pelleted from the cleared supernatant 
at 9,000 rpm for 90 min at 4
o
C in a SLA-3000 Super-Lite rotor for the Sorvall
®
 RC5C centrifuge 
(both Thermo Fisher Scientific Inc.). The pellet was resuspended in 0.5 ml PBS and left at 4C 
overnight. A 10 ml 5 to 15% w/v Ficoll 400 (Sigma-Aldrich, St. Louis, MO USA) gradient in a 13.2 
ml thin-wall polyallomer ultracentrifuge tube (Beckhman Coulter, Brea, CA USA) was prepared 
using a gradient maker. The resuspended pellet containing the virions was layered on top of the 
gradient and centrifuged for 2 hours at 12,000 rpm at 4C in a SW41 Ti swinging bucket rotor 
(Beckman Coulter) for the Sorvall
®
 Discovery
TM
 SE centrifuge (Thermo Fisher Scientific Inc.). The 
virion band was harvested from the side of the tube with a 19 gauge BD Microlance™ hypodermic 
needle (Becton Dickinson, Drogheda, Ireland) and resuspended in 10 ml PBS before being pelleted at 
25,000 rpm for one hour at 4
o
C in a SW41 Ti swinging bucket rotor for the Sorvall
®
 Discovery
TM
 SE 
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centrifuge. The virion pellet was resuspended in 100 µl PBS and stored at -80C in 20 µl aliquots. 
Virion proteins were analysed by SDS-PAGE and western blotting. 
2.3.7 TAP-tagged VP22 plasmid production and purificatication from infected cells 
In order to produce a tandem affinity purification (TAP) tagged VP22 plasmid we had to use a 
plasmid (pcDNA4) already available containing the Streptomycin-FLAG (SF-TAP) tag, which was  
amplified by PCR using the relevant primers (Rev: GGATCCCTTGTCATCGTCATCCTTGTA and 
For: AGATCTATGTGGTCTCATCCTCAGTTT) with a BamH1 site at the 5’ prime and a BglII site 
at the 3’ prime end. The PCR fragment was cloned into the TOPO vector accordingly to the 
manufacturer’s protocol (Invitrogen). The fragment was digested from the TOPO vector with BamH1 
and BglII enzymes and cloned to the pGE120 plasmid containing the flanking promoter sequences of 
the VP22 gene. The VP22 gene was then cloned after the SF-TAP at the BglII site producing the 
plasmid needed for the purification of protein complexes with VP22 (Fig. 2.1). 
Cells were lysed in 1 ml of ice cold lysis buffer and incubated on ice for 20 min. The cell 
debris including nuclei was spun down for 10 min at 10,000 rpm, 4ºC in a Sorvall
®
 Legend RT 
centrifuge (Thermo Fisher Scientific Inc.), then the lysate was filtered through a syringe (MILLEX 
GP, 0.22mm, Millipore). Clear lysate was incubated with 50 µl streptactin superflow resin (IBA) for 1 
hour at 4ºC rotating, then spun down for 30 sec at 7000 rpm and resin was transferred to microspin 
columns (GE Healthcare).  Supernatant was removed after 5 sec at 100 rpm centrifugation, followed 
by three washes with 250 µl wash buffer (centrifuge 5 sec at 100 rpm each wash).  The complexes 
were eluted in 250 µl desthiobiotin elution buffer (IBA) for 10 min while rotating. Eluted sample was 
then incubated with 25 µl anti-FLAG-M2-agarose (Sigma) in microspin column for 1 hour at 4ºC 
rotating, followed by a wash with 250 µl wash buffer and two washes with 250 µl TBS buffer 
(centrifuge 5 sec at 100 rpm each wash).  Finally, the bound complexes were eluted in 100 µl FLAG 
elution buffer after 10 min rotating incubation and mixed with 100 µl 2x SDS-loading buffer for 
Western blotting analysis. 
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Figure 2.1: The plasmid maps of pGE120 and SF-TAP VP22.  
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2.4 Antibodies 
Antibodies were used for Western blotting and immunofluorescence (IF). The primary and secondary 
antibodies used for these studies are listed in Tables 2.3 and 2.4.  
 
2.5 Protein techniques 
2.5.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)  
Protein samples were mixed at 1:1 ratio with 2X SDS-loading buffer and were denatured at 
100C for 3 min. For Western blots performed against gM, samples were denatured at 42C for 20 
min to prevent aggregation of this transmembrane protein. The samples were loaded onto 10-12% 
SDS-PAGE gel in 2x SDS-loading buffer and were run at 200 V for approximately 1 hour in SDS 
running buffer (see section 2.7) using the XCell SureLock
TM
 Mini-Cell gel tank system (Invitrogen). 
Full range Novex
®
 Sharp Pre-Stained Protein Standard markers (Invitrogen) were used to determine 
the size of the proteins.  
 2.5.2 Western Blotting 
Samples were transferred to a Whatman
®
 Protran
®
 nitrocellulose membrane (Whatman 
GmbH,Dassel, Germany) at 7 V overnight or 25 V for 2 hours. Transfer was carried out in the 
presence of transfer buffer (see section 2.7) using the XCell SureLock
™
 Mini-Cell system as per 
manufacturer’s instructions. Membranes were stained with 0.1% w/v Ponceau S solution in 5% v/v 
acetic acid (Sigma-Adrich) to check transfer efficiency and the dye was removed by briefly washing 
the membranes in water. Blocking was in 5% skimmed milk (Sigma-Aldrich) 0.1% v/v Tween
®
 20 
(Sigma-Aldrich) in PBS for 1 hour at room temperature or at 4C overnight. The milk was washed off 
the membranes with PBS and then the primary antibody was added for 1 hour, followed by three 10 
min washes in wash buffer consisting of 1% v/v Triton
®
 X-100 (Sigma-Aldrich) in PBS. Membranes 
were then incubated with the appropriate secondary antibody for 1 hour and washed as after the 
primary antibody incubation. All the antibodies were made up in 0.1% Tween/PBS; see Tables 2.3 
and 2.4 for antibody concentrations. All steps were performed with shaking (30 rpm) on a Stuart
®
 
Scientific gyro-rocker SSL2 (Sigma-Aldrich). Western blots were developed with 1ml of the  
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Table 2.3: Primary antibodies. All mouse antibodies are monoclonal and all rabbit antibodies 
polyclonal. WB, western blot; IF, immunofluorescence microscopy. 
 
 
 
 
 
 
 
Antigen Name Secondary Working dilution 
WB                  IF 
Source 
gB R69 Mouse 1:10000 Helena Browne 
gD LP14 Mouse 1:5000 Tony Minson 
gE 3114 Mouse 1:10000 David Johnson 
gH BBH1 Mouse 1:1000 Helena Browne 
gM Ab980 Rabbit 1:1000         1:500 Helena Browne 
GFP GFP Mouse 1:10000 Clontech 
GFP GFP Rabbit 1:1000 Clontech 
ICP0 11060 Mouse 1:200 Santa Cruz 
ICP27 H1113 Mouse 1:5000 Stephen Rice 
vhs vhs Rabbit 1:20000 Duncan Wilson 
VP13/14 5283 Rabbit 1:5000 In-house 
(Donnelly 2007) 
VP16 LP1 Mouse 1:5000         1:400 Tony Minson 
VP22 C-
terminus 
AGV600 Rabbit 1:20000 In-house (Elliott 
1997) 
VP22 N-
terminus 
AGV031 Rabbit 1:20000 In-house (Elliott 
1997) 
UL26 UL26 Rabbit 1:3000 John Wills 
UL11 UL11 Rabbit 1:3000 John Wills 
UL16 UL16 Rabbit 1:3000 John Wills 
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Table 2.4: Secondary antibodies. IgG (H+L), immunoglobulin G (heavy and light chains); IF, 
immunofluorescence microscopy; HRP, horseradish peroxidase; WB, western blot. 
 
 
 
 
 
 
 
 
 
Reactivity Details Application Working 
Dilution 
Source Catalogue 
number 
Mouse IgG (H+L) Goat Alexa Fluor
®
 488 IF 1:200 Invitrogen A11001 
Mouse IgG (H+L) Goat Alexa Fluor
®
 568 IF 1:200 Invitrogen A11004 
Mouse IgG (H+L) Goat HRP WB 1:10000 
Bio-Rad 
Laboratories 
170-6516 
Rabbit IgG TrueBlot
®
 HRP WB 1:1000 eBioscience 18-8816 
Rabbit IgG (H+L) Goat HRP WB 1:10000 
Bio-Rad 
Laboratories 
170-6515 
Rabbit IgG (H+L) Goat Alexa Fluor
®
 568 IF 1:200 Invitrogen A11011 
Rabbit IgG(H+L) Goat Alexa Fluor
®
 488 IF 1:200 Invitrogen A11008 
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enhanced chemiluminiscence SuperSignal
®
 WestPico system per membrane, exposed on to Fuji-Film 
RX NIF X-ray film (both Thermo Fisher Scientific Inc.) and developed using a JP-33 automatic X-
Ray film processor (Jungwon Precision Industries Co. Ltd, Seoul, Korea). Blots were digitalised 
using an Epson Perfection V700 Photo scanner. 
2.5.3 Coommasie blue and Silver staining SDS-PAGE gels 
SDS-PAGE gels were washed in water for 10 min and stained for one hour with 30 ml 
Pierce
®
 Imperial Protein Stain (Thermo Fisher Scientific Inc.). Gels were washed several times in 
water until protein bands were clearly visible. All steps were performed with agitation (30 rpm) on a 
Stuart
®
 Scientific gyro-rocker SSL3 (Sigma-Aldrich). Gels were dried in DryEase Cellophane 
(Invitrogen) and scanned in an Epson Perfection V700 Photo scanner. 
Pierce
®
 Silver Stain Kit (Thermo Fisher Scientific Inc.) was used to silver stain the SDS-
PAGE gels as per manufacturer’s instructions. Briefly, the gels were washed in ultrapure water twice 
for 5 min and fixed twice for 15 min each wash in 60% water: 30% ethanol: 10% acetic acid. 
Following fixation, the gels were washed twice for 5 min in 10% ethanol and then twice more for 5 
min in ultrapure water. The gels were incubated for 1 min in Sensitizer Working Solution (50 µl 
Sensitizer with 25 ml water) and then washed twice for 1 min in ultrapure water. Stain Working 
Solution (0.5 ml Enhancer with 25 ml Stain) was used to stain the gels for 30 min and then the gels 
were washed quickly twice for 20 sec with ultrapure water. Immediately the Developer Working 
Solution (0.5 ml Enhancer with 25 ml Developer) was added on the gel for 2-3 min until the desired 
band density was reached and was then stopped with Stop Solution (5% acetic acid) briefly. The gels 
were then washed for a further 10 min in Stop Solution before being dried in DryEase Cellophane and 
scanned in an Epson Perfection V700 Photo scanner. All steps were performed with agitation (30 
rpm) on a Stuart
®
 Scientific gyro-rocker SSL3 (Sigma-Aldrich). The water used for both staining 
procedures was sterile water. 
2.5.4 Immunoprecipitation 
Vero cells were seeded at 1.5x10
6
 per 6cm dish in 5ml medium. After 24 hours the cells were 
infected at a moi of 1. Wherever possible, GFP-tagged protein expression was confirmed 
microscopically using an Olympus IX70 microscope with an Olympus U-RFL-T UV burner 
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(Olympus, Tokyo, Japan). After 20 h the cell monolayer was washed in PBS and scraped into 1.1 ml 
radioimmunoprecipitation assay (RIPA) buffer (see section 2.7), incubated on ice for 20 min, before 
shearing the DNA  with a needle and then centrifuged at 12,000 rpm, 4C in an Eppendorf Centrifuge 
5402 for pelleting the cell debris. A lysate sample of 50 µl was taken into 50 µl 2x SDS loading buffer 
which formed the input sample. For immunoprecipation, 450 µl of lysate was incubated with 4 µl 
monoclonal or 10 µl polyclonal antibody for 4 hours rotating at 4C in a Stuart® Blood Tube rotator 
SB1 (Sigma-Aldrich). Protein A Sepharose (GE Healthcare, Uppsala, Sweden) beads were washed in 
PBS twice and 40 µl of 50% slurry were added to the lysate with the antibody and were incubated for 
1 hour at 4C rotating. The beads were washed five times in PBS and then resuspended in 40 µl 2x 
SDS loading buffer and denatured at 100
o
C for 3 minutes. 
2.5.5 Protein expression using a baculovirus system 
To express and purify full length VP22 fused to GST, a baculovirus expression vector system was 
used (BD Biosciences). Full length VP22 gene from pGE 155 plasmid was cloned into the transfer 
vector pAcG2T generating plasmid pAcG2T+VP22. A BD BaculoGold
TM
 Transfection kit (BD 
Biosciences) was used as per manufacturer’s guideline. Briefly, sf9 cells were seeded at a density of 
2x10
6
 in 6cm tissue culture dishes and allowed to settle for 10 min. The culture medium was removed 
and 1 ml Transfection Buffer A was added. 0.5 µg of BD BaculoGold Bright Baculovirus DNA and 2 
µg of pAcG2T+VP22 were mixed in a sterile Eppendorf tube and incubated for 5 min before adding 1 
ml of Transfection Buffer B and was mixed well. The mix was added drop-by-drop to the insect cells 
by gently rocking the plate backwards and forwards. After 4-hour incubation at 27C, the transfected 
cells were washed and fresh medium was added. The transfected cells were left to incubate at 27C 
for 5 days after which the supernatant was collected and centrifuged at 2,500 rpm for 5 min in a 
Sorvall® Legend RT centrifuge to remove any floating cells. The supernatant was stored at 4C. 
Recombinant virus was amplified to obtain a P1 stock by infecting four 35 mm tissue culture dishes, 
each containing 1x10
6
 sf9 cells. Supernatant of 0.5 ml was added to the cells and left for 1 hour to 
incubate at room temperature while rocking the dishes every 15 min. After 1 hour, fresh medium was 
added and the infected cells were incubated for 4 days at 27C. The cells were scraped into the 
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medium and spun down at 2,500 rpm in a Sorvall® Legend RT centrifuge for 5 min to remove cells 
and debris. Another round of amplification generated the P2 or master stock. This was done by 
infection of four 10 cm tissue culture dishes each containing 5x10
6
 sf9 cells with 1 ml of P1 stock in 3 
ml medium. Four days after infection, the supernatant was harvested and the P2 stock was titrated and 
stored at 4C.  
To make a working stock of the recombinant virus, 200 ml of sf9 cells at a density of 1x10
6
 (day 
before cells were split at 5x10
5 
per ml) were spun down for 5 min at 1,620 rpm in a Sorvall
®
 Legend 
RT centrifuge. The medium was removed and cells were infected with P2 stock at a moi of 0.1 in a 
total of 20 ml medium. Virus was incubated for 1 hour at room temperature on a roller. Cells were 
returned to a spinner flask and adjusted to 200 ml of medium. Cells were left at 27C for 4 days, 
working stock was harvested by centrifugation at 1,620 rpm for 5 min in a Sorvall® Legend RT 
centrifuge and supernatant was stored at 4
o
C for further use. 
2.5.6 Expression and purification of GST fused proteins from sf9 cells 
Full-length GST-VP13/14 and GST-VP22 fusion proteins were purified from 10
8 
baculovirus-
infected sf9 cells. Seventy-two hours after infection at a multiplicity of 3, cells were lysed in 10 ml 
lysis buffer (see section 2.7) and left on ice for 30 min, followed by centrifugation at 4000 x g for 30 
min at 4C. The soluble supernatant was added to 200 µl of 50% slurry of glutathione-Sepharose 4B 
beads and rotated for 1 h at 4C in a Stuart® Blood Tube rotator SB1 (Sigma-Aldrich), and any 
unbound proteins were washed off the beads after three washes with PBS. 
2.5.7 Expression and purification of GST fused proteins from bacteria 
GST fusion proteins (GST, GST-VP16, GST-gM and GST-gE) were expressed in Escherichia 
coli strain BL21. A  250 ml culture of bacteria (containing the appropriate antibiotics and 
chloramphenicol at 1/1000 dilution each) was grown in an innovaTM 4300 incubator shaker 
(Eppendorf) and induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) when the cells had 
reached the logarithmic state as judged by an OD550 of 0.4-0.5. After a further 3 hour incubation, the 
cells were pelleted for 15 min at 4,000 rpm 4C in a SLA-3000 Super-Lite rotor for the Sorvall® 
RC5C centrifuge (both Thermo Fisher Scientific Inc.), resuspended in 10 ml PBS containing protease 
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inhibitors (Roche) and 1 mg/ml lysozyme, and left on ice for 30 min. Following 1 min sonication, 1% 
Triton X-100 was added  and the extracts were incubated for further 30 min rotating at 4C in a 
Stuart® Blood Tube rotator SB1 (Sigma-Aldrich) and centrifuged at 4,000 rpm for 30 min at 4C in a 
Sorvall® Legend RT centrifuge. The soluble supernatant was added to 200 µl of 50% slurry of 
glutathione-Sepharose 4B beads (GE Healthcare) and rotated for 1 h at 4C in a Stuart® Blood Tube 
rotator SB1 (Sigma-Aldrich), and any unbound proteins were washed off the beads after three washes 
with PBS.  
2.5.8 Pull-down of transfected and infected extracts using GST-tagged proteins  
COS-1 cells were transfected with the relevant plasmids using Lipofectamine™ 2000 
(Invitrogen) and Vero cells were infected with the appropriate viruses in 6 cm dishes. Twenty four 
hours later, the cell monolayer was washed with PBS and the cells were harvested in 1 ml lysis buffer 
(see section 2.7). The samples were left on ice for 20 min and centrifuged for 30 min at 12,000 rpm at 
4C in an Eppendorf Centrifuge 5402. Fifty µl of extract was added to 50 µl 2x SDS-loading buffer 
which formed the input sample. A 450 µl volume of extract was mixed with the relevant GST fusion 
protein already bound to glutathione-Sepharose beads. Following 2.5 h of rotation at 4C in a Stuart® 
Blood Tube rotator SB1 (Sigma-Aldrich), the beads were washed three times in PBS buffer and 50 µl 
of 2x SDS-loading buffer was added on the beads. The samples were boiled and analysed by SDS-
PAGE and Western blotting.  
2.5.9 GFP trap® technique 
GFP trap® kit (Chromotek, Planegg-Martinsried, Germany) was used to purify GFP or YFP-
tagged proteins according to the manufacturer’s manual. Briefly, one day old confluent Vero cells 
were infected with viruses tagged with GFP on either VP22, VP16 or YFP-VP13/14 at a moi of 1. 
After 16h when cytopathic effect was visible and GFP-tagged protein expression was confirmed 
microscopically using an Olympus IX70 microscope with an Olympus U-RFL-T UV burner 
(Olympus, Tokyo, Japan), the monolayer was washed in PBS and harvested in 10mls of PBS. The 
cells were pelleted at 3000 rpm for 5 min at 4C in a Sorvall® Legend RT centrifuge (Thermo Fisher 
Scientific Inc.) and lysed in 1 ml 1x RIPA buffer (10x RIPA buffer diluted with Dilution buffer [both 
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provided by the kit] containing 1x protease inhibitors [Roche]) on ice for 20 min. The cell lysates 
were then centrifuged at 12,000 rpm, 4C in an Eppendorf Centrifuge 5402 for pelleting cell debris. 
Fifty µl of lysate was taken into 50 µl 2x SDS loading buffer which formed the input sample. The rest 
of the lysate was incubated with 15 µl washed GFP trap®  beads for 20 min rotating at 4C in a 
Stuart
®
 Blood Tube rotator SB1 (Sigma-Aldrich). The beads were washed twice in 500 µl Dilution 
buffer (containing 1x protease inhibitors [Roche] and 1% Nonidet P-40 substitute [Amresco Inc. OH, 
USA]) and then resuspended in 40 µl 2x SDS loading buffer and denatured at 100C for 3 minutes. 
For Western blots against gM, samples were denatured at 42
o
C for 20 min to prevent degradation of 
this transmembrane protein. Samples were stored at -20C. 
2.5.10 Fluorescent microscopy 
COS-1 cells were grown to 70% confluency on 16 mm cover-slips (VWR) in individual wells of 
a 12 well plate and transfected with plasmids expressing fluorescent proteins. Sixteen hours after 
transfection cells were washed twice in 500 µl sterile PBS and fixed for 20 min at room temperature 
in 300 µl 4% w/v paraformaldehyde (Sigma-Aldrich) in PBS. Cells were then washed twice in 500 µl 
sterile PBS before being washed in water and mounted in 20 µl 10% w/v Mowiol
®
 4-88 mounting 
medium (see section 2.7) with 0.1 µg/ml 4’,6-diamidino-2-phenylindole (DAPI) on SuperFrost® 
WHITE microscope slides (VWR). Slides were stored at 4C.  Images were acquired with a Zeiss 
Axiovert S100 TV inverted microscopy (Carl Zeiss Ltd, Oberkochen, Germany) in combination with 
Image-Pro 7.0 software (Media Cybernetics Inc., Bethesda, Md USA). 
2.5.11 Immunofluorescence staining 
Cells were permeabilised with 0.5 % Triton
®
 X-100 in PBS for 10 min after fixation. Cells 
were washed twice in 1 ml PBS and blocked in 1 ml of 10% NCS/ PBS for 20 min. Typically, 25 µl 
of primary antibody was added onto each cover slip in 10% NCS/PBS for 20 min. After washing with 
PBS twice for 10 min, 50 µl secondary antibody was added in 10% NCS/PBS for 10 min. Cells were 
washed twice in PBS and mounted as described in section 2.5.10. Slides were stored at 4C.  Images 
were acquired with a Zeiss Axiovert S100 TV inverted microscopy (Carl Zeiss Ltd, Oberkochen, 
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Germany) in combination with Image-Pro 7.0 software (Media Cybernetics Inc.,Bethesda, Md USA). 
Antibody dilutions are stated in Tables 2.3 and 2.4 
 
2.6 Bacteria strains and techniques 
The Escherichia coli strain HB101 (ECACC) was used to prepare all plasmids. Bacteria work 
was performed with sterile reagents and tools under a blue flame on the bench. Waste was disposed of 
in compliance with Imperial College health and safety policy. 
2.6.1 Glycerol stocks 
Glycerol stocks were prepared by adding 600 µl of starter culture to 400 µl of autoclaved 
glycerol (Sigma-Aldrich). Stocks were stored at -80C and kept frozen on ice throughout use. 
2.6.2 Preparation of competent bacteria 
HB101 cells from a glycerol stock were streaked onto a Luria-Bertani (LB) agar (see section 
2.7) plate without any antibiotics and incubated overnight at 37C in a Heraeus® T 5042 E gravity 
convection oven D 6450 Hanau (Thermo Fisher Scientific Inc.). The following day, a single colony 
was inoculated into 5 ml of LB media (see section 2.7) without antibiotics and incubated at 37C 
overnight in a Max-Q 4000 incubator shaker (Thermo Fisher Scientific Inc.). From the overnight 
culture 500 µl were used to inoculate 250 ml LB media and cells were grown in an innova
TM
 4300 
incubator shaker (Eppendorf) until they reached the logarithmic state at an OD590 of 0.4-0.6. Bacteria 
were recovered by centrifugation at 5,000 rpm for 5 min at 4C in a SLA -3000 Super-Lite rotor for 
the Sorvall
®
 RC5C centrifuge. Bacterial pellets were resuspended in 100 ml ice-cold sterile buffer (pH 
5.8) consisting of 12.2 g/L rubidium chloride, 30 mM KOAc, 10 mM CaCl2, 50 mM MnCl2 and 15% 
w/v glycerol (all reagents Sigma-Aldrich). Following 5 min incubation on ice, bacteria were 
recovered as before and resuspended in 10 ml ice-cold sterile buffer (pH 6.5) consisting of 10 mM 3-
(N-morpholino)propanesulfonic acid (MOPS), 75 mM CaCl2, 10 mM rubidium chloride and 15% w/v 
glycerol (all reagents Sigma-Aldrich). Following 15 to 60 min incubation on ice, competent cells were 
snap freezed in liquid nitrogen and stored as 100 µl aliquots at -80C. 
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2.6.3 Transformation of recombinant DNA into bacteria 
For transformation of DNA into bacteria, competent cells were thawed on ice and incubated 
with 5ng of DNA for 20 min. Cells were subjected to a 1 min heat-shock at 42C and returned back to 
ice for further 5 min before 1 ml LB media was added.  Cells were incubated at 37C for 1 hour in a 
Max-Q 4000 incubator shaker with constant shaking at 220 rpm. Cells were plated onto LB agar 
plates containing the appropriate antibiotic selection and incubated inverted at 37C overnight in a 
Heraeus
®
 T 5042 E gravity convection oven D 6450 Hanau (Thermo Fisher Scientific Inc.). 
 
2.7 Solutions and Buffers 
All solutions and buffer were made with ultra pure water from PURELAB OPTION-Q DV25 
(ELGA Process water, UK) unless otherwise stated. 
 
PBS (pH 7.2): NaCl (8.77 gL), Na2HPO412H2O (19.2 g/L), NaH2PO42H2O (6.55 g/L) (VWR) 
2X FORMAL SALINE SOLUTION: Formaldehyde (8% v/v) (Thermo Fisher Scientific Inc.), NaCl 
(0.291 M) (Sigma-Aldrich). 
0.1% CRYSTAL VIOLET SOLUTION: Crystal violet (2.45 mM) (Sigma-Aldrich), ethanol (15% 
v/v) (VWR). 
LB AGAR: Tryptone (10 g/L), yeast extract (5 g/L), NaCl (5 g/L), agar (15 g/L) (all reagents Sigma-
Aldrich). 
LB MEDIA: Tryptone (10 g/L), yeast extract (5 g/L), NaCl (5 g/L) (all reagents Sigma-Aldrich). 
AMPICILLIN: 50 µg/ml ampicillin in water and filtered through a 2m syringe filter 
KANAMYCIN: 30 µg/ml kanamycin in water and filtered through a 2m syringe filter 
CHLORAMPHENICOL: 34µg/ml chloramphenicol in ethanol 
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2X SDS-PAGE LOADING DYE: Tris-HCl (100 mM) (pH 7.0), SDS (4% w/v), beta-
mercaptoethanol (10% v/v), glycerol (20% w/v), bromophenol blue (0.2% w/v) (all reagents Sigma-
Aldrich). 
10% POLYACRYLAMIDE RESOLVING GEL: Acrylamide/bis-acrylamide (37.5:1) (10% w/v) 
(Bio-Rad Laboratories), Tris-HCl (0.375 M) (pH 8.8) (Bio-Rad Laboratories), SDS (0.1% w/v), 
N,N,N’,N’-tetramethylethylenediamine (0.05% v/v) (Sigma-Aldrich), ammonium persulphate (0.1% 
w/v) (Sigma-Aldrich). 
12% POLYACRYLAMIDE RESOLVING GEL: Acrylamide/bis-acrylamide (37.5:1) (12% w/v), 
Tris-HCl (0.375 M) (pH 8.8), SDS (0.1% w/v), N,N,N’,N’-tetramethylethylenediamine (0.05% v/v), 
ammonium persulphate (0.1% w/v). 
SDS-PAGE STACKING GEL: Acrylamide/bis-acrylamide (37.5:1) (4% w/v), Tris-HCl (0.13 M) 
(pH 6.8) (Bio-Rad Laboratories), SDS (0.1% w/v), N,N,N’,N’-tetramethylethylenediamine (0.1% 
v/v), ammonium persulphate (0.1% w/v). 
SDS-PAGE RUNNING BUFFER: Glycine (192 mM), Tris base (25 mM), SDS (1% w/v) (all 
reagents Sigma-Aldrich). 
SDS-PAGE GEL TRANSFER BUFFER: Glycine (192 mM), Tris base (25 mM), methanol (20% 
v/v) (VWR). 
RIPA BUFFER (pH 7.5): Tris-HCl (50 mM), NaCl (150 mM), SDS (0.1% w/v), sodium 
deoxycholate (1% w/v) (Sigma-Aldrich), Triton
®
 X-100 (0.2% v/v) (Sigma-Aldrich), 1X complete 
ULTRA Mini protease inhibitors (Roche Applied Science, Penzberg, Germany). 
LYSIS BUFFER FOR GST PURIFICATION FROM SF9 CELLS: Tris-HCl (20mM), Nacl 
(200mM) (both reagents from Sigma-Adrich), Nonidet P-40 substitute (0.5% v/v) (Amresco Inc. OH, 
USA), EDTA (1mM) (Sigma-Aldrich), 1x complete ULTRA Mini protease inhibitors (Roche Applied 
Science, Penzberg, Germany). 
LYSIS BUFFER FOR GST PULLDOWN: Tris-HCl (50mM) (pH 7.5), NaCl (200mM) (both 
reagents from Sigma-Adrich), Nonidet P-40 substitute (1%v/v) (Amresco Inc. OH, USA), EDTA 
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(1mM) (Sigma-Aldrich), 1x complete ULTRA Mini protease inhibitors (Roche Applied Science, 
Penzberg, Germany). 
MOWIOL
®
 4-88 MOUNTING MEDIUM WITH DAPI: Mowiol
®
 4-88 (10% w/v) (Sigma-
Aldrich), Tris-HCl (0.1 M) (pH 8.5), glycerol (25% w/v), DAPI dihydrochloride (0.1 µg/ml) (Sigma-
Aldrich). 
BUFFERS FOR TAP-VP22 PURIFICATION 
TBS BUFFER: 30 mM Tris-HCl, pH 7.4, 150 mM NaCl 
LYSIS BUFFER: TBS buffer, 0.5% Nonidet-P40, 1x complete ULTRA Mini protease inhibitors 
(Roche Applied Science, Penzberg, Germany) and phosphatase inhibitors (Sigma-Aldrich) 
WASH BUFFER: TBS buffer, 0.1% Nonidet-P40, protease and phosphatase inhibitors 
DESTHIOBIOTIN ELUTION BUFFER: TBS buffer, 2 mM desthiobiotin (IBA) 
FLAG ELUTION BUFFER: TBS buffer, 200 mg/mL Flag peptide 
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3.1 Chapter introduction 
To understand how HSV-1 tegumentation occurs, a thorough knowledge of the network of 
interactions is required. Protein-protein interactions between tegument-tegument proteins and 
tegument proteins with viral glycoproteins are thought to contribute to tegument assembly 
(Mettenleiter 2002). This thesis focuses on identifying the binding partners of the three major 
tegument protein VP22, VP16 and VP13/14.  Extensive investigation by our group and others has 
shown HSV-1 VP22 to interact with VP16, ICP0, gE and gM (Elliott et al. 1995; Maringer et al. 
2012; Maringer & Elliott 2010; O’Regan, Murphy, et al. 2007; O’Regan, Bucks, et al. 2007; Stylianou 
et al. 2009), whereas, VP16 was shown to be pulled down by GST-gH, as well as gB and gD by 
chemical cross-linking (Gross et al., 2003; Zhu & Courtney, 1994). Moreover, VP16 interacted 
directly with another major tegument protein- VP1/2- which is also required for VP16 addition to the 
capsid (Ko et al., 2010; Svobodova et al., 2012). Moreover, VP13/14 was shown to directly interact 
with another nucleocytoplasmic and RNA binding protein, ICP27 (Dobrikova et al., 2010). Three 
large yeast two-hybrid studies have revealed a list of potential binary protein interactions amongst 
tegument proteins and glycoproteins which may be involved in the process of tegumentation (Fossum 
et al., 2009; Lee et al., 2008; Vittone et al., 2005). Only a few of these binary interactions have been 
validated in infected cells, which urged us to search for interacting partners of three major tegument 
proteins, VP22, VP13/14 and VP16, during infection. In order to achieve this two systems were 
explored, Tandem Affinity Purification (TAP) and GFP trap®, as discussed in this chapter.  
 
3.2 Purification of protein complexes using TAP-tagged VP22 system 
The widely used TAP tag consists of a combination of a tandem Strep-tag II with a FLAG-tag 
and therefore was referred to as SF-TAP tag. This system was initially chosen because both moieties 
have a medium affinity and avidity to their immobilised binding partners; this allows the elution of 
SF-tagged proteins under native conditions using desthiobiotin in the first step and the FLAG 
octapeptide in the second step. Hence, the co-purification of high and low affinity complex partners 
could be achieved, and in this case the partners of VP22 were investigated using this method. 
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The SF-TAP tag was inserted at the 5’ end of the VP22 gene. The tag was placed there since 
all VP22 constructs generated in our lab were tagged at the N-terminus with green fluorescent protein 
(GFP). To test the system, initially, Vero cells were transfected with the recombinant SF-TAP tagged 
VP22 plasmid but the cells transfected poorly. As a consequence, we chose another cell type, HeLa 
cells, which we knew would transfect and infect well. HeLa cells were mock treated or transfected 
with SF-TAP VP22 expressing plasmid and were infected the following day with a VP22 knockout 
virus, Δ22v, at multiplicity of infection (moi) of 1. The cells were then harvested 20 hours post 
infection (hpi) in 1 ml lysis buffer for SF-TAP purification, as described in section 2.3.7. Samples 
were taken at each stage of the double purification of SF-TAP VP22, and were analysed by Western 
blotting.  
Even though SF-TAP tagged VP22 was purified, neither VP16 nor gE, two known interacting 
partners of VP22, were pulled down (Fig. 3.1B). It could be observed from the Western blots that 
VP16 and gE were not able to bind to Strep-II beads and were lost in the flow through. It should be 
noted that the band close to 60 kDa is the heavy chain from the FLAG beads, which was also seen in 
the mock samples when blotted for FLAG expression (Fig. 3.1A). Even though a significant amount 
of VP22 was lost in the flow through after binding to the Strep-II beads and because of its stickiness 
to the FLAG beads, SF-TAP tag VP22 was purified (Fig. 3.1B). Although numerous attempts to co-
purify VP16 and gE with SF-TAP VP22 were performed, and under different conditions, the result 
was the same. In conclusion, the SF-TAP system proved unsuccessful during this study, which led us 
to use a different method for the identification of these complexes. 
 
3.3 Investigating complexes involving VP22, VP13/14 and VP16 by GFP-trap analysis   
The GFP-trap® system utilises agarose beads coupled to a high quality GFP-binding protein 
for biochemical analysis of GFP fusion proteins and their interacting partners. This system is widely 
used for measuring enzyme activity and for pull down of interacting proteins, which could then be 
analysed by mass spectrometry (Frauer et al., 2011; Hofemeister et al., 2011; Nagel et al., 2011).  In 
this study VP22 was used as proof of principle, since this protein has been well characterised in our  
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Figure 3.1: Affinity purification of VP22. HeLa cells were (A) mock treated or (B) transfected with 
20 µg of SF-TAP tagged VP22 expressing plasmid, which were the following day infected with Δ22v 
at a multiplicity of 1. Twenty hours post-infection the cells were harvested in 1 ml lysis buffer for 
TAP purification. After centrifugation and filtration the clear lysate was incubated with 50 µl of 
streptactin superflow resin for an hour rotating at 4ºC. The beads with bound complexes were washed 
three times in wash buffer and followed by elution of the bound complexes in 250 µl desthiobiotin 
elution buffer. The eluted sample was then incubated with 25 µl FLAG-M2 agarose beads, and after 
washing the beads extensively, the bound complexes were eluted in 100 µl FLAG elution buffer. A 
sample was taken at every stage of the purification described and subjected to SDS-PAGE analysis 
followed by Western blotting against VP22, FLAG, VP16 and gE. The values on the left are 
molecular weights in kilodaltons (kDa). Asterisk indicates the heavy chain from the FLAG beads.  In: 
input sample, 1) flow through from streptactin beads, 2) wash, 3) desthiobiotin elution, 4) streptactin 
beads after elution, 5) flow through from FLAG beads, 6) wash, 7) FLAG beads after elution and 8) 
purified SF-TAP VP22    
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group. Vero cells were infected at a multiplicity of 1 with a virus expressing GFP tagged full-length 
VP22 (G22v) or a virus expressing GFP in place of VP22 (Δ22v) (Elliott & O’Hare, 1999; Elliott et 
al., 2005). GFP was precipitated using the GFP-trap beads from RIPA cell lysates collected 20 hpi. 
GFP and G22 were precipitated with equal efficiency, as seen from the silver and coomassie stained 
gels and the GFP blot in Figure 3.2. In this assay Δ22v was used as negative control. Several proteins 
were co-precipitated with the G22 compared to GFP, demonstrating that purified G22 had pulled 
down a number of interacting partners and the ones identified are indicated with arrows on the gels 
(Fig. 3.2 A & B). In order to identify these partners, Western blotting analysis was carried out using a 
range of antibodies. When blotted for VP16, the well-characterised interacting partner of VP22, 
evidently G22 had pulled it down (Elliott et al. 1995; O’Regan, Murphy, et al. 2007). In line with 
previous reports, G22 interacted with another three known interacting partners, gE, gM and ICP0, 
validating the system used for this study (Fig. 3.2C) (Maringer & Elliott, 2010; Maringer et al., 2012; 
O’Regan, Bucks, et al., 2007; Stylianou et al., 2009). Moreover, another tegument protein, VP13/14, 
was also shown to have co-purified with G22, an interaction previously suggested by a yeast two-
hybrid study (Fossum et al., 2009). VP22 was demonstrated, in transfected cells, to be part of another 
complex involving vhs and VP16, an interaction confirmed in this study as well (Fig. 3.2C ) (Taddeo 
et al., 2007). Next we addressed the question whether the UL11-UL16-UL21 was incorporated to the 
previously characterised VP22-ICP0-gE-gM complex via their known interactions with gE 
(Farnsworth et al., 2007; Han et al., 2011; Harper et al., 2010; Yeh et al., 2011). Interestingly, G22 
pulled down UL16 and UL21, but not UL11. We were unable to conclude whether gE was involved in 
this complex. 
The interaction between G22 and other glycoproteins - gD gC, gB and gH - was also tested 
and resulted in none of these glycoproteins to be able to bind to VP22. Although the inability of G22 
to interact with gD contradicts reports in the literature, it is consistent with experiments from our 
group where polyhistidine (His)-tagged VP22 purified from baculovirus-infected Sf9 insect cells was 
used to test the ability of VP22 to pull down gD from infected cells (Chi et al., 2005; Farnsworth et 
al., 2007; Stylianou et al., 2009). 
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Figure 3.2: VP22 and its interacting tegument or glycoprotein partners as shown by GFP-trap. Vero 
cells were infected with GFP-tagged VP22 expressing virus (G22v) and a virus expressing GFP in 
place of VP22 (Δ22v) at an moi of 1. Whole cell lysates were harvested at 20 hpi and processed using 
the GFP trap® system. Samples were then subjected to (A) silver and (B) coomassie staining and (C) 
Western blot analysis using antibodies indicated. The values on the left are molecular weights in kDa. 
Arrows indicate the interacting partners of G22 identified by Western blotting. 
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To determine novel interacting partners of VP16, Vero cells were infected with GFP-tagged 
VP16 expressing virus (G16v), which had the GFP fused at the N-terminus of VP16, and Δ22v at an 
moi of 1. The Δ22v virus was used as a negative control because VP16 is essential for virus growth 
(Weinheimer et al., 1992). The RIPA cell extracts were treated in similar fashion as for G22v. A 
number of proteins have been co-purified with G16 compared to the control GFP, as observed from 
the coomassie stained gel (Fig. 3.3B). A series of antibodies were used to identify and validate these 
possible interacting partners by Western blotting analysis and the ones identified are indicated on the 
coomassie gel with arrows. The well-characterised interaction between G16 and VP22 was first 
examined and demonstrated, although in reduced levels, possibly due to the less efficient binding of 
VP22 with this specific virus. The previously identified interaction between VP16 and VP13/14 was 
confirmed in this assay as well (Donnelly et al., 2007; Vittone et al., 2005). Furthermore, the 
interaction during infection of G16 with vhs was tested and achieved in this study (Fig. 3.3C); such 
interaction has also been shown in other studies (Lam et al., 1996; Smibert et al., 1994; Strand & 
Leib, 2004). On the other hand, G16 was not able to pull down ICP0, UL11, nor the UL16-UL21 
complex, indicating that VP16 was not incorporated into the VP22-UL16-UL21 complex. 
Interestingly, the only glycoprotein G16 could pull down was gM, since no other glycoprotein tested, 
gE, gB, gD, gC or gH, was able to bind to G16 (Fig. 3.3C).  This result differs from other groups’ 
findings, where VP16 has been pulled down by GST-gH and chemically cross-linked with gB and gD 
(Gross 2003, Zhu 1994). 
Previous studies from our group showed VP13/14 to interact with VP16 by Co-IP and with 
gM by GST pull down (Donnelly et al., 2007; Stylianou et al., 2009). In order to identify other 
interacting partners of VP13/14, Vero cells were infected with YFP-tagged VP13/14 expressing virus 
(Y13/14v) (Donnelly & Elliott, 2001a) and Δ22v at a moi of 1. For reasons of consistency and due to 
our VP13/14 knockout virus, which expressed mCherry and therefore required the RFP-trap® system 
instead of the GFP-trap®, it was decide that Δ22v was more appropriate as a negative control. GFP 
and YFP were precipitated using GFP trap® beads from whole cell lysate collected 20 hpi and treated 
as previously described. Y13/14 and GFP were precipitated in equal levels as observed from the silver  
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Figure 3.3: VP16 and its binding partners. Vero cells were infected with GFP-tagged VP16 
expressing virus (G16v) and Δ22v at a moi of 1, 20 hpi the whole cell lysate was harvested and 
processed using the GFP trap® system. Samples were then subjected to (A) silver and (B) coomassie 
staining and (C) Western blot analysis using antibodies raised against the proteins denoted. The values 
on the left are molecular weights in kDa. Arrows indicate the interacting partners of G22 identified by 
Western blotting. 
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and coomassie stain gels (Fig. 3.4A and B). Due to the high background of bands in the Y13/14v lane 
compared to the Δ22v lane in the coomassie and silver stained gels, it was difficult to determine 
whether these proteins pulled down were binding partners or background. However, Western blotting 
analysis was used to identify these partners, which are also indicated with arrows on the gels (Fig. 
3.4A and B), and showed that only a few of the proteins tested were pulled down with Y13/14, 
suggesting that these were specific to Y13/14. Moreover, the VP22-VP13/14 interaction, as 
previously indicated (Fig 3.2C), was corroborated since Y13/14 pulled down VP22 (Fig.3.4C). The 
investigation to identify or validate other interacting partners of VP13/14 continued with ICP27, since 
these proteins have been demonstrated to directly interact by Dobrikova and colleagues (Dobrikova et 
al., 2010). The interaction between Y13/14 and ICP27 was also shown during our experiments, 
confirming the previously reported data (Fig. 3.4C). Moreover, a recent paper has shown that 
VP13/14 is able to bind to vhs in the absence of other virus proteins (Shu et al., 2013). As with VP22 
and VP16, vhs was co-purified with Y13/14, suggesting a discrete sub-complex incorporating VP22-
VP16-VP13/14-vhs. A further interaction partner warranting examining was the tegument protein 
UL21, first demonstrated as a VP13/14 interaction partner in a yeast-two hybrid assay (Fossum et al., 
2009). This interaction was confirmed, and our understanding of it extended, by the work presented 
here (Fig. 3.4C). Consequently, UL16 and UL11 were examined, with results supporting Y13/14 pull 
down only the former. Taken together with G22 pulling down the same proteins, it could be proposed 
that another multi-component sub-complex exists involving VP22-VP13/14-UL16-UL21. Finally, we 
examined the interaction of Y13/14 with a number of glycoproteins and showed that there was no 
evidence of gH, gB, gE or gD being present in the precipitated protein complex (Fig. 3.4C). In line 
with our previous findings, gM was pulled down successfully by Y13/14 (Stylianou et al., 2009). 
 
3.3.1 Validating the GFP-trap system in an alternative cell line 
To verify that the observed protein interactions are not cell type specific, HaCat cells, which 
are human keratinocyte cells, were infected with G22v and Y13/14v viruses and analysed as before 
using the GFP trap®  system. The silver stain of the bound complexes with G22v and Y13/14v  
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Figure 3.4: VP13/14 and its interacting tegument or glycoprotein partners as shown by GFP trap. 
Vero cells were infected with YFP-tagged VP13/14 (Y13/14v) or Δ22 expressing viruses at a moi of 1 
and whole cell lysates were harvested at 20 hpi and processed using the GFP trap® system. Samples 
were then subjected to (A) silver and (B) coomassie staining and (C) Western blot analysis using 
antibodies raised against the indicated proteins. The values on the left are molecular weights in kDa. 
Arrows indicate the interacting partners of G22 identified by Western blotting. 
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Figure 3.5: Validating GFP-trap system in human cells. HaCat cells were infected with G22v or 
Y13/14v expressing virus at a moi of 1 and whole cell lysates were harvested at 20 hpi and processed 
using the GFP trap® system. Samples were then subjected to (A) silver staining and (B) Western 
blotting analysis. The values on the left are molecular weights in kDa. 
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purified from HaCat cells were comparable with the silver stains of the purified complexes from Vero 
cells (Fig. 3.2A and Fig. 3.5A). A selective range of antibodies was used for Western blotting. As 
seen before, G22 pulled down VP13/14 and vice versa (Fig. 3.5B). Furthermore, VP16 was pulled 
down by both proteins, as was UL16; however, VP13/14 interacted less efficiently with both proteins 
in this experiment. In addition, as previously shown neither G22 nor Y13/14 pulled down gD 
(Fig.3.5B). Therefore, since the expression of the viruses and the pull downs were also similar, it 
could be suggested that the cell type may have no effect in this study.  
 
3.4 Confirmation of the interaction between VP22, VP13/14 and VP16 
Since G22 pulls down VP13/14 from infected extracts by GFP trap® analysis, we wanted to 
further establish this interaction by co-immunoprecipitation (Co-IP) studies. Therefore, Vero cells 
were infected with wild type HSV-1 s17, Y13/14, G22v or ∆22v viruses at moi of 1. The soluble 
RIPA extracts of Y13/14v, G22v and ∆22v were subjected to immunoprecipitation with an antibody 
directed against GFP. Alongside, s17, Y13/14v, G22v and ∆22v extracts were immunoprecipitated 
with an antibody raised against the N-terminus of VP22 (referred to as VP22-N). VP16 provided a 
positive control for this study. Whilst equal precipitation levels of VP22 and GFP were obtained from 
all samples, neither VP22 nor VP13/14 could be co-immunoprecipitated in either assay. When VP22-
N was precipitated from the cell extracts, faint bands at sizes corresponding to VP13/14 and Y13/14 
appeared when blotting for VP13/14. These were confirmed to be background bands, as they were 
also present in the Δ22 pull down (Fig. 3.6A). However, VP13/14 was co-immunoprecipitated with 
VP22, when G22v and ∆22v extracts were immunoprecipitated with an antibody directed against the 
C-terminus of VP22 (referred to as VP22-C). This interaction was achieved only in the presence of 
VP22 (Fig. 3.6B). This data supports our previous results and confirms the interaction between VP22 
and VP13/14.  
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Figure 3.6: VP13/14 interacts with VP22 and VP16. Vero cells were infected with wild type HSV-1 
s17, Y13/14, G22v and Δ22v viruses at a moi of 1 and whole cell lysates were harvested at 20 hpi. 
RIPA lysates were immunoprecipitated with antibodies against (A) GFP or VP22-N or (B) VP22-C, 
and the resulting immunocomplexes were analysed by Western blotting using antibodies against 
VP22, VP13/14, GFP and VP16.  
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3.5 Chapter Summary 
Yeast two-hybrid studies have identified a wide range of potential protein interactions 
amongst tegument proteins (Fossum et al., 2009; Lee et al., 2008; Vittone et al., 2005). While some of 
these interactions have been validated in infected cells, other interactions such as between 
VP13/14and VP22 or UL21 were yet to be reported (Elliott et al. 1995; Maringer & Elliott 2010; 
Maringer et al. 2012; Ko et al. 2010). Even though yeast two-hybrid screens are among the most 
powerful methods to detect and analyse protein-protein interaction, they suffer from a significant 
degree of false negatives and false positives. In this chapter we have validated and identified, during 
infection, a range of interacting partners for the three major tegument proteins VP22, VP16 and 
VP13/14. Initially, we tried to use the SF-TAP VP22 system to purify the bound protein complexes 
with VP22, however this was unsuccessful. Although SF-TAP VP22 was successfully purified from 
the infected cells, neither VP16 nor gE –two known partners of VP22- were co-purified. This led us to 
use the GFP trap® system to screen for protein complexes pulled down by these three tegument 
proteins in infected cells. VP22 was used a proof of principle in this study, as it has been studied 
thoroughly in our group. In line with the literature, all of the known interacting partners of VP22 were 
successfully pulled down, further validating our decision to use this technique. Additionally, three 
novel partners of VP22 were identified during this study; these were the tegument proteins VP13/14, 
UL16 and UL21. VP16, on the other hand, pulled down VP22, vhs and VP13/14; the latter interaction 
will be further characterised in the following chapter. gM was shown to interact with VP16 and 
VP13/14 for the first time in infected cells. Furthermore, the interaction of VP13/14 with VP16 and 
ICP27 was corroborated when these proteins were co-purified with Y13/14. More interestingly, the 
novel interaction of VP13/14 to UL16, UL21 and vhs was demonstrated, indicating that these three 
major tegument proteins – VP22, VP16 and VP13/14 - share a number of interacting partners. Also, it 
was confirmed that these interactions may not be cell specific, as the same result was achieved for the 
selective complexes in HaCat cells as well. Taken together, these data suggest the presence of three 
potential sub-complexes involving VP22; one incorporating VP22-VP13/14-UL16-UL21, another 
VP22-VP16-VP13/14-gM and finally VP22-VP16-VP13/14-vhs.  
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4.1 Chapter Introduction 
VP13/14 is a major structural component of HSV-1 with approximately 1,800 copies in the 
virion tegument. Although non-essential for replication little is known about its role during infection 
(Heine et al., 1974). VP13/14 is a nucleocytoplasmic shuttling protein and has also been identified to 
have RNA binding activity (Donnelly & Elliott, 2001b; Donnelly et al., 2007). Another abundant 
protein is VP16, which is essential for secondary envelopment and egress (Mossman et al., 2000; 
Weinheimer et al., 1992). A yeast two-hybrid study first demonstrated the interaction between these 
two proteins, which was later validated by Co-IPs and in this study by GFP-trap analysis (Donnelly et 
al., 2007; Vittone et al., 2005). The main aim of this chapter was to demonstrate and describe the 
interaction between VP16 and VP13/14. 
4.2 VP16 interacts with the N-terminus of VP13/14 
The interaction of VP16 with VP13/14 was demonstrated by GFP-trap® studies in the 
previous chapter and in other reports (Donnelly et al., 2007; Stylianou et al., 2009; Vittone et al., 
2005). The region of VP13/14 involved in binding to VP16 was therefore analysed further in this 
chapter. This investigation was facilitated by the availability of a range of truncated VP13/14 variants 
tagged with GFP (see Fig. 4.1A, 4.2A and 4.3A) (Donnelly & Elliott, 2001b; Williams et al., 2008). It 
should be noted that VP13/14 contains a nuclear localisation signal (NLS) within its N-terminus 
consisting of three groups of four consecutive arginine clusters located at amino acids 9 to 12, 63 to 
66, and 72 to 75. These arginine clusters are represented by black boxes in the line drawings of 
VP13/14 presented below. In order to extend our observations on the VP16-VP13/14 interaction, full 
length VP16 fused to GST was first expressed and purified on glutathione-Sepharose beads, which 
was used for pull down assays (see Appendix Fig. A.1). COS-1 cells were transfected with plasmids 
expressing full length or truncated forms of GFP-tagged VP13/14 as described in panel A of Figure 
4.1 (Donnelly & Elliott, 2001b). The soluble extracts were then prepared and incubated with beads 
bound to GST-fused VP16. After extensive washing, the protein complexes bound to the beads were 
solubilised and analysed by SDS-PAGE, followed by Western blotting with an anti-GFP monoclonal 
antibody. The full length VP13/14 was bound to GST-VP16, indicating a direct interaction between  
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Figure 4.1: VP16 interaction domain is located at the N-terminus of VP13/14. (A) Line drawings of 
the GFP-13/14 fusion protein (Wt) and its truncation mutation forms used in this study. The NLS 
arginine clusters are shown as solid boxes. (B) COS-1 cells were transfected with plasmids expressing 
each of the GFP-tagged mutant forms of VP13/14 shown in panel A. The soluble extracts were 
incubated with GST- tagged VP16 beads and after extensive washing of the beads, the bound proteins 
were solubilised and analysed by SDS-PAGE, followed by Western blotting against GFP. I: input 
sample, B: GST fusion protein pull-down with cell extract. 
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these proteins since no other viral protein was required for this interaction to occur. Δ1-36 interacted 
efficiently with GST-VP16, while the Δ1-187 and Δ1-127 mutants were unable to bind to VP16 (Fig. 
4.1B). Hence, the 36 to 127 residues of VP13/14 were required for efficient binding to VP16.  
The interaction of VP16 was further tested with seven peptides (approximately 100 aa each) 
that span across the entire VP13/14 open reading frame. These peptides were tagged to a nuclear 
reporter consisting of a GFP fused to the simian virus 40 (SV40) NLS linker (Fig. 4.2A) (Williams et 
al., 2008). Only the first 104 residues of VP13/14 bound to GST-VP16 beads, while no other 
truncated form of VP13/14 showed any binding activity and neither did GFP nor GFP/NLS negative 
controls (Fig. 4.2B). The fainter bands present on the blot for the GST-VP16 pull-down were 
breakdown products of the truncated proteins, as seen from the inputs samples (Fig. 4.2B). 
Furthermore, the distribution of the electrochemical characteristics of each peptide was calculated 
using the MacVector program. The first 104 residues of VP13/14 proved to be highly basic with an 
isoelectric point of 12, as expected due to the arginine clusters. In comparison, the rest of the peptides 
reached isoelectric points as low as 4.2 (Fig. 4.2C).  Residues 300-410 and 597-692 of VP13/14 were 
also highly basic, with isoelectric points of 11.43 and 10.87, respectively. However, VP16 interacted 
only with first 104 residues of VP13/14 suggesting that this interaction does not occur only due the 
highly positive VP13/14. 
Next, it was determined whether the arginine clusters, which are termed NLS1, NLS2, and 
NLS3 respectively, were involved in the interaction of VP16 with VP13/14. To this end, a series of 
plasmids encoding GFP fused to a range of short N-terminal peptides of VP13/14 were used in a 
GST-VP16 pull down assay, as described in panel A of Figure 4.3 (Donnelly & Elliott, 2001b). These 
plasmids were transfected into COS-1 cells and the extracted lysates were incubated with beads bound 
to GST-VP16, as described previously. The bound proteins were then analysed by Western blotting 
against GFP. Residues 1 to 76 of VP13/14 (NLS 1+3), lacking the second arginine box by substituting 
the arginines with glycine, bound to VP16 as efficiently as residues 1 to 92 of VP13/14 fused to GFP 
(NLS1+2+3+) that included all three arginine boxes (Fig. 4.3B). This result refined the binding 
domain of VP16 to the first 76 residues of VP13/14 from the 104 residues. However, when the third  
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Figure 4.2: VP16 interacts only with the first 104 aa of VP13/14 in vitro. (A) Schematic diagram of 
GFP/SV40/NLS plasmids expressing the truncated forms of VP13/14 plasmids used in this study. (B) 
COS-1 cells were transfected with the plasmids described in panel A, and the soluble extracts were 
tested for the ability to bind to GST-VP16 bound to beads. The bound proteins were solubilised and 
analysed by SDS-PAGE, followed by Western blotting against GFP. The values on the left indicate 
the molecular weights in kDa. (C) The isoelectric point of each 100 aa of VP13/14 was measured 
according to the MacVector program 
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arginine box was deleted (NLS1+2) the interaction with VP16 was lost. On the other hand, residues 
63 to 76 of VP13/14 were unable to bind to GST-VP16 by itself, indicating the necessity of the first 
62 amino acids. NLS2, which expressed only residues 63 to 72 of VP13/14, did not bind to VP16 as 
anticipated (Fig. 4.3B). Thus, along with previous results (Fig. 4.1) the interaction domain of VP16 
with VP13/14 was delineated at residues 37 to 76 of VP13/14.  
4.3 VP16 co-localises with VP13/14 
Because VP16 and VP13/14 have been shown to bind biochemically, the effect of co-
expressing VP13/14 with VP16 on the localisation of these two proteins was explored.  GFP tagged 
VP13/14 transiently expressed in cells localised entirely within the cell nuclei, while exhibiting a 
range of patterns. In a proportion of nuclei the protein appeared diffuse or accumulated in the nucleoli 
in multiple speckled domains (Donnelly & Elliott, 2001b). By contrast, GFP-VP16 was equally 
distributed between the nucleus and the cytoplasm (La Boissière et al., 2004).   
Plasmids expressing yellow fluorescent protein tagged VP13/14 (YFP-VP13/14) and cyan 
fluorescent protein tagged VP16 (CFP-VP16), which were previously constructed in our lab, were 
used for this study. COS-1 cells seeded on cover slips were transfected individually or co-transfected 
with YFP-tagged VP13/14 and CFP-tagged VP16 expressing plasmids and were imaged using a Zeiss 
Axiovert S100 TV inverted microscope. When expressed alone, CFP-VP16 was distributed in a 
diffuse pattern in the nucleus and cytoplasm - although more nuclear. Whereas, when YFP-VP13/14 
was expressed alone it appeared diffuse in the nucleus but also was present in a small population in 
nuclear domains, as described in the literature (Fig. 4.4A). Co-expression of YFP-VP13/4 and CFP-
VP16 altered the localisation of both proteins significantly. VP16 was still present in the cytoplasm 
but also co-localised with VP13/14 in larger nuclear domains (Fig. 4.4B). 
4.4 Characterisation of HSV-1 unable to express VP13/14 
The interaction of VP13/14 with VP16 was biochemically proven by GFP trap® in chapter 3. 
In order to further investigate the relationship of these two proteins in the virus, a HSV-1 virus unable 
to express VP13/14 was used. This knockout virus expressed the mCherry fluorescent protein in place  
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Figure 4.3: Forty residues of VP13/14 were sufficient for binding to VP16. (A) Schematic diagram of 
the truncated forms of GFP expressing VP13/14 plasmids used in this study. (B) COS-1 cells were 
transfected with the plasmids described in panel A, and the soluble extracts were tested for the ability 
to bind to GST-VP16 beads. The bound proteins were analysed by SDS-PAGE, followed by Western 
blotting against GFP. The values on the left indicate the molecular weights in kDa. 
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Figure 4.4: VP16 co-localises with VP13/14 in large nuclear domains. (A) COS-1 cells grown on 
cover slips were transfected with plasmids expressing YFP-VP13/14 or CFP-VP16 and examined by 
live cell microscopy. (B) COS-1 cells grown on cover slips were co-transfected with the same 
plasmids as above. Images were captured using a Zeiss Axiovert S100 TV inverted microscope with a 
60x lens. Green: YFP-VP13/14 and Red: CFP-VP16 
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of VP13/14 (∆13/14) constructed in a BAC based on the KOS strain of HSV-1, kindly provided by Dr 
Colin Crump (University of Cambridge). In order to verify the deletion of VP13/14 and to compare 
the expression kinetics of different viral proteins, a multistep time course of infection was undertaken 
for BAC derived KOS strain and Δ13/14 viruses. Initially Vero cells were infected at a moi of 0.02 
and harvested at 8, 16, 24, 30 and 40 hours post infection (hpi). Equal amounts of whole cell extracts 
were subjected to SDS-PAGE and Western blotting analysis with antibodies specific for VP13/14, 
VP16, ICP0, ICP27, gD and gE (Fig. 4.5A). The proteins were detectable from 24 hpi (VP13/14, 
VP16 and ICP27) or 30 hpi (ICP0, gE and gD) and appeared to increase in intensity up to 40 hpi. As 
expected, VP13/14 was expressed in the BAC derived KOS virus but was absent from lysates of 
Δ13/14 infected cells. More importantly, steady-state levels of VP16 were similar in cells infected 
with both viruses, confirming that the expression of this protein was not affected by the deletion of 
VP13/14. The same applied to the expression of the glycoproteins gE and gD. In contrast, the 
expression of the immediate early protein ICP27, but not ICP0, was to some extent increased in 
Δ13/14 compared to the BAC derived KOS infected cells (Fig. 4.5A). Concurrently, the total virus 
produced at each point was harvested and titrated on Vero cells, in order to quantify virus production 
demonstrated on a multistep growth curve (Fig. 4.5B). Δ13/14 was first detected at 16 hpi with an 
approximate 5-fold reduction in total virus yield when compared to the total virus produced by BAC 
derived KOS, which reached a 10-fold reduction by 40 hpi (Fig. 4.5B). Thus, deletion of VP13/14 had 
a small effect on HSV-1viral replication, as has also been demonstrated in most alphaherpesviruses 
(Dorange et al. 2002; Kopp et al. 2002; Lobanov et al. 2010; Zhang & McKnight 1993).  
4.4.1 Phenotype analysis of Δ13/14 in human cell lines 
Due to the reduced virus production of Δ13/14 in Vero cells, the phenotype of this virus was 
subsequently analysed in cell lines with physiological relevance to HSV-1 natural infection, skin cells. 
The human foreskin cell line HFFF2 and human keratinocyte HaCaT cells were chosen for this 
experiment. Therefore, Vero, HFFF2 and HaCaT cells were infected with the HSV-1 wild type KOS 
strain, BAC derived KOS and Δ13/14 viruses. The titrations were performed in the presence of human 
serum (1%), which inhibits secondary plaque formation during titrations as it contains anti-HSV-1 
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neutralising antibodies. Plaques formed on Vero cell monolayers with the BAC-derived KOS and 
Δ13/14 viruses looked smaller, relatively to the wild type KOS strain. This suggests a defect in virus 
replication or production, although the plaques produced by the BAC-derived KOS virus were 
comparable with Δ13/14 plaques (Vero, Fig. 4.6A).  HFFF2 cells formed irregular plaques for all the 
viruses in which the cell monolayer did not detach completely from the culture plate (HFFF2, Fig. 
4.6A). This may reflect the irregular cell monolayer and incomplete cytopathology in these cells. In 
HFFF2 cells, Δ13/14 plaques looked smaller compared to KOS and BAC-derived KOS, however due 
to the morphology of the plaques it was difficult to confirm this observation (HFFF2, Fig. 4.6A). 
More strikingly, the HaCaT cells formed unidirectional trails of cytopathology emanating from the 
central plaque towards the side of the well, which have been described previously and termed “comet 
tails”.  These trails of cytopathology have been described in a number of different virus infections 
including human cytomegalovirus (HCMV), vaccinia virus and HSV-1, although in the absence of 
anti-viral antibodies in the media (O’Dowd et al., 2012; Roberts & Smith, 2008; Shinkai & Yoshino, 
1975). However in our studies, KOS-wt and BAC derived KOS produced these comet tails in the 
presence of human serum, whereas Δ13/14 formed small plaques (HaCat Fig. 4.6A). Dr Charlotte 
Sayers, a member of the Elliott group (Imperial College London) had previously demonstrated that 
the formation of comet tails during plaque formation was due to higher levels of extracellular virus 
released during infection in keratinocyte cells (personal communication). Hence, it could be 
concluded that the knockout VP13/14 virus had a defect in virus production and/or extracellular virus 
release compared to KOS wild type and BAC-derived KOS in HaCaT cells.      
The difference in comet tail formation was examined by infecting HaCaT cells with the three 
viruses as before in the presence or absence of human serum (1%) in the media. As shown in panel A, 
KOS and BAC-derived KOS formed comet tails in the presence of human serum; whereas in the 
absence of human serum the comet tails were more extensive, ultimately covering the whole 
monolayer of cells following 4 days post infection (Fig.4.6B). Conversely, Δ13/14 formed small 
comet tails only in the absence of human serum. 
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Figure 4.5: Influence of VP13/14 deletion on viral protein expression and production. (A) Vero cells 
were infected with Δ13/14 and BAC derived KOS (KOS-BAC) viruses at an moi of 0.02. The cells 
were harvested at 8, 16, 24, 30 and 40 hpi, and equal amounts of total cell lysates were analysed by 
SDS-PAGE and Western blotting for the denoted proteins. (B) Multi-step growth curve of Δ13/14 and 
KOS-BAC viruses. Total infectious virus was collected concurrently with the experiment described in 
(A) and titrated on Vero cells in triplicate –error bars. 
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4.4.2 Growth kinetics of Δ13/14 in HaCaT cells  
Due to the pronounced phenotypic difference in plaques of Δ13/14 from the KOS and BAC-
derived KOS in HaCats, a time-course similar to the one in Vero cells was performed in HaCat cells. 
Cells were infected with Δ13/14 or KOS wild type viruses at a moi of 0.02 and harvested at 8, 16, 24, 
30 and 40 hpi. The whole cell lysates were subjected to Western blotting analysis for the proteins 
shown in Figure 4.7A. At each time point the cell-associated and extracellular infectious progeny of 
each virus were collected and titrated onto Vero cells. The titre of each virus harvested after 1 hour of 
inoculation shown to be similar, indicating that after 1 hour the cells were infected with the same 
amount of virus and consequently a valid comparison could be made between the protein expression 
and growth kinetics of these viruses.      
Surprisingly, the protein expression of Δ13/14 virus was almost comparable to KOS wild type 
and appeared higher for VP22 and ICP27 (Fig. 4.7A). The proteins were detectable from 24 hpi and 
increased in concentration up to 40 hpi. The infectious progeny of Δ13/14 was detected from 16 hpi 
with a 10-fold titre reduction compared to the KOS wild type. These reached a 5-fold and 10-fold 
reduction at 24 and 40 hpi, respectively (Fig. 4.7B). Moreover, the virus release of Δ13/14 was 
reduced, which explains the inability to form comet tails in the presence of human serum (Fig 4.7C).  
The extracellular portion of infectious progeny of Δ13/14 became detectable at 16 hpi with a 10-fold 
reduction compared to KOS wild type and had a similar pattern as the cell-associated titres (Fig 4.7C). 
Therefore, when VP13/14 was deleted, a decrease in viral expression and release was observed in 
both human keratinocyte and Vero cells. 
4.4.3 Protein assembly into ∆13/14 virions 
The impact of the deletion of VP13/14 on the assembly of other tegument proteins and 
glycoproteins into HSV-1 virions was examined by gradient purification of extracellular particles 
from BHK infected cells with wild type strain KOS and ∆13/14 viruses. It proved quite difficult to 
purify ∆13/14 virions in a Ficoll gradient, although the multiple attempts and the increase of 
extracellular virus, there was no obvious virion band produced. Therefore, it was decided to collect  
Chapter 4                                              Characterisation of the interaction between VP16 and VP13/14   
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Comparison of plaque morphology of Δ13/14 with parental viruses. (A) Confluent 
HFFF2, HaCaT and Vero cells were infected with KOS wild type (KOS-wt), BAC-derived KOS 
(KOS-BAC) or Δ13/14 viruses, then fixed and stained after four days. (B) Confluent HaCat cells were 
infected as described above, after 1 hour of infection, the inoculums was replaced with media with or 
without human serum. After three and four days the cells were fixed and stained. 
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Figure 4.7: Growth characteristics of HSV-1 lacking VP13/14 in HaCat cells. Multi-step growth 
curves of KOS wild type and Δ13/14 were carried out by infecting HaCaT cells at an moi of 0.02, and 
harvested at the indicated times (A) for protein expression analysed by Western blotting for the 
denoted proteins and (B) for cell-associated or (C) released virus. All growth curves were carried out 
in triplicate –error bars.  
 
successive 1 ml gradient fractions, which were analysed by SDS-PAGE (Fig. 4.8A). Fractions 7 to 10 
were pooled, pelleted and resuspended in 100 µl PBS, as these fractions had a virion-like profile. 
Virions of KOS and ∆13/14 were equalised against the major capsid protein VP5, which also served 
as a loading control. Deletion of tegument protein VP13/14 was verified by Western blotting (Fig. 
4.8C). The general profile of Δ13/14 virions was comparable with the wild type KOS virus (Fig. 
4.8B); however the deletion of VP13/14 resulted in an increase in gB and/or gC assembly, as 
observed from the coomassie stained gel. The gB/gC band is indicated by an arrow in Figure 4.8B. 
However, blotting for gB presence in the virions showed that there were equivalent levels in the 
knockout virus as in the wild type virions (Fig. 4.8C). On the other hand, gC was shown to be 
packaged in the knockout virus but not the wild type, confirming the increased levels of gC observed 
on the coomassie gel for Δ13/14 (Fig. 4.8 B and C). Sedlackova and Rice also experienced this 
unexpected lack of gC packaging in one of their two separate KOS virion preparations, indicating the 
necessity of further investigation and repetition of these studies (Sedlackova & Rice, 2008). It should 
be noted that gC was not expressed in KOS infected cell extracts, in contrast to the ∆13/14 extracts 
where gC expression was detectable from 30 hpi (samples from the time course on HaCat cells, 
Fig.4.7). This unexpected inability to express gC explains why this glycoprotein was not packaged in 
KOS virions (Fig. 4.8D). It should be mentioned that although all three viruses (KOS-wt, BAC 
detived KOS and ∆13/14 viruses) used in these studies were from the same laboratory, there is a 
possibility that KOS wt acquired a mutation through time, use or transportation. Therefore, other wt 
KOS strains need to be compared with the KOS strain available in our lab to clarify this 
observation.Furthermore, VP22 assembly remained unaffected by the deletion of VP13/14, as 
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expected since gE and gM recruits VP22 into the virion (Maringer et al., 2012). Also, VP16, UL16 
and UL21 were packaged in equal levels in both viruses, indicating that VP13/14 is not involved in 
the recruitment of these tegument proteins into the virion although their interaction. Unexpectedly, 
ICP0 packaging was increased compared to the wild type, as was the packaging of gD. In agreement 
with previous studies on KOS virions, no detectable ICP27 protein was found in either KOS or 
Δ13/14 virion lysates by Western blotting analysis as this protein is non-associated with the virion 
(Sedlackova & Rice, 2008; Su et al., 2006; Yao & Courtney, 1992).  
4.5 Chapter Summary 
The interaction between VP13/14 and VP16 was first detected by yeast two-hybrid studies 
(Vittone et al., 2005). This interaction has since then been confirmed and extended by our reports of 
efficient binding of VP13/14 with VP16 by GST pull-down assay during transfection and by co-IP 
studies in infected cells (Donnelly et al., 2007; Stylianou et al., 2009). This interaction was also 
confirmed by GFP-trap in the previous chapter. Here, the interaction of VP16 with VP13/14 has been 
characterised in more detail and identified the interaction domain to be at the N-terminus of VP13/14 
and, more specifically, at the first 76 residues of VP13/14. In addition, the third arginine cluster of 
VP13/14 was proven to be essential for efficient binding with VP16, as well as the residues 37 to 60 
of VP13/14. It could be hypothesised that VP16 and VP13/14 form a complex due to the highly-
positive arginine boxes of VP13/14 and the negatively-charged activation domain of VP16. Although 
the interaction domain of VP16 with VP13/14 is highly basic, VP13/14 contains other basic residues 
that did not interact with VP16. Consequently, the charges are likely to facilitate the direct interaction 
of the two proteins but are not sufficient in itself. The interaction between VP13/14 and VP16 was 
also seen in a cellular lever, where co-expression of these proteins significantly altered their 
localisation and were co-localised in large nuclear domains. This observation supports the interaction 
of VP16 with the NLS domain of VP13/14.   
A VP13/14 knockout virus was characterised to examine the impact of VP16 interaction with 
VP13/14 in virus growth. The growth kinetics of the mutant virus were initially monitored and in 
agreement with other reports in other alphaherpesviruses, such as HSV-1, PRV, MDV and BHV-1, a  
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Figure 4.8: Tegument proteins and glycoproteins assemble into ∆13/14 virions. Extracellular virions 
were Ficoll-purified from confluent BHK cells infected at an moi of 0.02 with the KOS wild type or 
Δ13/14 viruses. (A) 1ml consecutive fractions were collected across the gradient of ∆13/14 and 
samples were analysed by coomassie blue-stained SDS-PAGE gel. Fractions 7 to 10 were pooled, 
concentrated and then analysed by (B) coomassie blue-stained SDS-PAGE gel along with KOS 
purified virions or (C) Western blotting using antibodies directed against VP5, VP13/14, VP16, VP22, 
ICP0, ICP27, UL16, UL21, gB, gD and gC. (D) Samples from the time course of KOS wild type and 
∆13/14 viruses on HaCat cells were blotted for gC expression. Identifiable virion components in the 
stained gel are annotated; molecular weight markers (kDa) are shown on the left. 
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decrease in virus growth was observed (Dorange et al., 2002; Kopp et al., 2002; Lobanov et al., 2010; 
Zhang & McKnight, 1993). A reduction in virus production and release was shown in Vero and 
human keratinocyte cells, when the knockout virus was compared with BAC-derived KOS and KOS 
wild type viruses, respectively. However, the protein expression was almost comparable between the 
viruses in both cell lines. When the assembly of VP16 and other tegument proteins and glycoproteins 
was tested, it was shown that VP16, VP22 and gB were unaffected by the deletion of VP13/14. ICP0 
and gD levels, on the other hand, were increased in the Δ13/14 virions compared with the wild type 
KOS virions. Moreover, ICP27 was not assembled in either virus as this protein is not associated with 
the virion; however this is observed only in KOS strain viruses (Sedlackova & Rice, 2008; Su et al., 
2006; Yao & Courtney, 1992). It should be mentioned that a publication by our group has shown 
ICP27 being packaged into virions of other HSV-1 wild type strains, strain 17 and sc16 (Maringer & 
Elliott, 2010). The demonstration of gC being expressed and packaged only into the Δ13/14 and not 
KOS wild type viruses requires further investigation. However, this experiment needs to be repeated 
to compare the Δ13/14 virions with virions with its parental BAC derived KOS virus. 
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5.1 Chapter Introduction 
The herpes simplex virus type 1 protein VP16 has been extensively studied in the context of 
its role as a powerful transactivator of viral IE gene expression (Campbell et al., 1984). The 490 
amino acids of VP16 can be divided into two domains. The N-terminal 410 aa that forms a complex 
with host proteins Oct-1 and HCF, and the highly acidic C-terminal 80 aa, which functions as an 
independent activation domain (Greaves & O’Hare, 1989; O’Hare, 1993; Stringer et al., 1990; 
Triezenberg at al., 1988). Additionally the activation domain can be further divided into two sub-
regions, the VP16N (or H1) comprising 413-456 aa and VP16C (or H2) consisting of 450-490 aa 
(Sullivan et al., 1998; Walker et al., 1993) (Fig. 5.1). Elliott and colleagues demonstrated the direct 
interaction of VP22 with the C-terminal sub-region of the activation domain of VP16 (Elliott et al. 
1995). Since in the previous chapter the domain VP13/14 interacting with VP16 was delineated to the 
N-terminus, the next step would be to define the domain of VP16 binding to the N-terminus of 
VP13/14. This chapter explores the interaction of VP22 and VP13/14 with the activation domain of 
VP16 in infected and transfected cells. 
 
5.2 Characterisation of the VP16 mutant lacking the C-terminus of the activation domain 
The starting point for this work was the existing data that VP22 interacts directly in vitro with 
the C-terminus of the activation domain of VP16 (Elliott et al. 1995).  As demonstrated in the 
previous chapter, VP13/14 also directly interacts with VP16. To further examine the relationship 
between VP22, VP13/14, and the activation domain of VP16, we made use of a virus lacking the last 
38 residues of the C-terminus (452-490aa) of the activation domain of VP16 (ΔCt) and its rescue 
mutant (ΔCtRev) based on the wild type KOS strain, kindly provided by Professor Triezenberg 
(Michigan State University) (Tal-Singer et al., 1999). Before using these HSV-1 mutant viruses, we 
first characterised their growth kinetics in Vero cells. A one-step growth curve showed that there was 
no major defect in virus production or release when the mutant virus ΔCt was compared with its 
revertant (Fig. 5.2A). The viral release from the mutant appeared to be a log down different from the 
revertant at 12 h, before reaching approximate equivalence at 24 h. Whereas, the cell associated virus 
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Figure 5.1: Line drawing of VP16. The activation domain of VP16 is shown in the grey box, which is 
then divided into N and C-terminal sub-domains (Sullivan et al., 1998; Walker et al., 1993). In light 
blue is indicated the interaction domain of VP16 with VP22  that was demonstrated by Elliott and 
colleagues (Elliott et al. 1995).  
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Figure 5.2: Growth characteristics of HSV-1 lacking the C-terminus of VP16. Single-step growth 
curves of ΔCt or ΔCtRev viruses were carried out by infecting confluent Vero cells at a multiplicity of 
2 and harvested at the indicated times for (A) cell-associated or released virus or (B) Western blotting 
analysis with antibodies as annotated. All growth curves were carried out in triplicate – error bars.  
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was similar in both viruses, as it started with less than half a log reduction of ΔCtv compared to the 
revertant and at 20 h the reduction reached almost 8 fold difference and finally by 24 h both viruses 
produced similar levels of virus. 
Concurrently with the growth curve, infected cells were harvested in SDS-PAGE loading dye 
for Western blotting analysis against antibodies for VP16, VP13/14, ICP0 and VP22 expression. The 
proteins were detectable from 12 hpi from cells infected with ΔCtRev, whereas cells infected with 
ΔCt had a delay in protein expression and the proteins were evident from 16 hpi except VP22 that was 
first seen at 12 hpi (Fig. 5.2B). Also, ICP0 and VP16 expression was noticeably reduced in ΔCtv, 
whereas VP22 and VP13/14 were similarly expressed in both viruses.  
  
5.3 The C-terminus of VP16 is essential and sufficient for binding to VP22 and VP13/14 during 
infection and transfection 
As mentioned previously, Elliott and colleagues were the first to show a direct interaction of 
VP16 with VP22 in vitro through the C-terminal (H2 region) activation domain of VP16. To verify 
the interaction of VP22 with the H2 region of the activation domain of VP16 during infection, Vero 
cells were infected at a multiplicity of 1 with the HSV-1 wild type strain KOS, ΔCt, ΔCtRev or Δ22v. 
Δ22 acted as a negative control. Even though VP22 was equally precipitated in all samples, only full 
length VP16 was co-precipitated (Fig. 5.3A), confirming the requirement for the C-terminus of VP16 
in its interaction with VP22 (Elliott et al. 1995). 
To characterise further the interaction between VP13/14 and VP16, VP13/14 was also 
immunoprecipitated from Vero cells infected with KOS, ΔCt or ΔCtRev viruses. VP13/14 was 
immunoprecipitated with equivalent efficiency in all the infected extracts. It was possible that the 
interaction between VP13/14 and VP16 was lost when the 38 residues of the C-terminal of VP16 were 
deleted and that this interaction was recovered with the revertant (Fig. 5.3B). However, this 
observation was difficult to be determined due to the appearance of the heavy chain on the blot for 
VP16 that are the same size as the VP16 mutant. 
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Figure 5.3: VP16 activation domain is required for binding to VP22 and VP13/14. Vero cells were 
infected with KOS, Δ22v, ΔCt or ΔCtRev at an moi of 1 and whole cell lysates were harvested at 18 
hpi. (A) VP22 or (B) VP13/14 were immunoprecipitated from RIPA soluble extracts and the resulting 
immunocomplexes were subjected to Western blot analysis using antibodies raised against VP22, 
VP13/14 and VP16 
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Since we demonstrated that VP13/14 and VP22 interact with the C-terminus of the activation 
domain of VP16 by Co-IPs, we wanted to further analyse this interaction with the use of GST pull 
downs. The range of plasmids, expressing truncated forms of VP16 fused to GST, used for this 
experiment are detailed in Figure 5.4A (kindly provided by Professor O’Hare). Plasmids expressing 
the full length VP16 (GST-VP16), its truncated forms, or GST alone were expressed in E. coli cells 
and the GST fusion proteins were then purified on glutathione–Sepharose beads (see Appendix I). 
Approximately equal amounts of the GST fusion proteins were used in the pull down assay, as 
determined by coomassie blue staining (Fig. 5.4B). Cells infected with the wild type HSV-1 s17 virus 
were then lysed in lysis buffer for GST pulldowns and incubated with equivalent amounts of purified 
GST fusion proteins bound to glutathione–Sepharose beads. After incubation and extensive washing 
with lysis buffer, the bound material was separated by SDS-PAGE and then analysed by Western 
blotting. VP22 was used as a positive control since this interaction has been previously demonstrated 
(Elliott et al. 1995). The full length GST-VP16 fusion protein pulled down VP13/14 from the infected 
cell lysate, whereas GST alone did not, indicating that the interaction is VP16 specific (Fig. 5.4C). 
Deletion of the whole activation domain (GST-16 -AD) or even the H2 sub-region (GST-16 H1) of 
VP16 failed to pull down VP13/14. In contrast, GST-VP16 AD did pull down VP13/14, supporting 
and validating our Co-IP results, that the region of VP16 required to facilitate the interaction with 
VP13/14 and VP22 lies within the C-terminal activation domain of the last 38 amino acids. 
 To validate those results further, the interaction of VP16 with VP22 and VP13/14 was shown 
to occur in the absence of other viral proteins by repeating these pull downs from transfected cell 
extracts. COS-1 cells were transfected with GFP-13/14 or GFP-22 expressing plasmids. Twenty hours 
later the transfected monolayers were lysed with lysis buffer for GST pull downs and a fraction of 
each cell lysate - input sample - was analysed for expression of the GFP fusion proteins by Western 
blotting (Fig. 5.4D). The remaining fraction of each cell lysate was incubated with equivalent amounts 
of purified GST fusion proteins bound to glutathione–Sepharose beads, as before. As shown for the 
infected cell extracts, only full length GST-VP16 and GST-VP16 AD were able to pull down GFP-
VP13/14. However, when 1 to 409 aa were deleted, the interaction intensity between VP16 and  
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Figure 5.4: VP22 and VP13/14 interact with the C-terminus of VP16 in infection and transfection. 
(A) Diagrammatic representation of the GST-VP16 constructs used. GST (black box) was fused to 
either full-length VP16 comprising the complex formation domain (white box) and the acidic 
activation domain (hatched box) or variants with mutations at these regions as indicated. (B) GST and 
GST fused to full length VP16 and its truncated mutants were expressed and purified from E.coli 
strain BL21 and analysed by SDS-PAGE, followed by coomassie blue staining. (C) Vero cells were 
infected with s17 at moi 1, cell lysates were then harvested at 18hpi in 1.1ml lysis buffer. (D) 
Subconfluent COS-1 cells were transfected with (i) GFP-13/14 or (ii) GFP-22 expressing plasmids, 
20h later the cells were harvested in 1.1ml lysis buffer for GST pull downs. The soluble extracts –
infected and transfected- were incubated with GST fused proteins described in panel A and the bound 
proteins were analysed by SDS-PAGE, followed by Western blotting against VP22, VP13/14 for the 
infected samples and GFP for the transfected samples. AD: Activation Domain, In: input sample. 
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VP13/14 was reduced, a reproducible result after multiple repeats of this experiment (Fig. 5.4D(i)). 
On the other hand, GFP-VP22 interacted equally well only with full length GST-VP16 and GST-
VP16 AD confirming and validating previous reports and our results from the infected extracts (Fig 
5.4D(ii)).   
The requirement of the C-terminus of VP16 to interact with VP13/14 was also observed in the 
protein localisation in transfected cells. In Figure 4.4, full length VP16 alters its diffuse pattern 
localisation to co-localise with VP13/14 in large nuclear domains. However, when GFP-VP13/14 was 
co-expressed with a VP16 mutant lacking the last 79 aa of VP16 (VP16Δ) in COS-1 cells this 
alteration in localisation did not occur. When expressed alone, VP16Δ was distributed in a diffuse 
pattern in the nucleus and cytoplasm, whereas GFP-VP13/14 was diffuse within the nucleus, but also 
displayed a large population that localised within nuclear domains. This localisation was sustained 
when these proteins were co-expressed as well (Fig. 5.5). These data validated and extended our 
results that VP13/14 interacts with the C-terminus domain of VP16 also in transfection.  
 
5.4 Virion packaging of VP13/14 is not dependent on its interaction with VP16 
The next step was to evaluate the role of the C-terminus of VP16 activation domain in the 
assembly of VP13/14 and other tegument proteins and glycoproteins into HSV-1 virions. In order to 
do so, extracellular particles were gradient purified from BHK cells infected with wild type strain 
KOS or ΔCt viruses. The purified virion samples were then analysed by SDS-PAGE followed by 
staining with coomassie blue or Western blotting. Virions were equalised against the major capsid 
protein VP5, which also served as a loading control. The general profile of ΔCt virions was unaltered 
compared to the wild type, with the exception of VP16 due to the deletion of the C-terminus of the 
protein (Fig. 5.6A). Interestingly, VP13/14 was packaged in the ΔCt virion, despite the clear 
importance of the C-terminus of VP16 for their interaction. As expected, the interaction with VP16 
was not required for the incorporation of VP22 into virions (O’Regan et al. 2007). Additionally, vhs 
was also packaged into virions in similar levels, indicating that the C-terminus of VP16 is not required 
for vhs assembly into the virion (Fig. 5.6B). Furthermore, the glycoproteins, gD, gB and gE, were  
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Figure 5.5: VP16 does not co-localise with VP13/14 when the C-terminus of VP16 is deleted. (A) 
COS-1 cells grown on cover slips were transfected with plasmids expressing YFP-VP13/14 or VP16Δ 
(1-411aa). Cells were fixed in 4% paraformaldehyde after 20 hours, followed by immunofluorescence 
staining performed with VP16 (LP1) antibody. (B) COS-1 cells grown on cover slips were co-
transfected with the same plasmids as above and treated as before. Images were captured using a Zeiss 
Axiovert S100 TV inverted microscope with a 60x lens. Green, GFP-VP13/14 and red, VP16Δ. 
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Figure 5.6: VP13/14 packaging into the virus particle is independent of VP16 interaction. (A) Virions 
were Ficoll-purified from confluent Vero cells infected at moi of 0.02 with the wild-type HSV-1 
strain KOS or ΔCt viruses. Samples were analysed by Coomassie blue staining SDS-PAGE gel; 
molecular weight markers (kDa) are shown on the left; identifiable virion components are annotated 
on the right. (B) Purified virions were subjected to Western blot analysis using antibodies directed 
against VP5, VP16, vhs, VP13/14, VP22, gD, gB and gE. 
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packaged in equivalent levels in both viruses. 
 
5.5 VP22 and VP13/14 equally interact with VP16 
Since VP22 and VP13/14 interact with the same region of VP16, we wanted to see whether 
these two proteins would compete in order to interact with VP16. In this study GST-VP16 was used 
as it binds efficiently to both VP22 and VP13/14. COS-1 cells were transfected with GFP-22 
expressing plasmid, 16 h post transfection the cells were harvested and increasing volumes of extracts 
were incubated with GST-VP16 beads in order to determine at which volume the beads were saturated 
with VP22. After incubation and extensive washing, the bound complexes and the flow-through were 
analysed by SDS-PAGE, followed by Western blotting against GFP. After observation of the flow-
through and the pull downs, it was decided that 500 µl of soluble extract was sufficient to saturate 
GST-VP16 beads, since both flow through and binding reached a peak at 500 µl of GFP-22 extract 
(Fig. 5.7A). Next, COS-1 cells were again transfected with GFP-22 or SV5-VP13/14 expressing 
plasmids, and at 16 h post transfection the cells were harvested and solubilised. As positive controls, 
500 µl of each soluble extract was incubated with GST-VP16 beads separately. First GST-VP16 
beads were saturated with 500 µl of GFP-22 soluble extract and after washing the beads, 400 µl, 800 
µl or 1.2 ml of SV5-VP13/14 soluble extract were incubated with the saturated beads. The beads were 
then washed again and the bound complexes were analysed by SDS-PAGE followed by Western 
blotting for GFP and SV5 expression. From the blots it was evident that both proteins bind equally 
and at the same time to VP16 and therefore appeared to be no competition for VP16 binding (Fig. 
5.7B). 
 
5.6 VP22 and VP13/14 interact but not through their interaction with VP16 
Given the evidence that VP22 and VP13/14 interact with VP16 at the same region and 
without competition, it can be suggested that these two proteins –VP22 and VP13/14 - interact 
through their common partner –VP16 - and potentially form a complex. In order to determine whether  
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Figure 5.7: VP22 and VP13/14 interact equally with VP16. (A) Subconfluent COS-1 cells were 
transfected with GFP-22 expressing plasmid. Soluble extracts of 100 µl, 200 µl, 300 µl, 400 µl, 500 
µl, 600 µl, 700 µl, 800 µl, 900 µl and 1000 µl aliquotes were incubated with GST fused VP16 beads 
in order to saturate the beads. The flow through and bound proteins were analysed by SDS-PAGE, 
followed by Western blotting against GFP. In: input sample. (B) Subconfluent COS-1 cells were 
transfected with GFP-22 or SV5- tagged VP13/14 expressing plasmids. 500µl of GFP-22 soluble 
extract was first incubated with GST-VP16 beads to saturate them and after washing the beads 400 µl, 
800 µl or 1.2 ml of SV5-VP13/14 soluble extract were incubated with the saturated beads. As positive 
controls, 500 µl of each soluble extract was incubated with GST-VP16 beads separately. The bound 
proteins were analysed by SDS-PAGE, followed by Western blotting against GFP or SV5. 
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VP22 and VP13/14 interact by their direct interaction to VP16, the ΔCt virus and its revertant were 
utilised. VP22 was immunoprecipitated from Vero cells infected with ΔCt, ΔCtRev or Δ22 viruses 
and the resulting complexes were analysed by Western blotting against VP22, VP13/14 and VP16. 
The VP22 C-terminus antibody was used in this study since only with this antibody could VP13/14 be 
co-immunoprecipitate with VP22 (see Fig. 3.6B). Also, for this experiment the Δ22 virus acted as a 
negative control. Equivalent levels of VP22 were precipitated from cells infected with ΔCt and its 
revertant. VP13/14 co-immunoprecipitated with VP22 at similar levels in the ΔCt and ΔCtRev 
viruses, suggesting these proteins are able to form a complex in the absence of VP16 (Fig. 5.8A). This 
observation was corroborated when GST-VP22 beads were used to pull down VP13/14 from ΔCt and 
ΔCtRev infected cells (Fig. 5.8B). Initially, GST-VP22 was expressed in sf9 insect cells and purified 
on glutathione-Sepharose beads.  GST alone bound on glutathione-Sepharose beads was used as 
control. GST-VP22 and GST bound to glutathione-Sepharose beads were incubated with ΔCt or 
ΔCtRev infected extracts and after washing the bound complexes were analysed by Western blotting. 
VP16 was used as the positive control in both assays, since this interaction has been previously 
proven. It should be noted that the band observed for GST-VP22 pull down of VP16 from ΔCt virus 
was believed to a background band of full length GST-VP22, due to its faintness, that had cross 
reacted with the VP16 antibody (Fig. 5.8B). Moreover, GST-VP22, as anticipated, pulled down 
VP13/14 from both viruses, although more efficient binding was observed with the ΔCtRev virus 
since VP16 interaction with VP22 and VP13/14 was restored (Fig. 5.8B).  
 
5.7 Chapter Summary 
In the previous chapter it was demonstrated that the first 76 residues of VP13/14 were 
sufficient for binding to VP16. In this chapter the VP16 domain that interacts with VP13/14 was 
defined. VP22 was used as a positive control in these studies as it has been previously reported that it 
interacts with the C-terminal of the activation domain of VP16. Co-immunoprecipitation studies 
during infection and GST pull downs from infected and transfected extracts proved that both - VP22 
and VP13/14 - interacted with the same C-terminal region of the activation domain of VP16. It was  
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Figure 5.8: VP22 and VP13/14 interact independently to their interaction with VP16. Vero cells were 
infected with ΔCt, ΔCtRev or Δ22v at a moi of 1 and whole cell lysates were harvested at 18 hpi.  (A) 
RIPA lysates were immunoprecipitated with VP22-C antibody, and the resulted immunocomplexes 
were analysed by Western blotting using antibodies against VP22, VP13/14 and VP16. (B) Infected 
extracts were incubated with GST tagged VP22 or GST alone bound to glutathione-Sepharose beads. 
Input and bound samples were analysed by SDS-PAGE, followed by Western blotting against VP13/4 
and VP16. Asterisk denotes GST-VP22 band that has cross reacted with VP16 antibody. 
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initially hypothesised that VP22 and VP13/14 form a complex through their interaction with VP16. 
However, VP22 co-precipitated VP13/14 when VP16 was not present in the complex, although VP16 
binding was necessary for more efficient binding between VP22 and VP13/14. Also these proteins did 
not appear to compete for binding opportunities with VP16. VP13/14 and VP16 localisation, as 
previously demonstrated, was dramatically altered when transiently co-expressed, they were shown to 
colocalise in large nuclear domains. This colocalisation was prevented when VP13/14 was co-
expressed with a mutant VP16 lacking the last 79 aa of the protein. This establishes the requirement 
for the C-terminal of VP16 for its interaction with VP13/14. 
The growth characteristics of the virus lacking the C-terminal sub-region of the activation 
domain of VP16 were also analysed. There was little effect on gene expression as VP22 and VP13/14 
expression was comparable in both viruses, although VP16 and ICP0 expression was reduced in the 
ΔCt virus compared to the revertant virus. This observation was in line with a report indicating that 
the N-terminal (H1 or VP16N) was more important than the C-terminal of the activation domain of 
VP16 for efficient activation of IE gene expression during lytic infection (Yang et al., 2002). In 
agreement with the literature, VP22 packaging was independent of its interaction with the activation 
domain of VP16 and assembled into the virions at wild type levels, as did vhs, whose interaction with 
VP16 has been mapped in residues 335 to 369 of VP16 (O’Regan, Murphy, et al., 2007; Schmelter et 
al., 1996).  Interestingly, VP13/14 was also assembled into ΔCt virions demonstrating that, although 
these proteins directly interact, at least the C-terminus of VP16 was not involved in recruiting 
VP13/14 into the virion. This proves the difficulty to identify which specific protein-protein 
interactions are involved in virus assembly. 
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6.1 Chapter Introduction 
Elliott and co-workers provided the first evidence that VP22 and VP16 directly interact, and 
since then the complex has been confirmed by other reports (Elliott et al. 1995; Hafezi et al. 2005; 
O’Regan, Murphy, et al. 2007; Stylianou et al. 2009). The C-terminus of VP22 has been shown to be 
both essential and sufficient for its interaction with VP16 and gE (Hafezi et al., 2005; O’Regan, 
Murphy, et al., 2007; Stylianou et al., 2009). Moreover, VP16 has been demonstrated to complex with 
another tegument protein, virion host shutoff protein, during infection and transfection (Lam et al., 
1996; Smibert et al., 1994). In addition, VP22 also interacted with vhs, but only in the presence of 
VP16 (Taddeo et al., 2007). In the same report it was demonstrated that VP22 and VP16 were 
required for the accumulation of vhs protein in tranfected cells but not the accumulation of vhs 
mRNA. Also, Taddeo and co-workers proposed that vhs protein sequesters mRNA in compartments 
inaccessible to translational machinery and that VP16 and VP22 rescue the mRNAs by interacting the 
vhs protein (Taddeo et al., 2007). 
VP22 is also involved in a different multi-component complex incorporating VP13/14-U16-
UL21, as demonstrated in chapter 3. This complex was first shown here and consequently its function 
is unknown. Moreover, UL16 and UL21 have been demonstrated not only to interact with each other 
but also the cytoplasmic tail of gE (Harper et al., 2010; Yeh et al., 2011), which raised the question 
whether VP22 interacts with UL16 and UL21 via their direct interaction with gE . This chapter 
explores the two discrete sub-complexes involving VP22 during infection. 
 
6.2 VP16 interacts with the C-terminus of VP22  
To confirm the domain of VP22 that facilitates interaction with VP16 was within the C-
terminus of VP22, a series of C-terminal truncation mutants were used in the context of a HIS-VP22 
fusion protein (Fig. 6.1A). The polyhistidine fused proteins were expressed and purified from E.coli 
on nickel Ni-NTA agarose beads before being evaluated in a HIS pull down assay for their ability to 
bind to VP16. Wild type HSV-1 s17 infected lysates were incubated with equivalent amounts of 
purified HIS fusion proteins bound to Ni-NTA beads (Fig. 6.1B). After 3 hour incubation, the beads 
were washed extensively to remove non-binding proteins and the resulting VP22-specific complexes  
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Figure 6.1: C-terminus HIS-tagged VP22 pulls down VP16 in infected cells.  (A) Schematic diagram 
of the HIS-tagged VP22 truncated forms used in this study. (B) HIS-tagged VP22 truncated mutants 
were expressed and purified from E.coli strain BL21 on nickel Ni-NTA agarose resin and analysed by 
SDS-PAGE, followed by coomassie blue staining. The values on the far left are molecular weights in 
kDa. (C) Vero cells were infected with s17 at an moi of 1, cell lysates were then harvested at 18hpi in 
1.1ml lysis buffer. The soluble extracts were incubated with approximately equal amounts of HIS 
fused proteins, as shown in panel B, and the bound proteins were analysed by SDS-PAGE, followed 
by Western blotting against VP16. In: input sample. 
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were analysed by SDS-PAGE, followed by Western blotting with the anti-VP16 antibody. In 
agreement with other reports, residues 254-301 of VP22 fused to HIS did not interact with VP16 
(Hafezi et al., 2005; O’Regan, Murphy, et al., 2007). However, when we tested the interaction of 
VP16 with the HIS-tagged VP22 160-301aa containing an internal deletion within the VP16 binding 
domain (Δ213-226aa) and HIS-VP22 159-257 aa, a reduction in binding was observed in comparison 
to VP16 binding with the 160-301 residues of VP22 (Fig. 6.1C). This implied that these 13 residues 
(213-226aa) within the VP16 binding domain were as important as the last 43 aa of VP22 for efficient 
binding to VP16. In addition, the deletion of the same 13 residues (213-226aa) has been previously 
demonstrated to abrogate the interaction of VP22 with gE and the packaging of VP22 into the virus 
particle but still interact with VP16, validating our result (Stylianou et al., 2009).  
In order to confirm the region of VP22 involved in binding to VP16 by transient transfection 
as well, a range of GFP-tagged N- and C-terminal truncations of VP22 were expressed in COS-1 cells 
and tested them in our GST-VP16 pull down assays (Fig. 6.2A). The N-terminal 160 residues of VP22 
showed no binding to GST-VP16, while the C-terminal 140 residues bound as efficiently as the full-
length protein, suggesting that no other virus protein was involved (Fig. 6.2B). In agreement with the 
infection studies by O’Regan and Hafezi, the VP16 binding domain was placed at the C-terminal 
region of VP22 (Hafezi et al., 2005; O’Regan, Murphy, et al., 2007). To define the N-terminal limit of 
the VP16 binding domain, we then used a number of mutants with larger N-terminal truncations of 
VP22 (Fig. 6.2A). Residues 174 to 301 and 160 to 301 both bound to VP16, while a further truncation 
of 18 residues from the N terminus (192-301aa) abolished the VP22-VP16 interaction (Fig. 6.2B). 
Thus, we could delineate the N-terminal limit of the VP16 binding domain of VP22 at residue 174 of 
the protein. The C-terminal limit of the VP16 binding domain was determined by using C-terminal 
truncation mutants expressing residues 1 to 212 and 1 to 226, respectively (Fig. 6.2B). However, 
neither of these proteins were able to bind to GST-VP16 in this pull down assay, although in a 
previous study VP16 coimmunoprecipitated with GFP-tagged VP22 in cells infected with G22 mutant 
expressing residues 1-212 (Hafezi et al., 2005). Hence, in the present study the region between 
residues 174 and 192 of VP22 was essential for interaction with VP16. Taken together these two 
assays, the minimal domain of VP22 that facilitates interaction with VP16 can be refined to 174 to  
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Figure 6.2: The residues 174 to 192 of VP22 were required for VP16 interaction.  (A) Schematic 
diagram of the GFP-tagged VP22 truncated forms used in this study. (B) COS-1 cells were transfected 
with the plasmids described in panel A, and 20 hours later the cell lysates were harvested in 1.1ml 
lysis buffer. The soluble extracts were incubated with GST-VP16 purified on glutathione-Sepharose 
beads and the bound proteins were analysed by SDS-PAGE, followed by Western blotting against 
GFP. In: input sample, B: bound. 
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257 residues of VP22. 
 
6.3 VP22 binding to vhs is mediated by VP16 in infection 
VP22 has been shown, in the literature and here, to be involved in a number of complexes, 
including the complex incorporating VP16-VP22-vhs. Taddeo and coworkers demonstrated that vhs 
interacts with VP22 only in the presence of VP16 in transfection (Taddeo et al., 2007). In addition, 
during our GFP-trap studies both GFP-tagged VP22 and VP16 pulled down vhs, further validating 
this tripartite complex in infected cells (see Figures 3.2B and 3.3B). To examine whether in infected 
cell extracts VP22 requires to interact with VP16 in order to bind to vhs, the mutant virus expressing 
VP16 with the C-terminal of the activation domain deleted and its revertant were used in a GST-VP22 
and GST-gE pull down assays. It should be mentioned that the vhs antibody is raised against GST-
vhs, therefore resulting in the presence of GST-VP22 and GST bands in the vhs blot (Fig. 6.3A, 
indicated by arrows). GST-VP22 was not able to bind to vhs from the ΔCt infected extract, as VP22-
VP16 interaction was abolished, compared to the ΔCtR virus where VP22 interaction with VP16 and 
consequently with vhs was restored. Neither VP16 nor vhs were pulled down by GST alone, 
indicating it was VP22 specific interaction (Fig. 6.3A). The same result was shared when GST-gE 
pulled down vhs only when VP16 was present in a complex with VP22, while VP22 bound efficiently 
to GST-gE in both extracts (Fig. 6.3B). Interestingly, VP16 bound to GST-gE but only through its 
interaction with VP22. Therefore, as suggested before in transfection studies, VP22 required VP16 in 
order to interact with vhs in infected cells. 
 
6.4 VP22 forms a complex with UL16 and UL21, which does not involve gE 
In chapter 3 it was demonstrated that a possible complex was formed between tegument 
proteins VP22, VP13/14, UL16 and UL21. Also, in a recent report UL16 was shown to directly 
interact with the cytoplasmic tail of gE, which is also a known partner of VP22 (O’Regan, Bucks, et 
al., 2007; Stylianou et al., 2009; Yeh et al., 2011). This raised the possibility that VP22 may be 
forming a complex with UL16 and UL21 via its interaction with gE. Since the GFP-trap system  
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Figure 6.3: VP22 pulls down vhs via its interaction with VP16. Vero cells were infected with ΔCtv or 
ΔCtRev at an moi of 1. Twenty hpi cells were harvested and the soluble extracts were incubated with 
(A) GST-tagged VP22 or (B) GST-gE and GST beads and the bound proteins, after washing, were 
analysed by SDS-PAGE, followed by Western blotting against vhs, VP22 and VP16. * indicates GST-
VP22 background band. Dot indicates the pull down of vhs by GST-gE 
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proved so fruitful, it was decided to use the same system to test if a previously characterised GFP-
tagged VP22 mutant that is unable to bind to both gE and gM, could still precipitate UL16 and/or 
UL21 (Stylianou et al., 2009). The cell lysates from Vero cells infected with full length G22, ΔgEbd 
or Δ22 viruses (Fig.6.4A) were treated as previously described for GFP-trap purification. The 
resulting complexes were blotted for gE and as expected it only co-purified with full length VP22, 
whereas the gE and gM binding mutation had no effect on VP22 interaction with either VP16 or 
VP13/14 (Fig. 6.4B). This result indicated that the interaction between VP22 and VP13/14 was 
independent to their relationship with gM. Interestingly, both UL16 and UL21 bound as efficiently 
with both variants of VP22 indicating that gE binding was not required for VP22 to interact with 
UL16 or UL21 (Fig. 6.4B).  
 
6.5 Chapter summary 
In the previous chapter it was demonstrated in multiple approaches the interaction of VP22 
with VP16 and the requirement of the C-terminus of the activation domain of VP16 for this 
interaction to exist. Also, in earlier reports the C-terminus of VP22 identified to be sufficient for the 
interaction with VP16. In this chapter, the VP22-VP16 interaction domain was confirmed to be within 
the C-terminus of VP22 during infection and transfection, which was demonstrated by HIS and GST 
pull down assays. In contrast to the report by Hafezi and colleagues showing the co-precipitation of 
VP16 with the residues 1-212 of VP22, in our GST-VP16 studies this interaction was not achieved 
(Hafezi et al., 2005). 
VP22 and VP16 were shown to form a complex with another tegument protein vhs (Taddeo et 
al., 2007). Even though VP16 has been demonstrated to directly interact with vhs, VP22 can interact 
with vhs only in the presence of VP16 when transiently transfected (Lam et al., 1996; Smibert et al., 
1994; Taddeo et al., 2007). Here, we have demonstrated this tripartite complex exists in infected 
extracts and VP22, as when transfected, interacts with vhs via their interaction with VP16. In a more 
recent report it was demonstrated that VP13/14 also interacts with vhs in absence of other viral  
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Figure 6.4: VP22 forms a multi-component complex with UL16 and UL21 independent to their 
interaction with gE. (A) Line drawings of the viruses used in this study. (B) GFP-trap was performed 
on lysates of Vero cells infected with G22v, ΔgEbd or Δ22v expressing viruses at an moi of 1. Input 
and pull down samples were subjected to SDS-PAGE and Western blotting as annotated. 
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proteins, and this interaction was confirmed in our GFP-trap studies from infected cells. The same 
GST-VP22 assay was used on ΔCt and ΔCtR infected extracts, where VP13/14 was shown to bind to 
GST-VP22 independently to their interaction with VP16 (see Fig. 5.8B). Taking together these 
results, it could be suggested that under these infection conditions VP13/14 also required VP16 to 
interact with vhs.   
VP22 was demonstrated, in chapter 3, to be involved in another complex, incorporating 
UL16, UL21 and VP13/14. Although UL16, and consequently UL21, was shown to interact with gE, 
as did VP22, the complex formed between VP22-UL16-UL21 did not involve gE as observed by 
GFP-trap analysis of a mutant VP22 virus unable to bind to gE or gM. In addition, VP22 and VP13/14 
that shared a common glycoprotein partner, gM, were still able to interact in the absence of VP22-gM 
interaction. Since VP22 and VP13/14 do not interact in the absence of other viral proteins and do not 
require VP16 or gM interaction to exist, it could be suggested that VP22 and VP13/14 interact via 
their binding to UL16 and UL21.  
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7.1 Chapter introduction 
Interactions between tegument proteins and viral glycoproteins are thought to contribute to 
tegument assembly (Mettenleiter 2002). HSV-1 VP22 is reported to interact with gD, gE and gM, 
while PRV VP22 is also known to bind to gM and gE (Chi et al., 2005; Farnsworth et al., 2007; 
Fuchs, Klupp, et al., 2002; O’Regan, Bucks, et al., 2007; Stylianou et al., 2009). In line with reports 
for PRV, we have also demonstrated in a recent publication that the double deletion of gE/gM in 
HSV-1 failed to package VP22, while both single deletions packaged it in wild type levels (Fuchs, 
Klupp, et al., 2002; Maringer et al., 2012). Another major tegument protein, VP13/14, has also been 
shown to interact with gM in transiently transfected cells and this interaction was confirmed in our 
GFP-trap analysis in infected cells (Stylianou et al., 2009). 
In this chapter the association of VP22 with gM was further analysed and the interaction of 
VP13/14 with gM was characterised during transfection. Data presented in section 7.2 were published 
in the Journal of Virology (Maringer et al., 2012).    
 
7.2 VP22 interaction with the cytoplasmic tail of gM 
To verify and reproduce the interaction of VP22 with the cytoplasmic tail of gM 
demonstrated by Co-IP studies and pull down assay during transfection, we tested the binding ability 
of VP22 with GST-gM in a range of viruses expressing truncated forms of VP22, described in panel 
A of Figure 7.1 (Maringer et al., 2012; Stylianou et al., 2009). We first expressed and purified on 
glutathione-Sepharose beads the C-terminal 126 residues of the cyoplasmic tail of gM (see Appendix 
A.1) and then carried out the pull down assay. The resulting complexes bound to GST-gM were then 
analysed by Western blotting for the presence of GFP-tagged VP22 (Fig. 7.1B). The region 160-301 
of VP22 was able to bind to the cytoplasmic tail of gM, confirming our Co-IP studies and agreeing 
with our pull downs during transfection (Maringer et al., 2012; Stylianou et al., 2009). Also, the 
region 108-301 of VP22 bound efficiently to GST-gM, while regions 192-301 and 212-301 of VP22 
failed to bind to GST-gM validating our previous findings (Stylianou et al., 2009). Although the virus  
Chapter 7                                                           Tegument proteins interact with envelope glycoproteins 
 
136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: VP22 interacts with GST-gM at the C-terminus of VP22 in infection. (A) Line drawings 
of the N- and C-terminal truncation forms of GFP-expressing VP22 viruses used in this study. (B) 
Vero cells were infected with viruses expressing each of the GFP-tagged mutant form of VP22 shown 
in panel A, and the soluble extracts were incubated with GST- tagged gM and GST beads and the 
bound proteins were analysed by SDS-PAGE, followed by Western blotting against GFP. The values 
on the left indicate the molecular weights in kDa. G represents GST controls. 
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expressing the region 192-301 of VP22 was expressed poorly, as observed from the input sample on 
Fig. 7.1B, we did not expect GST-gM to interact with this region of VP22 since this interaction was 
not shown by transient transfection in our earlier report (Stylianou et al., 2009). 
7.2.1 VP22 expressed in the absence of gE can still bind to gM 
In a recent publication from our group it was shown that gM required VP22 to form a 
complex with gE (Maringer et al., 2012). However, it proved difficult to detect a complex between 
gM and VP22 in the absence of gE (Fig. 7.2A, kindly provided by Dr Kevin Maringer), suggesting the 
possibility of gE being somehow required for the VP22-gM complex to form. This was observed 
when VP22 was immunoprecipitated from Vero cells infected with the glycoprotein deletion mutants’ 
ΔgE, ΔgM and double deletion ΔgEgM. Since these mutants viruses were derived from wild type 
sc16, this virus was used as a positive control, whereas Δ22 virus served as a negative control. Similar 
levels of VP22 were immunoprecipitated in all viruses. While VP22-gE binding was unaffected by the 
deletion of gM, gM co-immunoprecipitation with VP22 was particularly weak in the ΔgE virus (Fig. 
7.2A). Given that VP22 is not packaged in the ΔgEgM virus and requires to interact with gE and gM 
for its virion incorporation, the residual level of gM binding seen in Fig. 7.2A could represent the 
minimal interaction required for VP22 assembly. Interestingly, the absence of gE induced a mobility 
shift in VP22, as the VP22 band migrated more slowly in the gel compared to VP22 expressed in the 
presence of gE. It has been previously shown that this slow migrating form represented the 
phosphorylated form of VP22, whereas the faster migrating form corresponded to the non-
phosphorylated VP22, suggesting that gE is somehow required for the expression of the non-
phosphorylated form of VP22 (Elliott et al., 1996, 1999). 
Due to the weak binding and the inability to immunoprecipitate gM from these viruses 
because of the rabbit polyclonal antibody used, which also non-specifically co-precipitated the gE-gI 
Fc receptor complex (data not shown), we decided to use the GST-gM assay to determine if VP22 
expressed in ΔgE infected cells was capable of binding to gM. Therefore, GST-gM beads were 
incubated with sc16 (wt), ΔgE, ΔgM and ΔgEgM infected cell extracts and the resulting complexes 
bound to gM were then analysed by Western blotting for the presence of VP22. Although previously  
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Figure 7.2: VP22 interacts with gM when expressed in the absence of gE. (A) Vero cells infected 
with Δ22v, sc16 (wt), ΔgE, ΔgM or ΔgEgM viruses, at an moi of 1, were subjected to 
immunoprecipitation with an anti-VP22 antibody and analysed by Western blotting for the presence 
of VP22, gM and gE (figure kindly provided by Dr Kevin Maringer). The * indicated the 
immunoglobulin heavy chain. (B) GST-gM (gM) or GST alone (G) bound to glutathione sepharose 
beads were incubated with lysated extracts from Vero cells infected with wild type strain sc16 (Wt), 
ΔgE, ΔgM or ΔgEgM viruses at an moi of 1 and analysed by SDS-PAGE followed by Western 
blotting for VP22. G represents GST controls. 
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gM was not efficiently co-immunoprecipitated, in this study the VP22 population present in ΔgE  
infected cells had the ability to interact with GST-gM in the absence of gE, as efficiently as in wild 
type (Fig. 7.2B).  
7.2.2 The phosphorylated form of VP22 effected its interaction with gM 
Next, it was of interest to assess the effect of phosphorylation of the VP22-gM interaction, 
since it was demonstrated in Fig. 7.2 that there was no correlation between the posttranslational 
modification of VP22 and its ability to bind to gM. Plasmids and viruses expressing GFP-tagged 
VP22 in which the serine phosphorylation sites are mutated to alanines to mimic non-phosphorylated 
VP22 (P-) or glutamic acids to mimic the phosphorylated form of VP22 (P+) were used to test their 
binding with gM (Potel & Elliott, 2005). It should be mentioned that both variants of VP22, when 
expressed transiently, localised to the characteristic cytoplasmic bundles as observed for GFP-VP22. 
Also, both phosphorylation mutant viruses grew as efficiently as GFP-VP22 on Vero cells (Potel & 
Elliott, 2005). Therefore, the phosphorylation status of VP22 does not alter the localisation or the 
expression of this protein. 
COS-1 cells were transfected with the plasmids indicated in Fig. 7.3A and the lysed extracts 
were incubated with GST-gM bound to glutathione Sepharose beads. These pull downs resulted in 
VP22, with a constitutively high negative charge at its phosphorylation sites (P+), to be consistently 
bound to gM with less efficiency than the non-charged version (Fig. 7.3 B). This result showed that 
the specific interaction of VP22 with gM was possible in the absence of other viral proteins. Next, the 
same VP22 variants were tested for GST-gM binding during infection and corroborated that the 
charge status of VP22 matters for its interaction with gM (Fig. 7.3C).  
 
7.3 VP13/14 and glycoprotein M  
A recent publication by our group demonstrated a novel interaction between VP13/14 and 
GST-gM during transfection, which was confirmed in chapter 3 by GFP-trap® analysis in infected 
cells (Stylianou et al., 2009). Consequently we wished to characterise this interaction by delineating  
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Figure 7.3: The phosphorylated form of VP22 effected its interaction with gM in infected and 
transfected cells. (A) Line drawings of GFP-VP22 virus/plasmid and its phosphorylation mutant 
viruses/plasmids. In the phosphorylation-negative mutant (G22P-v) phosphorylation was abrogated by 
replacing serine phosphorylation sites with alanine residues. In the mutant mimicking the 
phosphorylated form of VP22 (G22P+v), serine phosphorylation sites were replaced with alanine or 
glutamic acid residues as indicated. (B) COS-1 cells were transfected with G22v, G22P-v, G22P+v or 
GFP expressing plasmids and (C) Vero cells were infected with G22v, G22P-v, G22P+v or Δ22v 
viruses. The soluble extracts were incubated with GST-tagged gM and GST alone beads and the 
bound proteins were analysed by SDS-PAGE, followed by Western blotting against GFP. The values 
on the left are molecular weights in kDa. 
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the interaction domain of VP13/14 with gM. The interaction of gM was tested with seven peptides 
(approximately 100 aa each) that span across the entire VP13/14 open reading frame. These peptides 
were tagged to a nuclear reporter consisting of a GFP fused to the simian virus 40 (SV40) NLS linker 
(Fig. 7.4A). GST-gM efficiently pulled down the first 104 residues of VP13/14 but not the 99-208 
residues. Also, the three peptides expressing VP13/14 residues 203 to 527 bound to gM, whereas the 
last two peptides did not interact with gM (Fig. 7.4B). The sequences of the seven constructs were 
examined to determine if there was any sequence repetition to explain the binding of GST-gM with 
the different regions of VP13/14, however there was no repetition. As a result, we were unable to 
define a minimal gM interaction domain within VP13/14 that retained optimal binding, as almost 
every truncation mutant protein examined bound to gM.    
To determine if gM was able to recruit full length VP3/14 to the secretory pathway in the 
same manner as gE with VP22 (Stylianou et al., 2009), COS-1 cells were co-transfected with 
plasmids expressing gM and GFP-VP13/14 and carried out immunofluorescence studies. As expected, 
gM expressed alone localised to the Golgi/TGN region of the cell, whereas VP13/14 was visible in the 
nucleus and in the nucleoli in multiple speckled domains (Fig. 7.5 single transfection). When these 
proteins were co-expressed, there was no evidence of co-localisation of VP13/14 and gM (Fig. 7.5 co-
transfection).  Hence, it could be concluded that although it was demonstrated the direct binding of 
gM with VP13/14 in the absence of other viral proteins, this interaction was not reproduced in the 
cellular environment. Although, it is possible that gM interacts with VP13 instead of VP14, which is 
major product of the UL47 gene when transiently expressed and therefore this tegument-glycoprotein 
relationship warrants further investigation. 
 
7.4 Chapter Summary 
This chapter characterised VP22-glycoprotein interactions and their contribution to tegument-
tegument complexes involving VP22. In previous transient transfection studies by our group, we were 
unable to delineate the minimal gM binding domain within VP22, as every truncation mutant protein  
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Figure 7.4: VP13/14 interacts with GST-gM in transfected extracts. (A) Line drawings of the 
corresponding seven peptides of VP13/14, used in this study, that were fused to GFP-SV40-NLS. (B) 
COS-1 cells were transfected with the above plasmids, and the soluble extracts were incubated with 
GST- tagged gM. The bound proteins were analysed by SDS-PAGE, followed by Western blotting 
against GFP. The values on the left indicate the molecular weights in kDa. 
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Figure 7.5: VP13/14 does not co-localise with gM. Subconfluent COS-1 cells cultures in 12-well 
plate containing cover slips were (A) transfected or (B) co-transfected with 0.2 µg per well of 
expressing GFP-VP13/14 and gM. Cells were fixed in 4% paraformaldehyde after 20 hours, followed 
by immunofluorescence staining performed with gM antibody. Images were captured using a Zeiss 
Axiovert S100 TV inverted microscope with a 60x lens. Green, GFP-VP13/14 and red, gM. 
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examined was greatly reduced in its ability to bind to gM (Stylianou et al., 2009). However, taking 
together our data from our previous transfection and our current infection studies we could conclude 
that residues 160 to 192 were required for VP22-gM binding. Next we assessed the effect of 
phosphorylation on the VP22-glycoprotein interaction. It showed that the non-phosphorylated form of 
VP22 bound to GST-gM as efficiently as the wild type, in comparison to the phosphorylated form of 
VP22. The same result was achieved during infection and transfection, suggesting that the modified or 
negatively charged VP22 limited the interaction efficiency with gM. In parallel to our studies, another 
member of the group was unable to detect binding between gM and VP22 in the absence of gE, which 
led us to carry out pull down assays of infected ΔgE, ΔgM and ΔgEgM cell extracts using a GST-gM  
fused protein bound to beads. These pull downs showed that VP22 had the ability to bind to GST-gM 
in the presence and absence of gE, indicating that VP22 interaction with gM is independent of gE.  
After our publication demonstrating VP13/14 binding to GST-gM in transiently transfected 
extracts, this interaction was confirmed in infected lysates by GFP-trap® assay in chapter 3. In this 
chapter we verified the interaction of the cytoplasmic tail of gM with VP13/14; however it was 
difficult to define the binding domain within VP13/14. Furthermore, this interaction did not result in a 
relocalization of either protein in co-transfected cells. 
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In this study we have established a defined network of protein-protein interactions 
encompassing over one third of HSV1 tegument proteins, and investigated three discrete multi-
component complexes in infected cells. These were: the previously defined VP22-gE-gM-ICP0 
complex that was involved in VP22 assembly into the virion; VP22-VP16-VP13/14-vhs, involved in 
regulation of virion host shutoff activity; and the novel VP22-VP13/14-UL21-UL16 complex of 
unknown function (Fig. 8.1). The results presented here have demonstrated that virus proteins, rarely 
function in isolation, but must be considered as a component in higher order protein networks that 
exist within infected cells (Fossum et al., 2009). These interactions should be interpreted in the 
context of larger and more complicated protein interaction networks active in HSV-1 (Fig. 8.2). 
8.1 Protein interactions and their possible effects on HSV-1 tegument packaging 
The herpesvirus tegument is located between the capsid, which contains the viral DNA, and 
the lipid envelope, which contains 20 or more virally encoded glycoproteins (Knipe et al. 2007). 
Although the tegument is comparable to the matrix found in a variety of other enveloped viruses, 
HSV-1 tegument is unusual due to the large number of proteins  recruited into the layer, numbering at 
least 23 proteins (Loret et al., 2008). 
Tegument proteins are known to play important roles in multiple stages of the herpesviruses 
life cycle. Of particular interest is the assembly of tegument proteins, many of which are poorly 
characterised and whose contribution to virion assembly is yet to be fully appreciated. It is believed 
that the synergy of a complex network involving a large and partially defined number of protein-
protein interactions between capsid proteins and tegument proteins, tegument-tegument proteins and 
tegument proteins with the cytoplasmic tails of envelope glycoproteins, facilitate the process of 
tegumentation, and play a critical role throughout the process of morphogenesis (Johnson & Baines, 
2011; Kelly et al., 2009; Mettenleiter et al., 2009). According to the currently accepted model of 
alphaherpesvirus morphogenesis, assembled capsids acquire inner tegument proteins, such as VP1/2 
the virally-encoded envelope glycoproteins, such as gE and gM. Finally, the capsid-inner tegument 
and UL37, in the cytoplasm once translocated from the nucleus. Simultaneously, within the  
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Figure 8.1: The three VP22-containing multi-component complexes identified in infected cells during 
this study. Blue circle: VP22-VP16-VP13/14-vhs, Green circle: VP22-VP13/14-UL21-UL16 and 
Purple circle: VP22-ICP0-gE-gM. 
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cytoplasm, the outer tegument proteins, like VP22, are proposed to attach onto the cytoplamic tails of 
assembly buds into this tegument-glycoprotein envelope to form the mature virus particle (Johnson & 
Baines, 2011; Mettenleiter et al., 2009).  
It would have been simple to confirm the proposed process of assembly if a single capsid 
protein or glycoprotein recruited a single tegument protein to the virion. However, studies on HSV-1, 
as well as on another alphaherpesvirus PRV, demonstrated that none of the previously identified 
interactions, with the exception of VP22-gE-gM and UL11-gE (Han et al., 2011; Maringer et al., 
2012), are essential for packaging of individual tegument proteins (Mettenleiter 2002). This indicates 
the complexity of identifying which specific protein-protein interactions are involved in virus 
assembly and the obvious redundancy amongst these interactions.  
The first report demonstrating the interdependent requirement of a single glycoprotein for the 
packaging of a tegument protein in HSV-1 was between the non-essential gE and the membrane-
bound tegument protein UL11 (Han et al., 2011). The direct interaction between these proteins has 
been demonstrated to occur between the cytoplamic tail of gE and the C-terminus of UL11 
(Farnsworth et al., 2007; Han et al., 2011). The cytoplasmic tail of gE has been shown to also directly 
interact with VP22 in HSV-1 and PRV studies, as did the cytoplasmic tail of gM (Fuchs, Klupp, et al., 
2002; Stylianou et al., 2009). In addition, like in PRV, double deletion of HSV-1 gE/gM abrogates 
VP22 packaging although single deletion of each glycoprotein will still permit packaging of this 
protein to wild type levels, indicating a redundancy in these glycoproteins and that VP22 can interact 
with the cytoplasmic tails of gE and gM (Fuchs, Klupp, et al., 2002; Maringer et al., 2012). VP22, on 
the other hand, has been shown to be required for the packaging of an immediate early protein, ICPO; 
although these proteins interact, it has not been proved if it is a direct interaction (Elliott et al., 2005; 
Maringer & Elliott, 2010). However, other interactions between tegument-tegument proteins or 
tegument-glycoproteins are not, possibly on their own, involved in the process of assembly into the 
virion, as presented in the studies here as well.  
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The novel interaction of VP13/14 with UL21 and UL16 demonstrated here, served a good 
example of showing the complexity of identifying which specific protein-protein interactions are 
involved in virus assembly, since the deletion of VP13/14 did not affect the packaging of these 
tegument proteins. Another noteworthy example would be that of the direct interaction of VP13/14 
with the C-terminus of the activation domain of VP16 which was not required for the packaging of 
VP13/14 into the virion. VP22 was also shown to directly interact with VP16, at the same domain as 
VP13/14, and as expected and mentioned above, VP22 was still packaged when the interaction 
domain of VP16 was deleted. Interestingly, when VP22 was deleted, the vhs packaging was greatly 
reduced although VP16 was packaged to wild type levels in this mutant virus, although the direct 
interaction of vhs is with VP16 and not VP22  (Ebert et al., 2013; Smibert et al., 1994; Taddeo et al., 
2007). Furthermore, VP16 has been proposed to be packaged into the virion via the inner tegument, 
through an interaction with the capsid-associated tegument protein VP1/2 (Ko et al., 2010). However, 
Svobodova and coworkers demonstrated that even when the interaction between VP16 and VP1/2 was 
abrogated, VP16 continued to be incorporated into nascent virions, suggesting that VP16 is recruited 
into the virion via an additional pathway (Svobodova et al., 2012). It therefore appears that the 
recruitment of a single tegument protein into the virion is likely to require the involvement of several 
other partners. However, efforts to study this network of interactions are hindered by the dramatic 
reduction in virus growth that usually occurs upon the simultaneously deletion of multiple proteins 
from the genome. 
8.2 A complex network of protein-protein interactions  
Certain techniques have taken a prominent role for researchers piecing together the network 
of interactions by examining individual protein binding pairs. Yeast two-hybrid (Y2H) screens are 
among the most powerful tools to detect protein-protein interaction and, in the case of herpesviruses, a 
wide range of protein relationships have been identified in large scale studies carried out using this 
system (Fossum et al., 2009; Lee et al., 2008; Stellberger et al., 2010; Vittone et al., 2005). However, 
the Y2H approach is considered limited by a predisposition to generate large numbers of false-
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negative or false-positive results and by the fact that only binary interactions can be identified. In 
subsequent studies, Y2H related approaches often fail to produce comparable results, making 
conclusions hard to refine (Uetz et al., 2006). In HSV-1, although a number of the identified 
interactions from Y2H studies have been validated in more-representative infected cells, other 
complexes have been identified in infected cells but not demonstrated by Y2H, including the VP16-
vhs interaction and VP13/14-ICP27 interaction (Dobrikova et al., 2010; Smibert et al., 1994).  
In these studies, two analyses were performed using infected cell lysates in order to define, in 
detail, the molecular interactions that occur between the major tegument proteins VP22, VP16 and 
VP13/14 and identify their interacting partners. Since these three tegument proteins are conserved 
among all alphaherpesviruses, these interactions observed in HSV-1 may well apply more broadly to 
other viruses. Initially, the widely used Tandem Affinity Purification (TAP) method, which allows for 
rapid purification of protein complexes under native conditions, was used to determine potential VP22 
interaction partners from the viral proteome. Although VP22 was successfully purified from the 
infected cells, neither VP16 nor gE – two known partners of VP22- could be co-purified. In other 
HSV-1 studies, the TAP method proved more successful, firstly demonstrating the interaction of the 
cytoplasmic tail of gE, which was TAP tagged, with the tegument protein UL16; and secondly 
confirming an interaction between TAP-tagged capsid proteins UL17 and UL25 (Farnsworth et al., 
2007; Toropova et al., 2011). Nonetheless, our second experimental approach, based on the 
purification of GFP-tagged proteins and their protein partners, proved more fruitful in our hands.  
There are several reports in the literature demonstrating that VP22 interacts with a number of 
tegument proteins and glycoproteins, such as VP16, ICP0, vhs, gE, gM and gD (Chi et al. 2005; 
Elliott et al. 1995; Farnsworth et al. 2007; Hafezi et al. 2005; Maringer & Elliott 2010; O’Regan, 
Murphy, et al. 2007; O’Regan, Bucks, et al. 2007; Stylianou et al. 2009; Taddeo et al. 2007) (Fig. 
8.2). These binding partners of VP22 were validated during our GFP-trap studies, with the exception 
of gD, which was not demonstrated to bind to VP22. Although this result conflicts with previous 
reports from other groups, it is consistent with experiments from within our own group and persists 
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Figure 8.2: Network of protein-protein interactions identified around the HSV-1 tegument proteins. A 
protein interaction network of capsid proteins, tegument proteins and glycoproteins in HSV-1, as 
described here and elsewhere (Coller et al. 2007; Dobrikova et al. 2010; Elliott et al. 1995; 
Farnsworth et al. 2007; Gross et al. 2003; Han et al. 2011; Ko et al. 2010; Lee et al. 2008; Ng et al. 
1998; Maringer & Elliott 2010; Meckes & Wills 2007; Smibert et al. 1994; Stylianou et al. 2009; Shu 
et al. 2013; Toropova et al. 2011; Vittone et al. 2005; Yeh et al. 2011; Zhu & Courtney 1994). Solid 
lines indicate direct interactions, double dashed lines show the indirect interactions between vhs or 
VP13/14 with VP22 and gE with UL21, and the broken lines indicate interactions not yet 
characterised as either direct or indirect. Green, purple and blue lines indicate the complexes 
investigated in this thesis and described in Fig. 8.1. Red solid and dotted lines indicate the novel 
interactions between VP16 and VP13/14 with gM shown here. 
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throughout extensive attempts in several alternative model systems (Maringer et al., 2012; Stylianou 
et al., 2009). Evidence for a VP22-gD interaction has mainly been derived from GST binding assays, 
due to weak binding in the more relevant immunoprecipitation system that were also accompanied by 
high levels of nonspecific association, (Chi et al., 2005; Farnsworth et al., 2007). Moreover, no other 
glycoprotein examined was co-purified with VP22 during our studies, confirming the selectivity of 
the co-precipitation.  
Three novel interaction partners of VP22 were identified in mammalian cells during these 
studies: the tegument proteins VP13/14, UL16 and UL21 (Fig. 8.1 and 8.2). Interestingly, VP13/14 
co-purified the same complex, consisting of VP22-UL16-UL21, indicating a novel multi-component 
complex. This complex does not include VP16 despite the previously demonstrated efficient binding 
of VP22 and VP13/14 with VP16 using this GFP-trap system. The interaction of VP22 with VP13/14 
and VP13/14 with UL21 was first demonstrated in a Y2H study (Fossum et al., 2009). It is 
noteworthy that VP22 has also been shown to interact with VP13/14 in VZV, homologues ORF9 and 
ORF11, respectively (Che et al., 2013), whereas UL16 and UL21 have been shown to interact in 
HSV-1 and PRV studies (Harper et al., 2010; Klupp et al., 2005). Hence, it could be suggested that 
the HSV-1 complex incorporating VP22-VP13/14-UL16-UL21 could be relevant in PRV and VZV 
viruses. 
UL16 and UL21 have also been shown to form a complex with membrane tegument protein 
UL11 and glycoprotein E, through their interaction with these proteins (Han et al., 2011; Loomis et 
al., 2003; Yeh et al., 2011). It was demonstrated that the function of gE, as a key mediator in cell-to-
cell spread and cell fusion, requires the cooperation of the triplex UL11-UL16-UL21 (Fig. 8.2) (Han 
et al., 2012). Due to the relationship of UL21 and UL16 with gE and VP22, it could be suggested that 
VP22 pulled down UL16 and UL21 via their interaction with gE. However, VP22 retained the ability 
to precipitate UL16 and UL21 when a VP22 mutant, unable to bind to gE or gM, was used in our GFP 
trap®  studies (Stylianou et al., 2009). Therefore, combining these findings, it could be suggested that 
UL21 and UL16 form a complex with VP22 and VP13/14 that is compositionally distinct from a 
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complex involving the membrane proteins UL11, gE, or gM. Since the function of such a complex is 
still unknown, further investigation is required to determine the mechanisms which control its 
initiation and assembly. From these initial data, it is possible to surmise that a sub-population of UL16 
and UL21 proteins which are associated with the capsids may perhaps act as scaffolding between 
VP22 and VP13/14 and the capsid during tegument assembly. Moreover, studies in our lab showed 
that VP22 does not interact with VP13/14 in the absence of other viral proteins, suggesting that UL16, 
UL21, or both proteins, are necessary for the activation of this interaction. In the case of the UL11-
UL16-UL21-gE complex, UL21 was required for the activation of UL11-UL16 interaction, whereas 
UL11 activated the UL16-gE binding (Han et al., 2012). It is noteworthy, that despite our own studies 
and those in the literature reporting no binding between VP22 and UL11, the deletion of UL11 had an 
effect on VP22 packaging, reducing it by 30% to 50%, suggesting a connection between these 
proteins (Han et al., 2011). It is possible that the two proteins work synergistically to promote the 
trafficking and packaging of the complex, as they share a number of interaction partners.  
In a more recent report from a different alphaherpesvirus, Varicella Zoster Virus (VZV)  
proteins ORF9 and ORF11, homologues of HSV-1 VP22 and VP13/14 respectively, were shown to 
directly interact (Che et al., 2013). ORF9 protein was also shown to be necessary for the recruitment 
of the ORF11 protein to the TGN region for virion assembly (Che et al., 2013). This is the first report, 
after the HSV-1 Y2H study, which clearly demonstrated the existence of this binary interaction. 
During our studies, the interaction between VP22 and VP13/14 during infection was also 
demonstrated. In contrast to the VZV homologues, the interaction between these two proteins was not 
direct, potentially the result of further viral proteins being required for binding to occur. Although 
both proteins are conserved among the alphaherpesviruses, the necessity of these proteins for viral 
replication or other viral functions differ, in keeping with several other VZV proteins that have been 
found to diverge to various degrees from their HSV-1 homologues (Cohen et al., 1993; Kinchington et 
al., 1995; Kinchington et al., 1992). Deletion of VP13/14 from HSV-1, PRV, BHV-1 and MDV 
resulted in delayed replication in comparison to the parental virus, whereas deletion of ORF11 from 
VZV did not have any effect on growth kinetics, indicating that ORF11 functions are not required for 
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efficient virus growth in vitro (Che et al., 2008; Dorange et al., 2002; M. Kopp et al., 2002; Lobanov 
et al., 2010; Zhang & McKnight, 1993; Zhang et al., 1991). On the other hand, ORF9 is essential for 
VZV replication, as is the MDV homologue, whilst in HSV-1 and PVR, VP22 remains dispensable 
(del Rio et al., 2002; Dorange et al., 2002; Elliott et al., 2005; Tischer et al., 2007). These proteins 
also differ in localisation, with ORF9 protein localising predominantly within the cytoplasm, whilst 
VP22 localises mainly in the cytoplasm with a small population in the nucleus (Cilloniz et al., 2007; 
Elliott et al., 2005). However, these two proteins appear to share similar mechanisms since both 
interact with viral transactivators, although the VZV transactivator protein is IE62, whose HSV-1 
homologue is ICP4 and not the homologue of VP16 (Cilloniz et al., 2007; Kinchington et al., 1992). 
In a recent publication by our group it was demonstrated that VP22 formed a complex with 
ICP0 and glycoproteins gE and gM (Maringer et al., 2012). In our GFP-trap study, however, VP16 
and VP13/14 did not pull down gE nor ICP0, even though both tegument proteins interacted with 
VP22 and gM. In the same report it was shown that VP22 was not packaged into the virion when both 
gE and gM were deleted. In contrast, VP16 continued to be packaged into the virion when gM was 
deleted, suggesting an alternative route for VP16 assembly (Maringer et al., 2012). VP16 has also 
been shown to interact with other cytoplasmic domains of glycoproteins B, D, and H, offering a 
number of potential interaction pathways for incorporation into the assembling virion, although in our 
studies VP16 was not able to pull down either of these glycoproteins (Gross et al., 2003; Zhu & 
Courtney, 1994). Moreover, to date, VP13/14 has been shown to interact with only a single 
glycoprotein, gM, which could suggest that gM acts as the recruitment intermediate during virion 
assembly. However, during our studies presented here, as well as others conducted within our lab, it 
was shown that VP13/14 was packaged into the virion when gM was deleted, despite the novel 
interaction of VP13/14 with GST-gM that we observed in the absence of other viral proteins. In 
addition, VP13/14 was not relocated from the nucleus where it was localised, to the secretory pathway 
to colocalise with gM, suggesting that gM is unlikely to be an efficient direct binding partner of 
VP13/14 in the cellular environment, although further investigation is required to clarify the 
relationship between these proteins. 
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In line with other reports in HSV-1 and PRV, mutations or deletion of gE prevented the 
appearance of the non-phosphorylated form of VP22. The slow-migrating form of VP22 has 
previously been shown to represent the phopshorylated form of VP22, whilst the faster-migrating 
form represented the non-phosphorylated variant (Elliott et al., 1996, 1999; Han et al., 2011; Lyman 
et al., 2003). Since the non-phosphorylated VP22 is predominantly packaged into the virion, gE may 
be required for maintaining or establishing a non-phosphorylated VP22 form for assembly into the 
virion. Although the mechanism remains unclear, it is possible that gE alters VP22 localisation or 
prevents VP22 being targeted by casein kinase II or UL13, both of which are known to be involved in 
VP22 phosphorylation (Coulter et al., 1993; Elliott et al., 1996). Since the gM-VP22 interaction was 
reduced in the absence of gE, this could imply that VP22 phosphorylation might regulate the gM-
VP22 interaction. This hypothesis was verified when the phosphorylated form of VP22 bound poorly 
to GST-gM compared to the wild type VP22 and non-phosphorylated form of VP22. In addition, 
during our GST-gM studies VP22 was bound to gM in the absence of gE, demonstrating that VP22 is 
able to interact with gM in vitro, which means that VP22 and/or gM do not localise correctly in the 
absence of gE to interact efficiently. These results suggest that gE is the major glycoprotein binding 
partner of VP22, with optimal recruitment of gM into a complex with VP22 depending on gE. This 
agrees with previous observations that gE, but not gM, recruits VP22 to the secretory pathway in 
transfected cells, which may imply that gE is required for the efficient compartmentalisation of VP22 
preceding an interaction with gM (Stylianou et al., 2009).  
8.2.1 VP22 forms a complex with vhs and two more tegument proteins, VP16 and VP13/14 
VP22, although a non-essential protein, has a demonstrable involvement with a number of 
protein complexes, as described above. These include a complex involving VP16 and vhs, the virion 
host shutoff protein, which was also demonstrated in our GFP-trap studies (Taddeo et al., 2007). The 
function of vhs, which is to degrade both host and viral mRNA via an endoribonucleolytic cleavage, 
has been shown, initially, to be down-regulated by VP16 through direct interaction between the two 
proteins (Lam et al., 1996; Smibert et al., 1994; Smiley, 2004). This function of VP16 was first 
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observed when viruses lacking VP16 showed unrestrained vhs activity, leading to complete 
translational arrest (Lam et al., 1996). Taddeo and coworkers showed that VP22 was additionally 
required for the neutralisation of the RNase activity of vhs. In the same report, it was demonstrated 
that VP22 interacted with vhs in transiently transfected cells, but only in the presence of VP16 
(Taddeo et al., 2007). As anticipated, vhs incorporation was shown to be dependent on its direct 
binding to VP16 during infection, as it did not have the capacity to interact directly with VP22. It is 
believed that VP16 modulates the vhs activity, together with VP22, at late stages of infection, 
allowing viral protein synthesis to be maintained. The Roizman group continued their investigation on 
vhs activity and identified another two regulators and binding partners of vhs, VP13/14 and ICP27, 
that have also been shown to interact with each other (Dobrikova et al., 2010; Shu et al., 2013; 
Taddeo et al., 2010). In agreement with these reports, our GFP-trap studies confirmed the interaction 
of VP13/14 with vhs and ICP27 in infected cells, extending the observation of vhs interaction with 
VP13/14 in the absence of other viral proteins (Shu et al., 2013; Taddeo et al., 2010). As three of the 
four known regulators of vhs are tegument proteins, and all attenuate or neutralise the activity of vhs, 
it may be that they function at different times during viral replication or in different environments. In 
contrast to the late stage activities of VP16 and VP22 in the replication cycle, VP13/14 and ICP27 
activities could be targeting polyribosomes assembled after the entry of the virus into cells. This 
hypothesis is based on the recent observations of VP13/14 and ICP27 association with the 
polyadenylated-binding protein (PABP) and the evidence that vhs degrades mRNA in polyribosomes 
(Dobrikova et al., 2010; Lam et al., 1996; Taddeo et al., 2007; Taddeo, Zhang, & Roizman, 2009).  
 A number of viruses unable to express VP22 (Δ22) have been shown to acquire secondary 
mutations in the vhs gene, which abrogated the vhs activity and led to the conclusion that vhs is lethal 
in the absence of VP22 (Sciortino et al., 2007). In contrast to these observations, the Δ22 virus 
generated in our lab by homologous recombination, and was used as a control in the studies analysed 
in this thesis, maintained a wild type vhs gene and had no obvious additional secondary mutations 
(Ebert et al., 2013). However, this virus failed to shut off protein synthesis, implying that vhs activity 
was not associated with this virus. This lack of activity is possibly due to the greatly reduced vhs 
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packaging observed in Δ22 virions, compared to the HSV-1 wild type virions, even though VP16 was 
packaged in equal volumes in both viruses (Ebert et al., 2013; Gillian Elliott et al., 2005).  
8.2.2 Understanding the interaction between VP13/14 and VP16  
VP16 has been extensively studied in the context of its role as a powerful transactivator of 
viral IE gene expression (Campbell et al., 1984). Earlier reports suggested that VP13/14 modulates the 
transactivation activity of VP16 during transient transfection as shown by the tardiness of immediate 
early genes of  viruses unable to express VP13/14; although, it should also be noted that VP13/14 is 
non-essential for virus growth for HSV-1 (Barker & Roizman, 1990; McKnight et al., 1987; Zhang & 
McKnight, 1993; Zhang et al., 1991).  This implies that VP16 and VP13/14 might be capable of 
associating with each other during infection. A Y2H study initially demonstrated a weak interaction 
between these major tegument proteins (Vittone et al., 2005). As our studies are focused on protein-
protein interactions, further characterisation of this complex was a priority. Interestingly, these studies 
showed that the interaction domain of VP16 with VP13/14, in infected and transiently transfected 
cells, was delineated to the activation domain of VP16, and more specifically the C-terminal of the 
activation domain (H2 – residues 452 to 490). The same interaction domain of VP16 was shared with 
VP22, an interaction previously shown by Elliott and co-workers, however VP22 and VP13/14 did 
not compete for binding to VP16 when transiently expressed (Elliott et al. 1995). It was initially 
hypothesised that VP22 interacted with VP13/14, as did vhs, by virtue of their direct binding to VP16, 
however it was demonstrated that VP22 interacts with VP13/14 independently of the presence of 
VP16 in the complex. This supports the novel complex identified between VP22-VP13/14-UL16-
UL21, as discussed previously, since VP22 and VP13/14 do not interact in the absence of other viral 
proteins.  
In support of the direct interaction of VP13/14 with the C-terminal of the activation domain 
VP16, the localisation of the proteins did not alter when VP13/14 was co-expressed transiently with a 
VP16 mutant lacking the VP13/14 interaction domain. Whereas, when full length VP13/14 and VP16 
were co-expressed, their localisation was dramatically changed and they were observed to colocalise 
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in large nuclear domains. These large punctuate domains were also reported in the literature when the 
cellular localisation of VP13/14 was examined in live cells (Donnelly & Elliott, 2001b). In the same 
report it was shown that although VP13/14 localised entirely in the cell nucleus, it exhibited a range 
of patterns, including multiple speckled domains, as seen in our fluorescent studies in which VP13/14 
was expressed alone. Moreover, the fact that the VP16 interaction with VP13/14 was narrowed down 
to the 76 residues of the N-terminus of VP13/14, which contains its nuclear localisation signal, 
supports the colocalisation of these proteins. Also it is possible that since VP13/14 may modulate the 
transactivation function of VP16, which takes place within the nucleus, VP13/14 may play a role in 
importing VP16 into the nucleus. Although, VP16 exhibits no particular targeting to the nucleus when 
transiently expressed, at early stages of infection VP16 localised efficiently to the nucleus (La 
Boissière et al., 2004; Morrison et al., 1998). Moreover, VP13/14 was still packaged in the VP16 
mutant virus, suggesting an alternative route for assembly into the virion although the direct and 
possibly fundamental interaction of VP13/14 with VP16. In line with other reports, VP22 packaging 
was not dependent on its interaction with VP16 and was packaged to wild type levels in this mutant 
virus, as was vhs, which have been previously shown to directly bind to residues 335 to 369 of VP16 
(O’Regan  et al. 2007; Schmelter et al. 1996).   
The deletion of VP13/14 created a delay in replication in all alphaherpesviruses, except for 
VZV (Che et al., 2011; Dorange et al., 2002; Kopp et al., 2002; Lobanov et al., 2010; Zhang & 
McKnight, 1993). Our results from a knockout VP13/14 virus confirmed previous findings, since 
virus production was reduced 10-fold compared to its parental virus, despite comparable gene 
expression. In line with HSV-1, deletion of the VZV homologue of VP13/14, ORF11, resulted in 
reduced expression of immediate early proteins (Che et al., 2011; Shu et al., 2013; Zhang & 
McKnight, 1993). Since we did not examine the mRNA levels, and did not observe a decrease in 
immediate early proteins during our studies, it is difficult to imply that VP13/14 modulates the 
transactivation activity of VP16.  
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The purification of virions from the virus lacking VP13/14 proved very challenging. After 
extensive optimisation, extracellular virions were collected. As mentioned previously, the packaging 
of the tegument proteins being tested - VP22, VP16, UL16, and UL21 – was not affected by the 
deletion of VP13/14. Since ICP0 assembly is dependent upon VP22, it was expected that ICP0 would 
be packaged into the VP13/14 knockout virus, but not in higher amounts than observed in the HSV-1 
KOS strain (Maringer & Elliott, 2010). In agreement with previous studies which demonstrated that 
ICP27 is not a virion-associated protein, no detectable ICP27 protein was found in either KOS and 
∆13/14 virion (Sedlackova & Rice, 2008; Su et al., 2006; Yao & Courtney, 1992). However, this 
counters a study from our group which demonstrated the recruitment of ICP27 into extracellular 
infectious particles from the wild-type HSV-1 strains 17+, sc16 and HFEM (Maringer & Elliott, 
2010). Additionally, Loret and coworkers noted minor variations in the profiles of virus particles 
purified from HeLa and BHK-21 cells (Loret et al., 2008). Taken together, these reports and the fact 
that our group routinely isolates virions from BHK-21 cells, while other groups used Vero, HEp-2, or 
HeLa cells, may imply that ICP27 packaging might be cell type-specific (Loret et al., 2008; 
Sedlackova & Rice, 2008; Su et al., 2006; Yao & Courtney, 1992). However, Maringer and Elliott did 
not test F and KOS strains for packaging of ICP27. Since both viruses in this study here are based on 
the KOS strain and virions were purified from BHK-21 cells, we could suggest the ICP27 assembly is 
virus strain-specific. Questions remain as to how such an essential and multifunctional protein, such 
as ICP27, is able to fulfil its important roles during the infection cycle and yet, within KOS and F 
strains, be notably absent during the assembly of nascent virions. It has previously been shown that 
the expression of gC is highly dependent on ICP27 during infection (Rice & Knipe, 1990; Smith et 
al., 1992). Although, ICP27 was expressed in KOS infected lysates, gC expression was absent and, 
consequently, it was not packaged into the KOS virions, in contrast to a report demonstrating the 
expression and packaging of gC in KOS virions (Sedlackova & Rice, 2008). This absence of gC did 
not affect the viral growth of the KOS virus since it is a non-essential glycoprotein, although gC 
and/or gB have been shown to bind to glycosaminoglycan (GAG) chains of heparan sulphate on the 
cell membrane and form the initial contact of the virus with the host cell (Spear & Longnecker, 2003). 
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Nonetheless, this was an unexpected result which warrants further investigation. Furthermore, the 
phenotype of the virus lacking VP13/14 was examined in a cell line that had physiological relevance 
to HSV-1 natural infection, the human keratinocyte cell line HaCat. As observed in other 
alphaherpesviruses, this virus exhibited reduced capacity for cell-to-cell spread, based on the small-
plaque phenotype (Che et al., 2013; Kopp et al., 2002; Lobanov et al., 2010).   
In conclusion, this study demonstrated the direct interaction between two major tegument 
proteins, VP16 and VP13/14, and the independence of assembly into the virion from this interaction. 
This result further confirms the growing evidence that incorporation of tegument proteins into the 
virion is a complex process with significant redundancy. 
 
8.3 Future directions 
From our results, presented here, it has become apparent that our experimental approach using 
the GFP-Trap system could be more broadly applicable to investigate the interaction partners of 
VP22, VP13/14 and VP16. In this study one third of tegument proteins were examined, providing a 
substantial foundation for larger subsequent screens. It would also be of great interest to trial the use 
of the GFP-Trap® protocol to other tegument proteins, such as VP1/2, which is a particular target of 
interest due to its potential role as an scaffold protein during assembly due to its demonstrated 
interactions with both capsid proteins and tegument components such as UL25 and VP16 (Coller et 
al., 2007; Ko et al., 2010; Vittone et al., 2005). Studying targets such as this would contribute to our 
understanding of the protein-protein interaction network that exists within infected cells. 
From a functional perspective, it would be important to characterise the function of the newly 
demonstrated multi-component complex involving VP22-VP13/14-UL16-UL21, as well as 
determining whether VP22 and VP13/14 interact directly with, either or both, UL21 and UL16. Also, 
with the use of the wide range of truncated forms of VP13/14 and VP22 at our disposal, the 
interaction domain with UL21 and UL16 could be defined with relative ease. Although deletion of 
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VP13/14 did not affect the assembly of UL16 and UL21, it would be prudent to check whether 
VP13/14 packaging was dependent on either of these proteins.  
To examine whether VP13/14 plays a role in importing VP16 into the nucleus during 
infection, the VP13/14 knockout virus could be used to check VP16 localisation at early stages of 
infection. It may also be worthwhile to further examine the VP13/14 knockout virus by infecting cells 
at a high multiplicity in order to produce a one-step growth and to analyse the effect this mutation has 
on mRNA levels of immediate early gene expression, which may provide further evidence relating to 
VP13/14 modulation of VP16 transactivation activity. Also, repetition of virion purification is 
required for ∆13/14 to facilitate comparison with its parental virus, the BAC derived KOS virus. 
Additionally, the failure of gC to be expressed and packaged in the KOS wild type virus warrants 
further examination. This could be achieved by comparing this KOS virus to other virus strains – s17, 
sc16, F and HFEM. This would be complemented by a comparison between our own KOS strain and 
one from a different lab, as there is a possibility that of our wild type virus may have acquired 
secondary mutations over time, since KOS strain virus does express and package gC (Sedlackova & 
Rice, 2008). 
   It would be interesting to investigate whether it is possible to interchange tegument proteins 
between different viruses, e.g. replacing HSV-1 VP22 with the VZV homologue ORF9, and vice 
versa. If the mutant viruses are viable, this might imply that the functions of VP22 in these viruses are 
compatible across different host environments. A plethora of question would arise; concerning the 
incorporation of ICP0 into the virion, the localisation of these proteins, and the protein-protein 
interactions facilitating such a result. 
Finally, future studies using the siRNA knockout technology could significantly increase the 
efficiency of these types of investigation, allowing a more complete picture of tegumentation to be 
rapidly constructed. Coupling such an approach with immunofluoresence data would help the nature 
of these interactions to be determined - for example, perhaps allowing the trafficking of VP22 to be 
monitored during the procession knock-down of a variety of different tegument proteins.  
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8.4 Concluding remarks 
This work has contributed to the identification of specific tegument protein complexes which 
exists in infected cells, and has established a defined network of protein-protein interactions which 
encompass over one third of HSV-1 tegument proteins. A novel direct interaction between VP16 and 
VP13/14 was defined, and it was demonstrated that both proteins assemble into virions independently 
from this interaction. These results will help improve our understanding of the wider protein 
interaction networks that lead to the assembly of the herpesvirus tegument.  
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APPENDIX 
Purification steps of GST fused proteins 
 
 
 
 
 
 
 
GST-VP16 and mutants 
 
 
 
 
 
 
 
GST fused cytoplasmic tails of gE and gM 
 
 
 
 
 
 
Figure A.1: Purification of GST fused proteins used in this thesis. All GST fused proteins were 
expressed and purified from E. coli strain BL21, except GST-VP13/14 and GST-VP22 that were 
expressed and purified from sf9 cells, and analysed by SDS-PAGE, followed by Coomassie blue 
staining. Label description: B for before IPTG induction, A after IPTG induction, 1 is cell lysate, 2 is 
supernatant after protein bound to beads, 3 is the wash of beads, 4 is purified protein on beads. 
Molecular weights are shown on the left as kDa. 
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